

CURRICULUM VITAE de Dominique COSTAGLIOLA

1. Biographie résumée

Dominique Costagliola, experte en biostatistique, en épidémiologie, en santé publique et dans le domaine de l'évaluation du médicament, est directrice de recherches émérite à l'INSERM au sein de l'Institut Pierre Louis d'Epidémiologie et de Santé Publique (Sorbonne Université, INSERM) dont elle a été directrice de 2014 à 2018, puis directrice adjointe de 2019 à août 2021. Elle a été lauréate du prix Recherche de l'Inserm en 2013 pour ses recherches sur l'infection à VIH/SIDA commencées en 1986 et est membre de l'Académie des Sciences depuis 2017. En 2020 elle a obtenu le grand prix INSERM pour son implication dans la recherche sur la COVID-19.

Elle étudie les paramètres cachés de l'infection à VIH (incidence, moment de la transmission mère-enfant, cascade, ...), les stratégies d'utilisation des traitements antirétroviraux, et la morbidité sévère, en particulier les cancers et les maladies cardiovasculaires chez les personnes vivant avec le VIH. Plus récemment elle travaille dans le domaine de la prévention du VIH et des IST. Elle est co-responsable d'un work-package du projet européen EU-Response visant à mettre en place un réseau de recherches cliniques opérationnel en Europe dans le domaine des maladies transmissibles émergentes.

À côté de son activité de recherche, elle a une forte implication dans l'expertise et l'aide à la décision en matière de santé pour le Ministère en charge de la Santé, et les différentes Agences et dans l'évaluation scientifique en France et en Europe. Pendant l'épidémie de COVID-19, elle a fait partie du conseil scientifique Covid-19 de l'ANRS MIE (ex REACTing) et a été très impliquée dans l'évaluation de projets de recherche sur la maladie en France et en Europe. Elle a été membre du Groupe d'experts européens de haut niveau proposant une feuille de route vers la stabilisation de la pandémie de Covid-19 dans la région européenne de l'OMS (2021-2023). Elle est membre du Scientific Advisory Board de l'ANRS-MIE.

Depuis juin 2017, elle est membre de l'Association AIDES et de son conseil d'administration.

2. État civil

Dominique COSTAGLIOLA, née le 17 mai 1954 à Asnières-sur-Seine (92).

3. Adresse

Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP)
INSERM, Sorbonne Université
56 Bd V Auriol, CS81393, 75646 PARIS Cedex 13
Tel 33 (0)6 15 19 03 79
E-mail dominique.costagliola@iplesp.upmc.fr

4. Diplômes

- Maîtrise de physique, Université Paris VI 1975
- Ingénieur civil de l'École Nationale Supérieure des Télécommunications (ENST) 1977
- Fifteenth Graduate Summer Session in Epidemiology, Minneapolis (Minnesota) 1980
- Thèse de Doctorat de Troisième cycle, spécialité Biomathématiques (Université Paris VII) 1981

5. Emplois

- 1 février 1982 - 28 décembre 1984 Attaché de recherche INSERM
- 29 décembre 1984 - 31 janvier 1986 Chargé de recherche 2ème classe INSERM
- 1 février 1986 - 6 juillet 1991 Chargé de recherche 1ère classe INSERM
- 7 juillet 1991 – 30 septembre 2001 Directeur de recherche 2ème classe INSERM
- 1 octobre 2001 -31 décembre 2008 Directeur de recherche 1ère classe INSERM
- 1 avril 2007->31 mars 2012 Contrat d'interface avec l'AP-HP Service de Maladies infectieuses et tropicales Pitié-Salpêtrière

▪ 1 janvier 2009 – 31 août 2021
▪ 1^{er} septembre 2021 ->

Directeur de recherche classe exceptionnelle INSERM
Directeur de recherche émérite INSERM

6. Fonctions de direction

Directrice du Service Commun 4 de l'INSERM de 1992 à 2001. Le Service Commun était responsable de projets de pharmaco-épidémiologie (Coordination de la Base de Données hospitalières française sur l'infection à VIH et du réseau France-COAG) et du développement de recherches en biostatistiques et en épidémiologie clinique appliquées à l'infection à VIH.

Directrice de l'équipe 0214 de l'INSERM créée en janvier 2002 à la Pitié-Salpêtrière intitulée « Epidémiologie clinique et traitement de l'infection à VIH » transformée en UMR-S 720 en janvier 2005 (jusqu'en 2008).

Directrice de l'UMR-S 943 INSERM et UPMC Epidémiologie, stratégies thérapeutiques et virologie cliniques dans l'infection à VIH, constituée de 3 équipes entre 2009 et 2013.

Directrice de l'Institut Pierre Louis d'Epidémiologie et de Santé Publique UMR-S 1136 INSERM et Sorbonne Université, constitué de 8 équipes, 247 personnes dont 56 chercheurs ou enseignants chercheurs, entre 2014 et 2018, puis Directrice adjointe de janvier 2019 à août 2021.

7. Activités d'enseignement

- Responsable du module Pharmaco-Epidémiologie et Risque Thérapeutique (30h, 3 crédits) dans le Master 2 de Santé Publique et Management de la Santé, spécialité Epidémiologie (Université Pierre et Marie Curie) et spécialité Méthodes en Evaluation Thérapeutique (Université Denis Diderot) de 2006 à 2014.
- Co-responsable du module Intégration, Pharmacovigilance, Pharmaco-Epidémiologie (15h, 1,5 crédits) dans le Master 2 BIP spécialité pharmacologie clinique et expérimentale (Université Pierre et Marie Curie) de 2009 à 2014.
- EACS HIV summer school : Cours annuel dans le cadre de l'European AIDS Clinical Society de 2011 à 2022 et membre du 'steering committee'.
- Responsable de l'école doctorale Pierre Louis de Santé Publique à Paris ED 393 de janvier 2011 à décembre 2018 et membre du bureau et du comité de suivi de janvier 2019 à septembre 2021. L'ED est accréditée à Sorbonne Université et à l'Université de Paris, l'Institut Pasteur étant associé.

8. Formation à et par la recherche

- Direction de stages de Master 2 (Santé Publique et Management de la Santé, Paris 6 et 7, Santé Publique Paris 11)
- Direction de thèses (19 thèses soutenues, 3 accompagnements de thèse en VAE).

9. Organisation de congrès et séminaires

- Colloque du XXI^{ème} anniversaire de la Revue d'Epidémiologie et de Santé Publique, Paris, 28 et 29 Novembre 1996 (Membre du Comité Scientifique)
- Conférence Internationale « Santé, Précarité et Vulnérabilité en Europe » (Membre du Comité Scientifique), Paris, 15 et 16 novembre 1996
- Colloque International « Réduction du risque viral, sécurité du don et changements organisationnels en transfusion sanguine (Organisateur scientifique), Paris, 28 et 29 mai 1997
- Membre du Comité Scientifique des 1^{ères} Journées d'Epidémiologie et de Santé Publiques; 25, 26 et 27 novembre 1999; Pointe-à-Pitre, France.
- Membre Comité Scientifique du Séminaire scientifique de Pharmaco-épidémiologie (ADELF et SNIP); 25 et 26 mai 2000; Paris, France.
- Membre du Comité Scientifique du Congrès de la Fédération Nationale des Centres de Lutte contre le SIDA, 5 et 6 octobre 2000, Nantes, France.
- Membre du Comité Scientifique du Congrès "Statistical Methods in Biopharmacy, Integrating issues of efficacy, Safety and Costs" organisé par la Société Française de Statistique, Groupe Biopharmacie, 24 et 25 septembre 2001, Paris, France.
- Membre du Comité d'Organisation du Colloque International sous le patronage de l'OMS Europe - Risques, Sécurité Sanitaire et Processus de Décisions; Mars, 21-22; Paris, France.
- Membre du conseil scientifique 1st EACS RESISTANCE AND PHARMACOLOGY WORKSHOP October 28th 2003, Varsovie, Pologne.

- Membre du conseil scientifique de l'International Workshop of HIV Observational Databases de 2000 à 2013 et présidente du 8^{ième} workshop organisé en 2004 à Montreux, Suisse.
- Membre du Conseil scientifique International HIV Drug Resistance Workshop (2005-2007)
- Co-Chair du Workshop on Quantitative Methods for Research on Antiviral Resistance, May 11-12, 2006, Boston, MA, USA.
- Membre du conseil scientifique de l'EACS conference depuis la 12^{ième} (2009, 2011, 2013, 2015, 2017, 2023)
- Membre du Conseil scientifique de la 1^{ière} conférence francophone d'épidémiologie clinique, conférence thématique de l'ADELFI, 10-11 mai 2007, Bordeaux, France et de la 2^{ième} conférence francophone d'épidémiologie clinique, conférence thématique de l'ADELFI, 22-23 mai 2008, Nancy, France.
- Membre du conseil scientifique de la conférence francophone sur le VIH/hépatites AFRAVIH (2014, 2016, 2018).
- Track B co-lead et membre du 'Conference Advisory Committee' de la 9th IAS Conference on HIV Science (IAS 2017) en juillet 2017 à Paris.
- Membre du comité scientifique du HIV Glasgow Congress 2020, 2022, 2024

10. Gestion de la recherche et expertise

1983-1986	Commission Scientifique Spécialisée n°8 de l'INSERM.
1988-1991	Commission de Spécialistes section 38 de l'Université Paris 7.
1993-1999	Conseil d'Administration de l'INSERM.
1999-2003	Commission CGRA1 (Ingénierie et expertise) de l'IRD.
2000	Jury d'admission du concours CR1-CR2 INSERM 2000
2000-2002	Intercommission scientifique Spécialisée n°4 de l'INSERM
2001->	Comité INSERM pour l'évaluation des CIC
2000-2008	Commission Scientifique Spécialisée de l'AFSSA
2001-2004	Conseil Scientifique du GIS Infections à Prions
2007	Comité d'évaluation de l'appel d'offres CTRS/RTRS
2007-2010	Présidence de la Commission Scientifique Spécialisée Biologie des Interactions Hôtes Agresseurs, Symbiotes et Commensaux (BIHASC) de l'INRA.
2010-2012	Jury de concours DR1 INRA.
2007-2009	Conseil Scientifique de l'AFSSA.
2008	Jury d'admission du concours DR2 INSERM 2008
2009-2010	Déléguée scientifique AERES pour l'épidémiologie et la santé publique
2011	Jury d'admission du concours CR1-CR2 INSERM 2011
2012-2016	Présidence de la Commission Scientifique Spécialisée 9 de l'INSERM (Santé publique, santé des populations : épidémiologie, biostatistique, sciences humaines, économiques et sociales)
2014-2018	Membre de la CRMBSP de l'AP-HP, nommée par l'INSERM
2014-2019	Vice-présidente du conseil stratégique de l'UFR de médecine de Sorbonne Universités UPMC
2015-2018	Membre du collège des conseillers scientifiques de l'ITMO Santé Publique (Aviesan)
2014-2018	Membre du groupe thématique de programmation scientifique Santé Publique (Aviesan)
2016-2020	Membre du Conseil Scientifique de la Fondation AP-HP
2017-2020	Présidente du Comité d'Evaluation Scientifique Santé Publique de l'ANR
2018-2024	Vice Présidente du jury du PHRC National
2019-2021	Vice Doyenne Déléguée Recherches Faculté de Médecine Sorbonne Université
2020-2021	Membre du conseil scientifique Covid-19 de REACTing (REsearch and ACTion targeting emerging infectious diseases), devenu ANRS MIE.
2020, 2022	Membre du comité d'évaluation ERC Advanced LS7
2024	Présidente du comité d'évaluation ERC Advanced LS7
2021 ->	Membre du SAB de l'ANRS-MIE
1996-2001	Membre de l'Action Coordonnée n°5 Essais thérapeutiques) de l'ANRS.
2005-2017	Membre de l'Action Coordonnée n°5 Essais thérapeutiques) de l'ANRS.
2001-2003	Présidence de l'Action Coordonnée n°7 Cohortes de l'ANRS.
2003-2017	Membre de l'Action Coordonnée n°7 Cohortes de l'ANRS

2001-2011	Membre de l'Action Coordonnée n°11 « Virologie Médicale » de l'ANRS
1998 -2003	Membre de la sous-action 18-2 « Contexte thérapeutique et prise en charge » de l'Action Coordonnée n°18 « Comportement, prévention, prise en charge » de l'ANRS.
2010-2017	Membre de l'Action Coordonnée 18 Recherches en prévention du VIH/sida de l'ANRS
1999-2002	Membre de l'Action coordonnée n°21 « Homeostasie Lymphocytaire » de l'ANRS
1999-2012	Membre de l'Action coordonnée n°23 « Dynamique de l'épidémie » de l'ANRS.
2012-2018	Présidente de l'Action coordonnée n°23 « Dynamique des épidémies VIH, VHB et VHC » de l'ANRS
1993-1996	Membre du Comité sectoriel scientifique n°3 Recherche Clinique et Epidémiologie de l'ANRS.
1999-2002	Membre du Comité sectoriel scientifique n°5 Santé Publique de l'ANRS.
2018->	Présidente de l'Action coordonnée n°47 Dynamique des épidémies VIH, VHB et VHC de l'ANRS
1993-2001	Comité de rédaction de la Revue d'Épidémiologie et de Santé Publique.
2005-2011	Comité éditorial de AIDS
2006-2012	Comité éditorial de Médecine Sciences
2014-2018	Membre de l'International Advisory Board de Lancet HIV
2018->	Comité éditorial panel de HIV Medicine
1994 ->	Lecteur pour Biometrics, JASA, American Journal of Epidemiology, European Journal of Epidemiology, International Journal of Epidemiology, AIDS Research and Human Retroviruses, AIDS, HIV medicine, Antiviral Therapy, Clinical Infectious Diseases, Journal of Infectious Diseases, Journal of Acquired Immune Deficiency Syndromes, Journal of Antimicrobial Chemotherapy, Retrovirology, Arteriosclerosis, Thrombosis, and Vascular Biology, Transfusion clinique et Biologique, Annals of internal medicine, New england Journal of Medicine, Plos Medicine, Lancet HIV.
1992->	Comité indépendant de plusieurs essais thérapeutiques (ANRS, AP-HP, Industrie).
1994-2000	Biostatisticien du Comité Technique du CIC Saint-Antoine.
1998-2006	Membre de la Commision d'évaluation de la Direction de la Recherche Clinique de l'AP-HP.
1999-2003	Membre du Comité technique régional de cardiologie de l'Agence Régionale d'hospitalisation d'Ile de France.
1993->	Expert auprès de l'Agence Française de Sécurité Sanitaire des Produits de Santé et de l'Agence du Médicament Européenne, pour l'AMM.
1996-2000	Membre du Comité de validation des Références Médicales Opposables (RMO) de l'Agence Française de Sécurité Sanitaire des Produits de Santé
1996-2004	Expert auprès de la Commission de la transparence (Agence Française de Sécurité Sanitaire des Produits de Santé).
1997-1999	Membre suppléant du Comité d'Orientation de l'Observatoire National des prescriptions et consommations des médicaments dans les secteurs ambulatoires et hospitaliers.
1997-1999	Membre du groupe de travail sur la pharmacovigilance des médicaments psychotropes.
1997-2001	Consultant en Epidémiologie et Biostatistique pour l'Agence Française de Sécurité Sanitaire des Produits de Santé.
2001-2007	Membre titulaire de la Commission Nationale de Pharmacovigilance.
1994-1997	Membre du Groupe de travail de coordination des enquêtes descriptives sur le VIH constitué par le RNSP.
1995-1996	Membre du Groupe de travail sur la Charge Virale (présidé par Pr J Dormont et Pr F Brun-Vezinet).
1997-2018	Membre du Groupe de travail sur la prise en charge des patients séropositifs pour le VIH (présidé par le Pr J Dormont, puis le Pr J-F Delfraissy puis le Pr P Yéni, puis le Pr Morlat).
1998	Coordination du sous-groupe Epidémiologie et Santé Publique du groupe d'experts sur l'intérêt de la détection des acides nucléiques des virus VIH, VHB et VHC en matière de transfusion sanguine et de greffe constituée par la Direction Générale de la Santé sous la direction du Pr. F Brun-Vézinet.
2000-2002	Membre du groupe de travail n°1 « Critères, méthodes et procédures utilisés dans les processus de décision pour assurer la sécurité sanitaire » du Comité national de sécurité sanitaire.

2000-2001	Membre du Comité Scientifique de Suivi de l'étude pilote des tests rapides de détection de l'ESB.
2001-2004	Membre du Comité d'Experts Spécialisés ESST de l'AFSSA et présidente du groupe de travail «épidémiologie » du CES ESST
2001-2005	Membre du Conseil National du SIDA
2003	Expert de la conférence de consensus INSERM/ANAES sur la vaccination contre l'hépatite B.
2004	Expert lors de l'audition publique ANAES/AFSSAPS sur le traitement hormonal substitutif de la ménopause
2004-2005	Responsable du groupe de travail sur les études relatives aux traitements hormonaux substitutifs de l'Agence française de sécurité sanitaire des produits de santé
2005-2008	Membre de la Commission d'Evaluation des Stratégies de Santé de la Haute Autorité de Santé.
2008-2011	Membre de la Commission d'Evaluation Economique et de Santé Publique de la Haute Autorité de Santé.
2011	Présidente du groupe 2 « Renforcer la Surveillance du Médicament » des Assises du médicament
2013	Chargée avec B Bégaud d'une mission sur la surveillance et la promotion du bon usage du médicament en France par la Ministre des affaires sociales et de la santé.
2000-2004	Membre du jury du prix du Dr Norbert Marx (Prix de la Société Française de Statistique pour des travaux récents de Statistique appliquée ayant fait l'objet d'une publication dans les domaines de l'épidémiologie, la santé publique, la santé sociale ou l'économie de la santé).
2017-2024	Membre de la CNEDIMTS (Commission nationale d'évaluation des dispositifs médicaux et des technologies de santé) de la Haute Autorité de Santé.
2021-2023	Membre du Groupe d'experts européens de haut niveau proposant une feuille de route vers la stabilisation de la pandémie de Covid-19 dans la région européenne de l'OMS.
2022->	Membre du Conseil Scientifique du GIS Epiphare.
2022->	Membre du Conseil Scientifique de l'Institut Pascal (Université Paris Saclay).
2022->	Membre du Conseil de Surveillance de la FRM

11. Prix et distinctions

Grand Prix INSERM 2020

Membre de l'académie des sciences (élue en décembre 2017)

Prix Line Renaud 2014, décerné par la FRM.

Prix Recherche INSERM 2013.

Prix Louis Daniel Beauperthuy 2006, décerné par l'Académie des Sciences.

Chevalier de l'ordre national de la Légion d'honneur (8 mars 2006), promue Officier (19 janvier 2015).

Chevalier de l'ordre national du Mérite (9 avril 1996), promue commandeur (JO 1 janvier 2021).

12. Associations scientifiques

Association Des Epidémiologistes de Langue Française, International AIDS Society, Société Française de Biométrie et Biometric Society.

13. Association d'usagers

Membre de l'association AIDES au titre de personnalité qualifiée et membre du conseil d'Administration au titre de personnalité qualifiée.

14. Domaines de compétence

- Biostatistique, épidémiologie notamment pharmacoépidémiologie et épidémiologie clinique, dont essais thérapeutiques, modélisation.
- Infection à VIH, hémophilie, médicament, transfusion, COVID-19.

15. Langues

Français (langue maternelle) et anglais (lu, parlé et écrit).

16. Publications dans des revues à comité de lecture répertoriées par Medline

H index 82 ISI Web of Knowledge, 1^{ère} publication en 1979, ResearcherID: H-5849-2011

Orcid 0000-0003-0765-0869

1979-1987

1. Stupfel M, Costagliola D. Lifelong variations in heart rates in SPF Sprague Dawley rats of both sexes. Statistical correlations with body weights. *Pflugers Arch* 1979;380(2):189-95.
2. Costagliola D, Valleron AJ. [Adaptation to life events: its measure and effect upon health. A review from 1975 to 1978 (author's transl)]. *Rev Epidemiol Sante Publique* 1980;28(2):209-20.
3. Smadja-Joffe F, Le Bousse-Kerdiles MC, Costagliola D, Klein B, Malaise EP, Jasmin C. Cellular proliferation in the spleen of DBA/2 mice infected with a myeloproliferative sarcoma virus(MPSV). *Exp Hematol* 1981;9(2):137-48.
4. Basdevant A, Costagliola D, Lanoe JL, Goldgewicht C, Triomphe A, Metz F, Denys H, Eschwege E, Fardeau M, Tchobroutsky G. The risk of diabetic control: a comparison of hospital versus general practice supervision. *Diabetologia* 1982;22(5):309-14.
5. Triomphe A, Lanoe JL, Costagliola D, Basdevant A, Eschwege E, Tchobroutsky G, Fardeau M. [Multidiscipline aspects and approach to the evaluation of care for diabetics]. *Cah Sociol Demogr Med* 1982;22(1):5-21.
6. Poitrenaud J, Vallery-Masson J, Costagliola D, Darcet P, Lion MR. [Retirement, psychological well-being and health: longitudinal study of a population of Parisian executives]. *Rev Epidemiol Sante Publique* 1983;31(4):469-82.
7. Bourgeois CA, Costagliola D, Laquerriere F, Bard F, Hemon D, Bouteille M. In situ arrangement of non-bearing chromosomes in the interphase nucleus of *Aotus trivirgatus*. *J Cell Sci* 1984;69:107-15.
8. Slama G, Haardt MJ, Jean-Joseph P, Costagliola D, Goicolea I, Bornet F, Elgrably F, Tchobroutsky G. Sucrose taken during mixed meal has no additional hyperglycaemic action over isocaloric amounts of starch in well-controlled diabetics. *Lancet* 1984;2(8395):122-5.
9. Bard F, Bourgeois CA, Costagliola D, Bouteille M. Rotation of the cell nucleus in living cells: a quantitative analysis. *Biol Cell* 1985;54(2):135-42.
10. Bornet F, Haardt MJ, Costagliola D, Blayo A, Slama G. Sucrose or honey at breakfast have no additional acute hyperglycaemic effect over an isoglucidic amount of bread in type 2 diabetic patients. *Diabetologia* 1985;28(4):213-7.
11. Slama G, Bornet F, Rosset T, Costagliola D, Haardt MJ, Jean-Joseph P, Grigoresco C, Tchobroutsky G. [Do simple sugars have a place in the diabetic diet?]. *Journ Annu Diabetol Hotel Dieu* 1985:277-89.
12. Elgrably F, Costagliola D, Varenne P, Denys H, Sebag-Lanoe R, Haardt MJ, Slama G, Tchobroutsky G. [Insulin therapy in aged patients]. *Journ Annu Diabetol Hotel Dieu* 1986:261-4.
13. Sebag-Lanoe R, Costagliola D, Delesalle MC, Eschwege E, Denys H. [Is insulin-treated diabetes a cause for institutionalization after age 70?]. *Journ Annu Diabetol Hotel Dieu* 1986:255-60.
14. Bornet FR, Costagliola D, Rizkalla SW, Blayo A, Fontvieille AM, Haardt MJ, Letanoux M, Tchobroutsky G, Slama G. Insulinemic and glycemic indexes of six starch-rich foods taken alone and in a mixed meal by type 2 diabetics. *Am J Clin Nutr* 1987;45(3):588-95.
15. Costagliola D, Downs AM. Incubation time for AIDS. *Nature* 1987;328(6131):582.
16. Coulibaly M, Costagliola D, Zittoun J, Mary JY. Modifications of hemato-biological parameters in pregnant women in a migrating population in northern Cameroon: prevalence of anemia, iron and folates deficiencies. *Int J Vitam Nutr Res* 1987;57(2):173-8.

1988

17. Hejblum G, Costagliola D, Valleron AJ, Mary JY. Cell cycle models and mother-daughter correlation. *J Theor Biol* 1988;131(2):255-62.
18. Jeannel D, Niel G, Costagliola D, Danis M, Traore BM, Gentilini M. Epidemiology of toxoplasmosis among pregnant women in the Paris area. *Int J Epidemiol* 1988;17(3):595-602.
19. Triomphe A, Flori YA, Costagliola D, Eschwege E. The cost of diabetes in France. *Health Policy* 1988;9(1):39-48.

1989

20. Chwalow AJ, Costagliola D, Stern J, Mesbah M, Eschwege E. Telephone versus face to face interviewing as a means of collecting data relevant to the management of diabetes among general practitioners in France: a randomized design. *Diabete Metab* 1989;15(4):157-60.
21. Costagliola D, Chawlow AJ, Simon D, Eschwege E. Some keys factors in the clinical diagnosis of non insulin-dependent diabetes: a multinational comparison. *Diabete Metab* 1989;15(1):51-2.
22. Costagliola D, Mary JY, Brouard N, Laporte A, Valleron AJ. Incubation time for AIDS from French transfusion-associated cases. *Nature* 1989;338(6218):768-9.
23. Le Pont F, Costagliola D, Massari V, Valleron AJ. Blood donation and HIV infection: impact of seroconversion delay on the sensitivity of the testing procedure. *Rev Epidemiol Sante Publique* 1989;37(2):97-102.

1990

24. Chwalow AJ, Costagliola D, Mesbah M, Moret L, Eschwege E. SMBG in NIDDM patients treated by general practitioners in France. *Diabetes Care* 1990;13(4):454.
25. Jeannel D, Costagliola D, Niel G, Hubert B, Danis M. What is known about the prevention of congenital toxoplasmosis? *Lancet* 1990;336(8711):359-61.
26. Le Pont F, Massari V, Jullien AM, Costagliola D, Valleron AJ. Anti-HBc testing can decrease the residual risk of transfusion-related HIV transmission by more than one third. *Vox Sang* 1990;59(4):248-50.

1991

27. Chwalow AJ, Costagliola D, Mesbah M, Moret L, Eschwege E. [Diagnosis and evaluation of educational strategies for non-insulin-dependent diabetics and their treating physicians in France]. *Journ Annu Diabetol Hotel Dieu* 1991:253-9.
28. Costagliola D, Delaunay C, Moutet JP, Kankambega P, Demeulemeester R, Donnet JP, Papoz L, Eschwege E. The prevalence of diabetes mellitus in the adult population of Guadeloupe as estimated by history or fasting hyperglycemia. *Diabetes Res Clin Pract* 1991;12(3):209-16.
29. Costagliola D, Flahault A, Galinec D, Garnerin P, Menares J, Valleron AJ. A routine tool for detection and assessment of epidemics of influenza-like syndromes in France. *Am J Public Health* 1991;81(1):97-9.
30. Downs AM, Ancelle-Park RA, Costagliola D, Rigaut JP, Brunet JB. Transfusion-associated AIDS cases in Europe: estimation of the incubation period distribution and prediction of future cases. *J Acquir Immune Defic Syndr* 1991;4(8):805-13.
31. Driss F, Costagliola D, Marie B, Ekindjian OG, Eme D, Berthelot P, Nalpas B. A rational attitude toward serum alanine aminotransferase measurement by blood banks, based on a longitudinal study of a cohort of repeat blood donors. *Transfusion* 1991;31(3):201-4.
32. Elgrably F, Costagliola D, Chwalow AJ, Varenne P, Slama G, Tchobroutsky G. Initiation of insulin treatment after 70 years of age: patient status 2 years later. *Diabet Med* 1991;8(8):773-7.
33. Green LW, Costagliola D, Chwalow AJ. [Educational diagnosis and evaluation of educational strategies (PRECEDE Model): practical methodology for inducing changes in behavior and health status]. *Journ Annu Diabetol Hotel Dieu* 1991:227-40.
34. Marechal V, Nicolas JC, Joab I, Costagliola D, Lefrere JJ. Epstein-Barr virus transactivator antibodies in HIV infection. *Lancet* 1991;338(8766):574.

1992

35. Chevret S, Costagliola D, Lefrere JJ, Valleron AJ. A new approach to estimating AIDS incubation times: results in homosexual infected men. *J Epidemiol Community Health* 1992;46(6):582-6.
36. Costagliola DG, Girot R, Rebullia P, Lefrere JJ. Incidence of AIDS in HIV-1 infected thalassaemia patients. European and Mediterranean W.H.O. Working Group on Haemoglobinopathies and CooleyCare. *Br J Haematol* 1992;81(1):109-12.
37. de Montalembert M, Costagliola DG, Lefrere JJ, Cornu G, Lombardo T, Cosentino S, Perrimond H, Girot R. Prevalence of markers for human immunodeficiency virus types 1 and 2, human T-lymphotropic virus type I, cytomegalovirus, and hepatitis B and C virus in multiply transfused thalassemia patients. The French Study Group On Thalassaemia. *Transfusion* 1992;32(6):509-12.
38. Guiguet M, Mary M, Costagliola D, Armengaud M, Cartier F, Micoud M, Mouton Y, Sobesky G, Valleron AJ. Trends in zidovudine prescription since 1987 in AIDS-free HIV-positive French patients attending university hospitals. *AIDS* 1992;6(11):1405-6.

39. Lefrere JJ, Mariotti M, Wattel E, Lefrere F, Inchauspe G, Costagliola D, Prince A. Towards a new predictor of AIDS progression through the quantitation of HIV-1 DNA copies by PCR in HIV-infected individuals. *Br J Haematol* 1992;82(2):467-71.
40. Renard F, Costagliola D, Van Hemeldonck LA, Wollast E. [Estimate of seroprevalence of HIV infection in Belgium using the back calculation method]. *Rev Epidemiol Sante Publique* 1992;40(3):175-81.

1993

41. Blanche S, Calvez T, Rouzioux C, Ortigao MB, Taburet AM, Ferroni A, Debre M, Wintrebert F, Singlas E, Costagliola D, Griscelli C. Randomized study of two doses of didanosine in children infected with human immunodeficiency virus. *J Pediatr* 1993;122(6):966-73.
42. Retel O, Costagliola D, Valleron AJ. [Analysis of delay in reporting of acquired immunodeficiency syndrome in France]. *Rev Epidemiol Sante Publique* 1993;41(6):447-53.
43. Rouzioux C, Costagliola D, Burgard M, Blanche S, Mayaux MJ, Griscelli C, Valleron AJ. Timing of mother-to-child HIV-1 transmission depends on maternal status. The HIV Infection in Newborns French Collaborative Study Group. *AIDS* 1993;7 Suppl 2:S49-52.
44. Rude N, Costagliola D, Valleron AJ. Cumulative incidence of HIV infection and AIDS case prediction in France. *Lancet* 1993;342(8868):436-7.
45. Rude N, Costagliola D, Valleron AJ. [Prevalence of HIV infection in France before the introduction of early treatment: estimation by back-calculation]. *Rev Epidemiol Sante Publique* 1993;41(6):437-46.
46. Sahmoud T, Laurian Y, Gazengel C, Sultan Y, Gautreau C, Costagliola D. Progression to AIDS in French haemophiliacs: association with HLA-B35. *AIDS* 1993;7(4):497-500.

1994

47. Calvez T, Costagliola D. [Risk of the appearance of inhibitors linked to the administration of factors VIII and IX. Review of the literature]. *Transfus Clin Biol* 1994;1(6):427-35.
48. Chwalow AJ, Costagliola DG, Mesbah M, Eschwege E. Management of type 2 diabetes mellitus in France: attitudes and practices among a representative sample of general practitioners. *Diabete Metab* 1994;20(5):458-64.
49. Costagliola D. When is the epidemic warning cut-off point exceeded? *Eur J Epidemiol* 1994;10(4):475-6.
50. Costagliola DG, de Montalembert M, Lefrere JJ, Briand C, Rebullia P, Baruchel S, Dessi C, Fondu P, Karagiorga M, Perrimond H, et al. Dose of desferrioxamine and evolution of HIV-1 infection in thalassaemic patients. *Br J Haematol* 1994;87(4):849-52.
51. Dimier-David L, Billon N, Costagliola D, Jaillon P, Funck-Brentano C. Reproducibility of non-invasive measurement and of short-term variability of blood pressure and heart rate in healthy volunteers. *Br J Clin Pharmacol* 1994;38(2):109-15.
52. Massari V, Costagliola D, Valleron AJ. Estimation of the number of HIV-seropositive patients known to general practitioners in France. *AIDS* 1994;8(8):1190-1.
53. Massari V, Elghouzzi MH, Agis F, Rannou C, Gordien E, Costagliola D, Lefrere JJ. Epidemiologic comparison of human T-lymphotropic virus type I-infected blood donors from endemic and nonendemic regions over a 3-year period. *Transfusion* 1994;34(3):198-201.
54. Morand-Joubert L, Costagliola D, Bludau H, Petit JC, Lefrere JJ. Predicting progression of HIV disease: usefulness of acid-dissociated p24 antigen. *J Acquir Immune Defic Syndr* 1994;7(7):676-80.

1995

55. Christeff N, Winter C, Gharakhanian S, Thobie N, Wirbel E, Costagliola D, Nunez EA, Rozenbaum W. Differences in androgens of HIV positive patients with and without Kaposi sarcoma. *J Clin Pathol* 1995;48(6):513-8.
56. Cohen A, Guyon P, Chauvel C, Abergel E, Costagliola D, Raffoul H, Valty J, Diebold B. Relations between Doppler tracings of pulmonary regurgitation and invasive hemodynamics in acute right ventricular infarction complicating inferior wall left ventricular infarction. *Am J Cardiol* 1995;75(7):425-30.
57. Cohen A, Guyon P, Johnson N, Chauvel C, Logeart D, Costagliola D, Valty J. Hemodynamic criteria for diagnosis of right ventricular ischemia associated with inferior wall left ventricular acute myocardial infarction. *Am J Cardiol* 1995;76(4):220-5.
58. Costagliola D. [HIV-1 infection: how are long-term asymptomatic subjects characterized?]. *Rev Epidemiol Sante Publique* 1995;43(3):289-90.
59. Costagliola D, Mary-Krause M. Can antiviral agents decrease the occurrence of Kaposi's sarcoma? Clinical Epidemiology Group from Centres d'Information et de Soins de l'Immunodeficiency Humaine. *Lancet* 1995;346(8974):578.

60. Gozlan J, el Amrani M, Baudrimont M, Costagliola D, Salord JM, Duvivier C, Picard O, Meyohas MC, Jacomet C, Schneider-Fauveau V, et al. A prospective evaluation of clinical criteria and polymerase chain reaction assay of cerebrospinal fluid for the diagnosis of cytomegalovirus-related neurological diseases during AIDS. *AIDS* 1995;9(3):253-60.
61. Le Pont F, Costagliola D, Massari V, Valleron AJ. Estimation of the size of the HIV/AIDS epidemic due to blood transfusion in France. *Int J Epidemiol* 1995;24(2):441-5.
62. Le Pont F, Costagliola D, Rouzioux C, Valleron AJ. How much would the safety of blood transfusion be improved by including p24 antigen in the battery of tests? *Transfusion* 1995;35(7):542-7.
63. Mesbah M, Chwalow AJ, Balkau B, Costagliola D, Vauzelle-Kervroedan F, Eschwege E. Prevalence of non-insulin dependent diabetes as perceived by general practitioners in France. *Rev Epidemiol Sante Publique* 1995;43(3):225-30.
64. Mikol J, Costagliola D, Polivka M, Thiebaut JB, Trotot P. [The epidemiology of cerebral lymphoma in AIDS]. *J Neuroradiol* 1995;22(3):204-6.
65. Rouzioux C, Costagliola D, Burgard M, Blanche S, Mayaux MJ, Griscelli C, Valleron AJ. Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model. The HIV Infection in Newborns French Collaborative Study Group. *Am J Epidemiol* 1995;142(12):1330-7.

1996

66. Costagliola D, Mary-Krause M. Zidovudine in patients with HIV infection. *Ann Intern Med* 1996;124(3):372; author reply 372-3.
67. Failde I, Balkau B, Costagliola D, Moutet JP, Gabriel JM, Donnet JP, Eschwege E. Arterial hypertension in the adult population of Guadeloupe, and associated factors in subjects of African origin. *Rev Epidemiol Sante Publique* 1996;44(5):417-26.
68. Le Pont F, Costagliola D, Valleron AJ, Rouzioux C. Correction: How much would the safety of blood transfusion be improved by including p24 antigen in the battery of tests? *Transfusion* 1996;36(2):191-2.

1997

69. Chouquet C, Burgard M, Richardson S, Rouzioux C, Costagliola D. Timing of mother-to-child HIV-1 transmission and diagnosis of infection based on polymerase chain reaction in the neonatal period by a non-parametric method. *AIDS* 1997;11(9):1183-4.
70. Christeff N, Gharakhanian S, Thobie N, Wirbel E, Dalle MT, Costagliola D, Nunez EA, Rozenbaum W. Effect of interferon alpha on high serum androgen concentrations in HIV positive men with Kaposi's sarcoma. *J Clin Pathol* 1997;50(4):341-5.
71. Funck-Brentano I, Costagliola D, Seibel N, Straub E, Tardieu M, Blanche S. Patterns of disclosure and perceptions of the human immunodeficiency virus in infected elementary school-age children. *Arch Pediatr Adolesc Med* 1997;151(10):978-85.
72. Goubar A, Costagliola D. Estimate of HIV incidence in childbearing women in the Paris area, France. *AIDS* 1997;11(5):699-701.
73. Salhi Y, Costagliola D. Long-term nonprogression in HIV infection. Clinical Epidemiology Group from the Centre d'Information et de Soins de l'Immunodeficiency Humaine. *J Acquir Immune Defic Syndr Hum Retrovirol* 1997;16(5):409-11.

1998

74. Cohen A, Logeart D, Costagliola D, Chauvel C, Boccara F, Vu-Lamisse N, Benhalima B, Blanchard-Lemoine B, Buyukoglu B, Valtj J. Usefulness of pulmonary regurgitation Doppler tracings in predicting in-hospital and long-term outcome in patients with inferior wall acute myocardial infarction. *Am J Cardiol* 1998;81(3):276-81.
75. Heard I, Schmitz V, Costagliola D, Orth G, Kazatchkine MD. Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. *AIDS* 1998;12(12):1459-64.
76. Jubault V, Burgard M, Le Corfec E, Costagliola D, Rouzioux C, Viard JP. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy. *AIDS* 1998;12(17):2358-9.
77. Katlama C, Valantin MA, Matheron S, Coutellier A, Calvez V, Descamps D, Longuet C, Bonmarchand M, Tubiana R, De Sa M, Lancar R, Agut H, Brun-Vezinet F, Costagliola D. Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection. *Ann Intern Med* 1998;129(7):525-31.
78. Le Moing V, Bissuel F, Costagliola D, Eid Z, Chapuis F, Molina JM, Salmon-Ceron D, Brasseur P, Leport C. Decreased prevalence of intestinal cryptosporidiosis in HIV-infected patients concomitant to the widespread use of protease inhibitors. *AIDS* 1998;12(11):1395-7.

79. Pancino G, Leste-Lasserre T, Burgard M, Costagliola D, Ivanoff S, Blanche S, Rouzioux C, Sonigo P. Apparent enhancement of perinatal transmission of human immunodeficiency virus type 1 by high maternal anti-gp160 antibody titer. *J Infect Dis* 1998;177(6):1737-41.
80. Roux P, Ha MC, Brucker G, Costagliola D. Pneumocystis and pneumocystosis in Europe at the end of the 20th century. *FEMS Immunol Med Microbiol* 1998;22(1-2):87-91.
81. Salhi Y, Costagliola D, Rebutta P, Dessi C, Karagiorga M, Lena-Russo D, de Montalembert M, Girot R. Serum ferritin, desferrioxamine, and evolution of HIV-1 infection in thalassemic patients. *J Acquir Immune Defic Syndr Hum Retrovirol* 1998;18(5):473-8.
82. Samb B, Badiane M, Kony S, Larouze B, Faye MA, Sow PS, Badiane S, Metro A, Costagliola D, Ndoye I, Delaporte E, Coll-Seck AM, Coulaud JP. Is it necessary to conduct trials with trimethoprim-sulphamethoxazole amongst HIV-infected individuals in Africa? *AIDS* 1998;12(4):447.
83. Uchuya M, Fleury A, Graus F, Costagliola D, Liblau R, Merle-Beral H, Theodorou I, Delattre JY. Lack of association between human leukocyte antigens and the anti-Hu syndrome in patients with small-cell lung cancer. *Neurology* 1998;50(2):565-6.

1999

84. Candotti D, Calvez V, Autran B, Costagliola D, Rouzioux C, Agut H. Decreased peripheral circulation of HIV-infected cells in a subset of long-term nonprogressors. The French ALT Study Group. *J Acquir Immune Defic Syndr* 1999;21(3):253-5.
85. Candotti D, Costagliola D, Joberty C, Bonduelle O, Rouzioux C, Autran B, Agut H. Status of long-term asymptomatic HIV-1 infection correlates with viral load but not with virus replication properties and cell tropism. French ALT Study Group. *J Med Virol* 1999;58(3):256-63.
86. Chouquet C, Richardson S, Burgard M, Blanche S, Mayaux MJ, Rouzioux C, Costagliola D. Timing of human immunodeficiency virus type 1 (HIV-1) transmission from mother to child: bayesian estimation using a mixture. *Stat Med* 1999;18(7):815-33.
87. Deuffic S, Costagliola D. Is the AIDS incubation time changing? A back-calculation approach. *Stat Med* 1999;18(9):1031-47.
88. Huillard d'Aignaux J, Costagliola D, Maccario J, Billette de Villemeur T, Brandel JP, Deslys JP, Hauw JJ, Chaussain JL, Agid Y, Dormont D, Alperovitch A. Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France. *Neurology* 1999;53(6):1197-201.
89. Le Corfec E, Chevret S, Costagliola D. Visit-driven endpoints in randomized HIV/AIDS clinical trials: impact of missing data on treatment difference measured on summary statistics. *Stat Med* 1999;18(14):1803-17; discussion 1819.
90. Le Corfec E, Le Pont F, Tuckwell HC, Rouzioux C, Costagliola D. Direct HIV testing in blood donations: variation of the yield with detection threshold and pool size. *Transfusion* 1999;39(10):1141-4.
91. Lievre L, Meyohas MC, Costagliola D. Impact of opportunistic diseases on survival in HIV-infected patients in France, 1992-1997. Clinical Epidemiology Group from Centres d'Information et de Soins de l'Immunodeficiency Humaine. *AIDS* 1999;13(13):1789-90.
92. Magierowska M, Theodorou I, Debre P, Sanson F, Autran B, Riviere Y, Charron D, Costagliola D. Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1-infected individuals. *Blood* 1999;93(3):936-41.
93. Phillips AN, Grabar S, Tassie JM, Costagliola D, Lundgren JD, Egger M. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. *AIDS* 1999;13(15):2075-82.
94. Saura C, Courouce AM, Pillonel J, Costagliola D, Flan B, Defer C, Coste J, Rouzioux C. Risk-benefit analysis of nucleic acid testing: the French experience. *Biologicals* 1999;27(4):343-8.
95. Tassie JM, Gasnault J, Bentata M, Deloumeaux J, Boue F, Billaud E, Costagliola D. Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. Clinical Epidemiology Group. French Hospital Database on HIV. *AIDS* 1999;13(14):1881-7.

2000

96. Anduze-Faris BM, Fillet AM, Gozlan J, Lancar R, Boukli N, Gasnault J, Caumes E, Livartowsky J, Matheron S, Lepout C, Salmon D, Costagliola D, Katlama C. Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients. *AIDS* 2000;14(5):517-24.
97. Bernillon P, Lievre L, Pillonel J, Laporte A, Costagliola D. Record-linkage between two anonymous databases for a capture-recapture estimation of underreporting of AIDS cases: France 1990-1993. The Clinical Epidemiology Group from Centres d'Information et de Soins de l'Immunodeficiency Humaine. *Int J Epidemiol* 2000;29(1):168-74.

98. Faure S, Meyer L, Costagliola D, Vaneensberghe C, Genin E, Autran B, Delfraissy JF, McDermott DH, Murphy PM, Debre P, Theodorou I, Combadiere C. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. *Science* 2000;287(5461):2274-7.
99. Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, Weiss L. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. *Ann Intern Med* 2000;133(6):401-10.
100. Grabar S, Pradier C, Le Corfec E, Lancar R, Allavena C, Bentata M, Berlureau P, Dupont C, Fabbro-Peray P, Poizot-Martin I, Costagliola D. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. *AIDS* 2000;14(2):141-9.
101. Kazatchkine MD, Van PN, Costagliola D, Mohammed AS, Ledoine JM, Troccaz M, Belec L. Didanosine dosed once daily is equivalent to twice daily dosing for patients on double or triple combination antiretroviral therapy. The AI454-147 Team. *J Acquir Immune Defic Syndr* 2000;24(5):418-24.
102. Le Corfec E, Rouzioux C, Costagliola D. [HIV-1 quantitative dynamics in vivo: a review of mathematical models]. *Rev Epidemiol Sante Publique* 2000;48(2):168-81.
103. Salmon-Ceron D, Mazon MC, Chaput S, Boukli N, Senechal B, Houhou N, Katlama C, Matheron S, Fillet AM, Gozlan J, Leport C, Jeantils V, Freymuth F, Costagliola D. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy. *AIDS* 2000;14(8):1041-9.
104. Spano JP, Salhi Y, Costagliola D, Rozenbaum W, Girard PM. Factors predictive of disease progression and death in AIDS-related Kaposi's sarcoma. *HIV Med* 2000;1(4):232-7.

2001

105. Abgrall S, Matheron S, Le Moing V, Dupont C, Costagliola D. Pneumocystis carinii pneumonia recurrence in HIV patients on highly active antiretroviral therapy: secondary prophylaxis. *J Acquir Immune Defic Syndr* 2001;26(2):151-8.
106. Abgrall S, Rabaud C, Costagliola D. Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era. *Clin Infect Dis* 2001;33(10):1747-55.
107. Besson C, Goubar A, Gabarre J, Rozenbaum W, Pialoux G, Chatelet FP, Katlama C, Charlotte F, Dupont B, Brousse N, Huerre M, Mikol J, Camparo P, Mokhtari K, Tulliez M, Salmon-Ceron D, Boue F, Costagliola D, Raphael M. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. *Blood* 2001;98(8):2339-44.
108. Calvez T, Biour M, Costagliola D, Jullien AM, Laurian Y, Rossi F, Rothschild C, Sie P. The French haemophilia cohort: rationale and organization of a long-term national pharmacosurveillance system. *Haemophilia* 2001;7(1):82-8.
109. Descamps D, Calvez V, Izopet J, Buffet-Janvresse C, Schmuck A, Colson P, Ruffault A, Maillard A, Masquelier B, Cottalorda J, Harzic M, Brun-Vezinet F, Costagliola D. Prevalence of resistance mutations in antiretroviral-naive chronically HIV-infected patients in 1998: a French nationwide study. *AIDS* 2001;15(14):1777-82.
110. Duran S, Solas C, Spire B, Carrieri MP, Fuzibet JG, Costagliola D, Lacarelle B, Moatti JP. 'Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?' A comparison between patients' self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. *AIDS* 2001;15(8):1075-7.
111. Goubar A, Costagliola D. HIV incidence estimates among women of childbearing age in the area around Paris, France: no evidence for any effect of age or time. *J Acquir Immune Defic Syndr* 2001;27(5):492-8.
112. Loubiere S, Rotily M, Durand-Zaleski I, Costagliola D. Including polymerase chain reaction in screening for hepatitis C virus RNA in blood donations is not cost-effective. *Vox Sang* 2001;80(4):199-204.
113. Maynard M, Lievre L, Sow PS, Kony S, Gueye NF, Bassene E, Metro A, Ndoye I, Ba DS, Coulaud JP, Costagliola D. Primary prevention with cotrimoxazole for HIV-1-infected adults: results of the pilot study in Dakar, Senegal. *J Acquir Immune Defic Syndr* 2001;26(2):130-6.
114. Mouroux M, Descamps D, Izopet J, Yvon A, Delaugerre C, Matheron S, Coutellier A, Valantin MA, Bonmarchand M, Agut H, Massip P, Costagliola D, Katlama C, Brun-Vezinet F, Calvez V. Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy. *Antivir Ther* 2001;6(3):179-83.
115. Ngo-Giang-Huong N, Candotti D, Goubar A, Autran B, Maynard M, Sicard D, Clauvel JP, Agut H, Costagliola D, Rouzioux C. HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression. *AIDS Res Hum Retroviruses* 2001;17(15):1435-46.

116. Serfaty L, Costagliola D, Wendum D, Picard O, Meyohas MC, Girard PM, Lebas J, Delamare C, Poupon R, Housset C. Impact of early-untreated HIV infection on chronic hepatitis C in intravenous drug users: a case-control study. *AIDS* 2001;15(15):2011-6.

2002

117. Calvez V, Costagliola D, Descamps D, Yvon A, Collin G, Cecile A, Delaugerre C, Damond F, Marcelin AG, Matheron S, Simon A, Valantin MA, Katlama C, Brun-Vezinet F. Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial. *Antivir Ther* 2002;7(3):211-8.
118. Chouquet C, Autran B, Gomard E, Bouley JM, Calvez V, Katlama C, Costagliola D, Riviere Y. Correlation between breadth of memory HIV-specific cytotoxic T cells, viral load and disease progression in HIV infection. *AIDS* 2002;16(18):2399-407.
119. del Giudice P, Mary-Krause M, Pradier C, Grabar S, Dellamonica P, Marty P, Gastaut JA, Costagliola D, Rosenthal E. Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus. *J Infect Dis* 2002;186(9):1366-70.
120. Dulioust E, Du AL, Costagliola D, Guibert J, Kunstmann JM, Heard I, Juillard JC, Salmon D, Leruez-Ville M, Mandelbrot L, Rouzioux C, Sicard D, Zorn JR, Jouannet P, De Almeida M. Semen alterations in HIV-1 infected men. *Hum Reprod* 2002;17(8):2112-8.
121. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. *Lancet* 2002;360(9327):119-29.
122. Gaboulaud V, Parquet A, Tahiri C, Claeysens S, Potard V, Faradji A, Peynet J, Costagliola D. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort. *Br J Haematol* 2002;116(2):383-9.
123. Huillard d'Aignaux JN, Cousens SN, Maccario J, Costagliola D, Alpers MP, Smith PG, Alperovitch A. The incubation period of kuru. *Epidemiology* 2002;13(4):402-8.
124. Katlama C, Carcelain G, Duvivier C, Chouquet C, Tubiana R, De Sa M, Zagury L, Calvez V, Autran B, Costagliola D. Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study--ANRS 082. *AIDS* 2002;16(15):2027-34.
125. Leruez-Ville M, Dulioust E, Costagliola D, Salmon D, Tachet A, Finkielsztejn L, De Almeida M, Silbermann B, Sicard D, Jouannet P, Rouzioux C. Decrease in HIV-1 seminal shedding in men receiving highly active antiretroviral therapy: an 18 month longitudinal study (ANRS EP012). *AIDS* 2002;16(3):486-8.
126. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, Matheron S, Lamotte C, Guiramand S, Costagliola D, Brun-Vezinet F, Clavel F, Girard PM. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. *AIDS* 2002;16(5):727-36.
127. Tassie JM, Grabar S, Lancar R, Deloumeaux J, Bentata M, Costagliola D. Time to AIDS from 1992 to 1999 in HIV-1-infected subjects with known date of infection. *J Acquir Immune Defic Syndr* 2002;30(1):81-7.
128. Thibault V, Delaugerre C, Calvez V, Costagliola D, Tubiana R, Katlama C. Interleukin 2 treatment does not modify hepatitis B or C replication in human immunodeficiency virus-infected patients: results from a randomized control trial. *Hepatology* 2002;35(1):238-9.

2003

129. Abgrall S, Duval X, Joly V, Descamps D, Matheron S, Costagliola D. Clinical and Immunologic Outcome in Patients with Human Immunodeficiency Virus Infection, According to Virologic Efficacy in the Year after Virus Undetectability, during Antiretroviral Therapy. *Clin Infect Dis* 2003;37(11):1517-26.
130. Ait-Arkoub Z, Robert-Visse C, Calvez V, Costagliola D, Autran B, Candotti D, Agut H. No influence of human herpesvirus 8 infection on the progression of HIV-1 infection in initially asymptomatic patients. *AIDS* 2003;17(9):1394-6.
131. Bossi P, Peytavin G, Lamotte C, Calvez V, Bricaire F, Costagliola D, Katlama C. High indinavir plasma concentrations in HIV-positive patients co-infected with hepatitis B or C virus treated with low doses of indinavir and ritonavir (400/100 mg twice a day) plus two nucleoside reverse transcriptase inhibitors. *AIDS* 2003;17(7):1108-10.
132. Brun-Vezinet F, Descamps D, Ruffault A, Masquelier B, Calvez V, Peytavin G, Telles F, Morand-Joubert L, Meynard JL, Vray M, Costagliola D. Clinically relevant interpretation of genotype for resistance to abacavir. *AIDS* 2003;17(12):1795-802.

133. Carcelain G, Saint-Mezard P, Altes HK, Tubiana R, Grenot P, Rabian C, de Boer R, Costagliola D, Katlama C, Debre P, Autran B. IL-2 therapy and thymic production of naive CD4 T cells in HIV-infected patients with severe CD4 lymphopenia. *AIDS* 2003;17(6):841-50.
134. Chaix ML, Descamps D, Harzic M, Schneider V, Deveau C, Tamalet C, Pellegrin I, Izopet J, Ruffault A, Masquelier B, Meyer L, Rouzioux C, Brun-Vezinet F, Costagliola D. Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. *AIDS* 2003;17(18):2635-2643.
135. Chene G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, Dabis F, Lundgren J, D'Arminio Monforte A, de Wolf F, Hogg R, Reiss P, Justice A, Leport C, Staszewski S, Gill J, Fatkenheuer G, Egger ME. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. *Lancet* 2003;362(9385):679-86.
136. Delaugerre C, Goullain K, Tubiana R, Carcelain G, Marcelin AG, Chouquet C, Mouroux M, Duvivier C, Autran B, Costagliola D, Katlama C, Calvez V. Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm³) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial). *Antivir Ther* 2003;8(3):233-7.
137. Duvivier C, Astriti M, Marcelin AG, Aït Mohand H, Schneider L, Agher R, Ghosn J, Bricaire F, Costagliola D, Calvez V, Peytavin G, Katlama C. Efficacy and safety of ritonavir/indinavir 100/400 BID in combination with two nucleoside analogues in antiretroviral treatment-naïve HIV-infected individuals. *Antivir Ther* 2003;8(6):603-9.
138. Goullain K, Salmon D, Gault E, Leport C, Katlama C, Matheron S, Costagliola D, Mazon MC, Fillet AM. Quantitation of cytomegalovirus (CMV) DNA by real-time PCR for occurrence of CMV disease in HIV-infected patients receiving highly active antiretroviral therapy. *J Med Virol* 2003;69(3):401-7.
139. Herida M, Mary-Krause M, Kaphan R, Cadranel J, Poizot-Martin I, Rabaud C, Plaisance N, Tissot-Dupont H, Boue F, Lang JM, Costagliola D. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. *J Clin Oncol* 2003;21(18):3447-53.
140. Kousignian I, Abgrall S, Duval X, Descamps D, Matheron S, Costagliola D. Modeling the time course of CD4 T-lymphocyte counts according to the level of virologic rebound in HIV-1-infected patients on highly active antiretroviral therapy. *J Acquir Immune Defic Syndr* 2003;34(1):50-7.
141. Kousignian I, Autran B, Chouquet C, Calvez V, Gomard E, Katlama C, Riviere Y, Costagliola D. Markov modelling of changes in HIV-specific cytotoxic T-lymphocyte responses with time in untreated HIV-1 infected patients. *Stat Med* 2003;22(10):1675-90.
142. Marcelin AG, Lamotte C, Delaugerre C, Ktorza N, Ait Mohand H, Cacace R, Bonmarchand M, Wirten M, Simon A, Bossi P, Bricaire F, Costagliola D, Katlama C, Peytavin G, Calvez V. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. *Antimicrob Agents Chemother* 2003;47(2):594-600.
143. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. *AIDS* 2003;17(17):2479-86.
144. Mazon MC, Fillet AM, Salmon D, Boukli N, Houhou N, Senechal B, Matheron S, Gozlan J, Leport C, Katlama C, Scieux C, Imbert BM, Deny P, Bour JB, Freymuth F, Chanzy B, Chaput S, Costagliola D. Quantitative markers for cytomegalovirus disease in HIV-infected patients receiving highly active antiretroviral therapy. *AIDS* 2003;17(5):784-6.
145. Thiebaut R, Jacqmin-Gadda H, Leport C, Katlama C, Costagliola D, Le Moing V, Morlat P, Chene G. Bivariate longitudinal model for the analysis of the evolution of HIV RNA and CD4 cell count in HIV infection taking into account left censoring of HIV RNA measures. *J Biopharm Stat* 2003;13(2):271-82.
146. Valantin MA, Aubron-Olivier C, Ghosn J, Laglenne E, Pauchard M, Schoen H, Bousquet R, Katz P, Costagliola D, Katlama C. Polylactic acid implants (New-Fill)(R) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. *AIDS* 2003;17(17):2471-7.
147. Vray M, Meynard JL, Dalban C, Morand-Joubert L, Clavel F, Brun-Vezinet F, Peytavin G, Costagliola D, Girard PM. Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088). *Antivir Ther* 2003;8(5):427-34.

2004

148. Autran B, Costagliola D, Murphy R, Katlama C. Evaluating therapeutic vaccines in patients infected with HIV. *Expert Rev Vaccines* 2004;3 Suppl 1(4):S169-S177.
149. Bonnet F, Lewden C, May T, Heripret L, Jouglu E, Bevilacqua S, Costagliola D, Salmon D, Chene G, Morlat P. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. *Cancer* 2004;101(2):317-24.

150. Bossi P, Peytavin G, Ait-Mohand H, Delaugerre C, Ktorza N, Paris L, Bonmarchand M, Cacace R, David DJ, Simon A, Lamotte C, Marcelin AG, Calvez V, Bricaire F, Costagliola D, Katlama C. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. *HIV Med* 2004;5(5):352-9.
151. Brun-Vezinet F, Costagliola D, Ait Khaled M, Calvez V, Clavel F, Clotet B, Haubrich R, Kempf D, King M, Kuritzkes D, Lanier R, Miller M, Miller V, Phillips A, Pillay D, Schapiro J, Scott J, Shafer R, Zazzi M, Zolopa A, DeGrutolla V. Clinically validated genotype analysis: guiding principles and statistical concerns. *Antiviral Therapy* 2004 ; 9(4) :465-78.
152. Deuffic-Burban S, Wong JB, Valleron AJ, Costagliola D, Delfraissy JF, Poynard T. Comparing the public health burden of chronic hepatitis C and HIV infection in France. *J Hepatol* 2004;40(2):319-26.
153. Deuffic-Burban S, Wong JB, Valleron AJ, Costagliola D, Delfraissy JF, Poynard T. Reply. *J Hepatol* 2004;41(2):354-5.
154. Grabar S, Kousignian I, Sobel A, Lebras P, Gasnault J, Enel P, Jung C, Mahamat A, Lang JM, Costagliola D. Immunologic and clinical responses to HAART over 50 years of age. Results from the French Hospital Database on HIV. *AIDS* 2004; 18(15):2029-2038.
155. Heard I, Potard V, Costagliola D, Kazatchkine M. Contraceptive use in HIV-positive women. *J Acquir Immune Defic Syndr* 2004;36(2):714-720.
156. Katlama C, Dominguez S, Goullain K, Duvivier C, Delaugerre C, Legrand M, Tubiana R, Reynes J, Molina JM, Peytavin G, Calvez V, Costagliola D, for the GIGHAART study group. Benefit of treatment interruption prior to salvage therapy in HIV-infected patients with multiple therapeutic failures: A randomized controlled trial (ANRS 097). *AIDS* 2004;18(2): 217-26.
157. Lastere S, Dalban C, Collin G, Descamps D, Girard PM, Clavel F, Costagliola D, Brun-Vezinet F. Impact of insertions in the HIV-1 p6 PTAPP region on the virological response to amprenavir. *Antivir Ther* 2004;9(2):221-7.
158. Marcelin AG, Affolabi D, Lamotte C, Ait-Mohand H, Delaugerre C, Wirden M, Voujon D, Bossi P, Ktorza N, Bricaire F, Costagliola D, Katlama C, Peytavin G, Calvez V. Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients. *J Med Virol* 2004;74(1):16-20.
159. Marcelin AG, Dalban C, Peytavin G, Lamotte C, Agher R, Delaugerre C, Wirden M, Conan F, Dantin C, Katlama C, Costagliola D, Calvez V. Clinically relevant interpretation of genotype and relationship with plasma concentrations for resistance to Saquinavir/Ritonavir in HIV-1 protease inhibitor experienced patients. *Antimicrobial Agents and Chemotherapy* 2004;48(12):4687-92.
160. Mary-Krause M, Herida M, Costagliola D, Lavole A, Cadranet J. In reply. *J Clin Oncol* 2004;22(7):1349-50.
161. Masquelier B, Tamalet C, Montes B, Descamps D, Peytavin G, Bocket L, Wirden M, Izopet J, Schneider V, Ferre V, Ruffault A, Palmer P, Trylesinsky A, Miller M, Brun-Vezinet F, Costagliola D and the ANRS AC11 resistance group. Genotypic determinants of the virological response to tenofovir DF in NRTI-experienced patients. *Antivir Ther.* 2004;9(3):315-323.
162. May T, Lewden C, Bonnet F, Heripret L, Bevilacqua S, Jouglu E, Costagliola D, Morlat P, Salmon D, Chêne G and le groupe d'étude Mortalité 2000. Causes et caractéristiques des décès des patients infectés par le VIH-1, en succès immuno-virologique sous traitement antirétroviral. *Presse Med* 2004;33(21):1487-1492.
163. Phillips A, Ledergerber B, Lundgren J, Hogg B, D'Arminio Monforte A, Castelli F, Walker S, Staszewski S, Dabis F, Gazzard B, Saag M, Petoumenos K, Johnson M, Scullard G, Gill J, James I, Fischer M, Mussini C, Klein M, Costagliola D for the Collaboration of HIV Cohorts. Nucleoside Analogue Use Before and During Highly Active Antiretroviral Therapy and Virus Load Rebound. *J Infect Dis* 2004;190(4):675-687.
164. Prasitwattanaseree S, Lallemand M, Costagliola D, Jourdain G, Mary JY. Influence of mother and infant zidovudine treatment duration on the age at which HIV infection can be detected by polymerase chain reaction in infants. *Antivir Ther* 2004;9(2):179-85.
165. Supervie V, Costagliola D. The unrecognized French BSE epidemic. *Vet Res* 2004;35(3):349-362.
166. Wirden M, Delaugerre C, Marcelin AG, Ktorza N, Ait Mohand H, Dominguez S, Schneider L, Ghosn J, Pauchard M, Costagliola D, Katlama C, Calvez V. Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy. *Antimicrob Agents Chemother* 2004;48(2):644-7.

2005

167. Alatrakchi A, Duvivier C, Costagliola D, Samri A, Marcelin AG, Kamkamidze G, Astriti M, Agher R, Calvez V, Autran B, Katlama C. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication. *AIDS* 2005; 19(1):25-33.

168. Barin F, Meyer L, Lancar R, Deveau C, Gharib M, Laporte A, Desenclos JC, Costagliola D. An immunoassay for the identification of recent HIV-1 infections: development, validation and use on dried serum spots. *J Clin Microbiol* 2005;43(9):4441-4447.
169. Bonnet F, Lewden C, May T, Heripret L, Jouglu E, Bevilacqua S, Costagliola D, Salmon D, Chene G, Morlat P. Opportunistic infections as causes of death in HIV-infected patients in the HAART era in France. *Scand J Infect Dis* 2005; 37(6-7): 482-487.
170. Costagliola D, Potard V, Duvivier C, Pradier C, Dupont C, Salmon D, Duval X for the French Hospital Database on HIV. Impact of newly available drugs on clinical progression in patients with virologic failure after exposure to three classes of antiretrovirals. *Antivir Ther* 2005; 10(4):563-573.
171. Delaugerre C, Peytavin G, Dominguez S, Marcelin AG, Duvivier C, Gourlain K, Amellal B, Legrand M, Costagliola D, Katlama C, Calvez V. Virological and pharmacological factors associated with the virological response of salvage therapy after an 8-week of treatment interruption in a context of very advanced disease (GIGHAART ANRS 097). *J Med Virol* 2005; 77(3): 345-350.
172. Descamps D, Chaix ML, André P, Brodard V, Cottalorda J, Deveau C, Harzic M, Ingrand D, Izopet J, Kohli E, Masquelier B, Mouajjah S, Palmer P, Pellegrin I, Plantier JC, Poggi C, Rogez S, Ruffault A, Schneider V, Signori-Schmück A, Tamalet C, Wirden M, Rouzioux C, Brun-Vezinet F, Meyer L, Costagliola D. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naïve chronically infected patients in 2001-2002. *J Acquir Immune Defic Syndr* 2005; 38(5):545-52.
173. Funck-Brentano I, Dalban C, Veber F, Quartier P, Hefez S, Costagliola D, Blanche S Evaluation of a peer support group therapy for HIV-infected adolescents. *AIDS* 2005; 19(14) :1501-1508.
174. Ghosn J, Guiguet M, Jardel C, Benyaou R, Zeller V, Simon A, Valantin MA, Amellal B, Assoumo L, Hogrel JY, Costagliola D, Katlama C, Lombès A. Muscle and liver lactate metabolism in HAART-treated and naïve HIV-infected patients: the MITOVIR study. *Antivir Ther* 2005; 10(4):543-550.
175. Ghosn J, Wirden M, Ktorza N, Peytavin G, Aït-Mohand H, Schneider L, Dominguez S, Bricaire F, Calvez V, Costagliola D, Katlama C. No benefit of a structured treatment interruption based on genotypic resistance in heavily pre-treated HIV-infected patients: the Reverse study. *AIDS* 2005; 19(15): 1643-1647.
176. Grabar S, Le Moing V, Goujard C, Egger M, Leport C, Kazatchkine M, Weiss L, Costagliola D. Response to HAART at 6 months and long-term disease progression in HIV-1 infection. *J Acquir Immune Defic Syndr* 2005; 39(3):284-292.
177. Heard I, Potard V, Foulot H, Chapron C, Costagliola D, Kazatchkine M. High rate of recurrence of cervical intraepithelial neoplasia after surgery in HIV-positive women. *J Acquir Immune Defic Syndr* 2005; 39(4):412-418.
178. Lewden C, Salmon D, Morlat P, Bevilacqua S, Jouglu E, Bonnet F, Heripret L, Costagliola D, May T, Chêne G and the Mortality 2000 study group. Causes of death among HIV-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. *Int J Epidemiol* 2005; 34(1):121-30.
179. Martinez V, Costagliola D, Bonduelle O, N'Go N, Schnuriger A, Théodorou I, Clauvel JP, Sicard D, Agut H, Debré P, Rouzioux C, Autran B and the ALT study group. Combination of HIV-1-specific CD4 Th1 responses and IgG2 antibodies is the best predictor for persistence of long-term non progression. *J Infect Dis* 2005; 191(12):2053-2063.
180. Masquelier B, Costagliola D, Schmuck A, Cottalorda J, Schneider V, Izopet J, Calvez V, Descamps D, Poggi C, Brun-Vézinet F and the ANRS resistance study group. Prevalence of complete resistance to at least two classes of antiretroviral drugs in treated HIV-1-infected patients: a French nationwide study. *J Med Virol* 2005; 76(4):441-446.
181. Sacre K, Carcelain G, Cassoux N, Fillet AM, Costagliola D, Vittecoq D, Salmon D, Amoura Z, Katlama C, Autran B, the RESTIMOP and ALT study groups. Repertoire, diversity and differentiation of HCMV-specific CD8 T cells are associated with immune protection against HCMV disease. *J Exp Med* 2005; 201(12):1999-2010.
182. Salmon-Ceron D, Lewden C, Morlat P, Bevilacqua S, Jouglu E, Bonnet F, Heripret L, Costagliola D, May T, Chene G.. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. *J Hepatol* 2005;42(6):799-805.
183. Stahl D, Lacroix-Desmazes S, Misra N, Karmochkine M, Kaveri S. V, Costagliola D, Sibrowski W, Kazatchkine MD. Alterations of self-reactive antibody repertoires in HIV disease: An insight into the role of T cells in the selection of autoreactive B cells. *Immunol Lett* 2005; 99(2) 198-208.
184. Tubiana R, Carcelain G, Vray M, Gourlain K, Dalban C, Chermak A, Rabian C, Vittecoq D, Simon A, Bouvet E, El Habib R, Costagliola D, Calvez V, Autran B, Katlama C for the Vacciter Study group. Therapeutic immunization with a Human Immunodeficiency virus (HIV) type 1 recombinant canarypox vaccine in chronically HIV-infected patients: the Vacciter Study (ANRS 094). *Vaccine* 2005; 23(34):4292-4301.

185. Wensing AMJ, van de Vijver DA, Angarano G, Åsjö B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kücherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, Eline L, de Coul O, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stöckl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CA on behalf of the SPREAD Programme. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. *J Infect Dis* 2005; 192(6): 958-966.

2006

186. Abgrall S, Yeni PG, Bouchaud O, Costagliola D, and the Clinical Epidemiology Group from the French Hospital Database on HIV. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir. *AIDS* 2006; 20(16): 2099-2106.
187. Boué F, Gabarre J, Gisselbrecht C, Reynes J, Cheret A, Bonnet F, Billaud E, Raphael M, Lancar R, Costagliola D. Phase II trial of CHOP plus rituximab in patients with HIV-associated non Hodgkin lymphoma. *J Clin Oncol* 2006; 24(25): 4123-4128.
188. Braibant M, Brunet S, Costagliola D, Rouzioux C, Agut H, Katinger H, Autran B, Barin F. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity. *AIDS* 2006 ; 20(15):1923-1930.
189. Descamps D, Delaugerre C, Masquelier B, Ruffault A, Marcelin AG, Izopet J, Chaix ML, Calvez V, Brun-Vézinet F, Costagliola D and the ANRS Resistance Group. Repeated HIV-1 Resistance genotyping external quality assessments improve virology laboratory performance. *J Med Virol* 2006; 78(2): 153-60.
190. Deuffic-Burban S, Costagliola D. Including pre-AIDS mortality in back-calculation model to estimate HIV prevalence in France, 2000. *Eur J Epidemiol* 2006; 21(5): 389-96.
191. Fardet L, Mary-Krause M, Heard I, Partisani ML, Costagliola D for the French Hospital Database on HIV. Influence of gender and HIV transmission group on initial HAART prescription and treatment response. *HIV Med* 2006; 7(8): 520-529.
192. Flandre P, Costagliola D. On the comparison of artificial network and interpretation systems based on genotype resistance mutations in HIV-1 infected patients. *AIDS* 2006; 20(16): 2118-2120.
193. Funck-Brentano C, Raphaël M, Lafontaine M, Arnould JP, Verstuyft C, Lebot M, Costagliola D, Rousset R. Effects of type of smoking (pipe, cigars or cigarettes) on biological indices of tobacco exposure and toxicity. *Lung Cancer* 2006; 54: 11-18.
194. Grabar S, Abraham B, Mahamat A, Del Giudice P, Rosenthal E, Costagliola D. Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement. *J Clin Oncol* 2006; 24(21): 3408-3414.
195. Grabar S, Weiss L, Costagliola D. HIV infection in older patients in the HAART era. *J Antimicrob Chemoth* 2006; 57(1): 4-7.
196. Heard I, Potard V, Costagliola D. Limited impact of immunosuppression and HAART on the incidence of cervical squamous Intraepithelial lesions in HIV-positive women. *Antivir Ther* 2006; 11(8): 1091-1096.
197. Hernán MA, Lanoy E, Costagliola D, Robins JM. Comparison of dynamic treatment regimes via inverse probability weighting. *Basic Clin Pharmacol Toxicol* 2006; 98(3): 237-242.
198. Hogg R, May M, Phillips A, Costagliola D, Sterne J, Sabin C, De Wolf F, Ledergerber B, D'Arminio Monforte A, Justice A, Gill J, Fusco G, Staszewski S, Rockstroh J, Chêne G, Egger M. Rates of disease progression according to initial HAART regimen A collaborative analysis of 12 prospective cohort studies. *J Infect Dis* 2006; 194(5): 612-622.
199. Lanoy E, Mary-Krause M, Tattevin P, Dray-Spira R, Duvivier C, Fischer P, Obadia Y, Lert F, Costagliola D and the Clinical Epidemiology Group of the French Hospital Database on HIV infection. Predictors identified for losses to follow-up among HIV-seropositive patients. *J Clin Epidemiol* 2006; 59(8): 829-835.
200. Launay O, Duval X, Dalban C, Descamps D, Peytavin G, Certain A, Mouajjah S, Ralaimazava P, Verdon R, Costagliola D, Clavel F for the ANRS 109 VISTA Study Group. Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109). *Antivir Ther* 2006; 11(7): 889-899.
201. Lewden C, Jouglé E, Alioum A, Pavillon G, Lièvre L, Morlat P, Salmon D, May T, G Chêne G, Costagliola D and the Mortalité 2000 Study Group. Number of deaths among HIV-infected adults in France in 2000, three-source capture-recapture estimation. *Epidemiol Infect* 2006; 134(6): 1353-1359.
202. Lievre L, Deveau C, Gerbe J, Enel P, Tran L, De Castro N, Costagliola D, Meyer L, the Primo Study Group, and the Clinical Epidemiology Group of the French Hospital Database on HIV. Yearly number of patients diagnosed with primary HIV-1 infection in France estimated by a capture-recapture approach. *AIDS* 2006; 20(18): 2392-2395.

203. Mary-Krause M, Billaud E, Poizot-Martin I, Simon A, Dhiver C, Dupont C, Salmon D, Roudière L, Costagliola D. Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy (cART). *AIDS* 2006; 20(12):1627-1635.
204. May MT, Sterne JAC, Costagliola D, Sabin CA, Phillips AN, Justice AC, Dabis F, Gill J, Lundgren J, Hogg RS, de Wolf F, Fätkenheuer G, Staszewski S, d'Arminio Monforte A, Egger M. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. *Lancet* 2006; 368: 451-458.
205. Roux C, Briot K, Dumarcet N, Bourgoin M, Chapurlat R, Christin-Maitre S, Cortet B, Costagliola D, Diebolt V, Lacoïn F, Letombe B, Oberlin F, Orcel P, Ravaud P, Seret P, Thomas T, Vogel JY, Barna A, Nouyrigat E, Veyries ML, Yoldjian I. Drug Treatment of postmenopausal osteoporosis: What's New in 2006. *Presse Med.* 2006; 35(10-C2):1529-1539.
206. Spano JP, Carcelain G, Katlama C, Costagliola D. Non-AIDS-defining malignancies in HIV patients: clinical features and perspectives. *Bull Cancer* 2006; 93(1): 37-42.
207. Supervie V, Costagliola D. How was the French BSE epidemic underestimated? *C R Biol* 2006; 329(2): 106-116.
208. van de Vijver DA, Wensing AMJ, Angarano G, Asjo B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kucherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, Op de Coul E, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stockl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CAB on behalf of the SPREAD Programme. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. *J Acquir Immune Defic Syndr* 2006; 41(3): 352-360.
209. Vieillard V, Costagliola D, Simon A, Debré P, and the French Asymptomatiques à Long Terme (ALT) Study Group. Specific adaptive humoral response against a gp41 motif inhibits CD4⁺ T cell sensitivity to NK lysis during HIV-1 infection. *AIDS* 2006; 20(14): 1795-1804.
210. Vignot M, Perez L, Lanternier F, Costagliola D, Caumes E, Bricaire F. La surveillance infirmière au cours des traitements antituberculeux. *Soins* 2006; 703: 19-21.

2007

211. Abgrall S, Yeni PG, Bouchaud O, Costagliola D, and the Clinical Epidemiology Group of the French Hospital Database on HIV. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first PI-containing antiretroviral combination to a three-drug regimen containing efavirenz, nevirapine or abacavir. *Clin Inf Dis* 2007; 44(1): 120-127.
212. Ahmed AA, Katlama C, Ghosn J, Guiguet M, Costagliola D. Evaluation of compliance with antiretroviral treatment of HIV patients in Djibouti, 2005. *East Mediterr Health J.* 2007;13(6):1286-1297.
213. Almeida JR, Price DA, Papagno L, Aït Arkoub Z, Sauce D, Bornstein E, Ashe TEr, Samri A, Schnuriger A, Theodorou I, Costagliola D, Rouzioux C, Agut H, Marcelin AG, Douek D, Autran B, Appay V. Superior control of HIV-1 replication by CD8⁺ T-cells is reflected by their avidity, functionality and clonal turnover. *J Exp Med* 2007; 204(10):2473-2485.
214. Calavas D, Supervie V, Morignat E, Costagliola D, Ducrot C. Complementary approach of data analysis and modelling to estimate the pattern of the BSE epidemic: the example of France. *Risk anal* 2007; 27(5): 1141-1150.
215. Chaix ML, Desquilbet L, Descamps D, Costagliola D, Deveau C, Galimand J, Goujard C, Signori-Schmück A, Schneider V, Tamalet C, Pellegrin I, Wirden M, Masquelier B, Brun-Vezinet F, Rouzioux C, Meyer L, for the French PRIMO Cohort Study Group (ANRS CO 06) and the French ANRS AC11 Resistance Study Group. Suboptimal virological response to HAART in patients infected with HIV-1 resistant strains and treated at the time of primary infection: The French ANRS Resistance Network Survey. *Antivir Ther* 2007; 12: 1305-1310.
216. Costagliola D. Observation versus intervention in the evaluation of drugs: the story of hormone replacement therapy. *C R Biol* 2007; 330(4): 347-355.
217. Costagliola D. Faut-il craindre une épidémie de grande taille pour le nouveau variant de la maladie de Creutzfeldt-Jakob? *Med Sci* 2007; 23(5): 550-550.
218. Costagliola D, Descamps D, Assoumou KL, Morand-Joubert L, Marcelin AG, Brodard V, Delaugerre C, Mackiewicz V, Ruffault A, Izopet J, Plantier JC, Tamalet C, Yerly S, Saidi S, Brun-Vezinet F, Masquelier B, and the ANRS AC11 Resistance Study Group. Prevalence of HIV-1 drug resistance in treated patients: A French nationwide study. *J Acquir Immune Defic Syndr* 2007; 46(1):12-18.
219. Flahault A, Costagliola D. Le dépistage du cancer du poumon par le scanner hélicoïdal est-il justifié ? *Med Sci* 2007; 23(3): 333-334.

220. Guiguet M, Furco A, Tattevin P, Costagliola D, Molina JM, and the French Hospital Database on HIV Clinical Epidemiology Group. HIV-associated *Isospora belli* infection: incidence and risk factors in the French Hospital Database on HIV. *HIV Med* 2007; 8(2): 124-130.
221. Kim MJ, Leclercq P, Lanoy E, Cervera P, Antuna-Puente B, Maachi M, Dorofeev E, Slama L, Valantin MA, Costagliola D, Lombes A, Bastard JP, Capeau J. A six-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients: the ANRS EP29 Lipostop Study. *Antivir Ther* 2007 ; 12: 1273-1283.
222. Lanoy E, Mary-Krause M, Tattevin P, Perbost I, Poizot-Martin I, Dupont C, Costagliola D and ANRS CO04 French Hospital Database on HIV Clinical Epidemiological Group. Frequency, determinants and consequences of delayed access to care for HIV infection in France. *Antivir Ther* 2007; 12(1): 89-96.
223. Lanternier F, Dalban C, Perez L, Bricaire F, Costagliola D, Caumes E. Tolerability of anti-tuberculosis treatment and HIV serostatus. *Int J Tuberc Lung Dis* 2007; 11(11): 1203-1209.
224. Malet I, Roquebert B, Dalban C, Wirlden M, Amellal B, Agher R, Simon A, Katlama C, Costagliola D, Calvez V, Marcelin AG. Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. *J Infect.* 2007; 54(4): 367-374.
225. May M, Sterne JAC, Sabin C, Costagliola D, Justice AC, Thiébaud R, Gill J, Phillips A, Reiss P, Hogg R, Ledergerber B, D'Arminio Monforte A, Schmeisser N, Staszewski S, Egger M for The Antiretroviral Therapy (ART) Cohort Collaboration. Prognosis of HIV-1 infected patients up to five years after initiation of HAART: collaborative analysis of prospective studies *AIDS* 2007; 21(9): 1185-1197.
226. Nakayama EE, Carpentier W, Costagliola D, Shioda T, Iwamoto A, Debre P, Yoshimura K, Autran B, Matsushita S, Theodorou I. Wild type and H43Y variant of human TRIM5a show similar anti-human immunodeficiency virus type 1 activity both *in vivo* and *in vitro*. *Immunogenetics* 2007; 59(6):511-515.
227. Potard V, Rey D, Mokhtari S, Frixon-Marin V, Pradier C, Rozenbaum W, Brun-Vezinet F, Costagliola D. First-line HAART regimens in 2001-2002 in the French Hospital Database on HIV: Combination prescribed and biological outcomes. *Antivir Ther* 2007; 12(3): 317-324.
228. Sakarovich C, Rouet F, Murphy G, Minga A, Alioum A, Dabis F, Costagliola D, Salamon R, Parry JV, Barin F. Do tests devised to detect recent HIV-1 infection provide reliable estimates of incidence in Africa ? *J Acquir Immune Defic Syndr* 2007; 45(1): 115-122.
229. Senda S, Blanche S, Costagliola D, Cibert C, Nigon F, Firtion G, Floch C, Parat S, Viegas-Péquignot E. Altered heterochromatin organization after perinatal exposure to Zidovudine (AZT). *Antivir Ther* 2007; 12(2): 179-187.
230. Soulie C, Marcelin AG, Ghosn J, Amellal B, Assoumou L, Lambert S, Duvivier C, Costagliola D, Katlama C, Calvez V. HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART. *AIDS* 2007; 21(16):2243-2245.
231. Sterne JA, May MT, Sabin CA, Phillips AN, Costagliola D, Chene G, Justice AC, de Wolf F, Hogg RS, Bategay M, d'Arminio Monforte A, Fätkenheuer G, Staszewski S, Gill JM, Egger M for the Antiretroviral Therapy Cohort Collaboration. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: Collaborative analysis of cohorts of HIV-1 infected patients. *J Acquir Immune Defic Syndr* 2007 ; 46(5):607-615.
232. Supervie V Costagliola D. Estimating incidence of the French BSE infection using a joint analysis of both asymptomatic and clinical BSE surveillance data. *Math Biosc* 2007; 209(1):90-107.
233. Supervie V Costagliola D. BSE risk assessment as a basis for updating French screening policy. *Risk anal* 2007, 27(5): 1131-1140.
234. Verdoux H, Ropers J, Costagliola D, Clavel-Chapelon F, Paoletti X. Serious psychiatric outcome of subjects prenatally exposed to diethylstilbestrol in the E3N cohort study. *Psychol Med* 2007; 37(9):1315-22.

2008

235. Assoumou L, Brun-Vézinet F, Cozzi-Lepri A, Kuritzkes D, Phillips A, Zolopa A, DeGruttola V, Miller V, Costagliola D on behalf of the Standardization and Clinical Relevance of HIV Drug Resistance Testing Project from the Forum for Collaborative HIV Research. Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response. *J Infect Dis* 2008; 198(4): 470-480.
236. Autran B, Murphy R, Costagliola D, Tubiana R, Clotet B, Gatell J, Staszewski S, Assoumou L, El-Habib R, Calvez V, Walker B, Kalama C and the ORVACS Study Group. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). *AIDS* 2008 ; 22(11): 1313–1322.
237. Braibant M, Agut H, Rouzioux C, Costagliola D, Autran B, Barin F. Characteristics of the env genes of human immunodeficiency virus type 1 quasispecies in long-term non progressors with broadly neutralizing antibodies. *J Acquir Immune Defic Syndr* 2008; 47(3): 274-284.

238. Costagliola D. Atteintes démyélinisantes du système nerveux central et vaccination contre l'hépatite B : un nouvel épisode de l'interminable saga française ! *Rev Epidem Sant Pub* 2008; 56(6): 379-381.
239. Costagliola D. Epidémiologie de l'infection à VIH en France et en Europe. *Rev Med Interne*. 2008; 29 Suppl 3: S266-8.
240. Costagliola D. Prix Nobel de Médecine 2008 (Françoise Barré-Sinoussi et Luc Montagnier) : Une vie consacrée à combattre le Sida. *Med Sci* 2008;24(11):979-980.
241. Costagliola D, Damond F, Palmer P, Rouzioux C, Brun-Vézinet F. One or two ELISA tests on the first serum sample for initial diagnosis of HIV-1 infection? *AIDS* 2008; 22(15):2042-2044.
242. Cozzi-Lepri A, Costagliola D, Brun-Vézinet F, De Grutolla V, Kuritzkes D, Cheng B, Miller V, Phillips AN. Initiatives for developing and comparing genotype interpretation systems: external validation of existing rule-based interpretation systems for abacavir against virological response. *HIV Med* 2008; 9(1): 27-40.
243. Delaugerre C, Flandre P, Marcelin AG, Descamps D, Tamalet C, Cottalorda J, Schneider V, Yerly S, le Goff J, Morand-Joubert L, Chaix ML, Costagliola D, Calvez V, and ANRS AC11 Resistance group. National survey of prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutation. *J Med Virol* 2008; *J Med Virol*. 2008 Mar 21;80(5):762-765.
244. Descamps D, Assoumou L, Masquelier B, Marcelin AG, Saidi S, Tamalet C, Cottalorda J, Plantier JC, Montes B, Izopet J, Peytavin G, Yerly S, Schneider V, Delaugerre C, Ferré V, Ruffault A, Pallier C, Morand-Joubert L, Chaix ML, Calvez V, Brun-Vézinet F, Costagliola D and the ANRS AC-11 Resistance Study group. French National Observatory of HIV-1 Infected Patients Experiencing Virological Failure while Receiving Enfuvirtide Antiretroviral Therapy Containing Regimen. *J Antimicrob Chemoth* 2008; 62(3):451-455.
245. Duvivier C, Ghosn J, Assoumou L, Soulié C, Peytavin G, Calvez V, Algarte Génin M, Molina JM, Bouchaud O, Katlama C, Costagliola D on behalf of the ANRS 121 study group. Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short term fat distribution: Hippocampe-ANRS 121 Trial. *J Antimicrob Chemoth* 2008; 62(4): 797-808.
246. Foulot H, Heard I, Potard V, Costagliola D, Chapron C. Surgical management of cervical intraepithelial neoplasia in HIV-infected women. *Eur J Obstet Gynecol Reprod Biol* 2008; 141(2): 153-7.
247. Grabar S, Lanoy E, Allavena C, Mary-Krause M, Bentata M, Fischer P, Mahamat A, Rabaud C, Costagliola D on behalf of the Clinical Epidemiology Group of the French Hospital Database on HIV. Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. *HIV Med* 2008; 9(4):246-256.
248. Guiguet M, Porter K, Phillips A, Costagliola D, Babiker A, on behalf of the CASCADE Collaboration. Clinical progression rates by CD4 cell category before and after the initiation of combination antiretroviral therapy (cART). *The open AIDS journal* 2008; 2: 3-9.
249. Guiguet M, Mary-Krause M, Ename B, Costagliola D, Grabar S. Influence of control selection in nested case-control studies: the example of exposure to antiretroviral treatment (ART) and the risk of myocardial infarction (MI) in the French Hospital Database on HIV (FHDH-ANRS CO4). *Pharmacoepidemiol Drug Saf* 2008 17(5): 468-474.
250. Heard I, Costagliola D. Le cancer du col de l'utérus, nouvelles stratégies de dépistage ? *Med Sci* 2008;24(11):977-8.
251. Kousignian I, Abgrall S, Grabar S, Mahamat, Teicher E, Rouveix E, Costagliola D and the Clinical Epidemiology Group of the French Hospital Database on HIV. Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in patients with uncontrolled viral replication and profound immunodeficiency. *Clin Infect Dis* 2008; 46:296-304.
252. Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D, Eric Jouglu E, Semaille C, Morlat P, Salmon D, Cacoub P, Chêne G, the ANRS EN19 Mortalité Study Group and Mortavic. Changes in causes of death among adults infected by the Human Immunodeficiency Virus (HIV) between 2000 and 2005. The "Mortalité 2000 & 2005" surveys (ANRS EN19 and Mortavic). *J Acquir Immune Defic Syndr* 2008; 48(5): 590-598.
253. Masquelier B, Assoumou KL, Descamps D, Bocket L, Cottalorda J, Ruffault A, Marcelin AG, Morand-Joubert L, Tamalet C, Charpentier C, Peytavin G, Antoun Z, Brun-Vézinet F, Costagliola D on behalf of the ANRS Resistance Study Group. Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/1 ritonavir. *J Antimicrob Chemoth* 2008; 61(6):1362-1368.
254. Meyssonnier V, Costagliola D, Caumes E. Nevirapine associated toxicity in Niger. *HIV Med* 2008; 9(1): 62-63.
255. Mouala C, Houzé S, Guiguet M, Abboud P, Pialoux G, Viget N, Costagliola D, Matheron S. Imported malaria in HIV-infected patients enrolled in the ANRS CO4 FHDH study. *J Acquir Immune Defic Syndr* 2008; 49(1): 55-60.

256. Mugavero MJ, May M, Harris R, Saag MS, Costagliola D, Egger M, Phillips A, Günthard HF, Dabis F, Hogg R, de Wolf F, Fatkenheuer G, Gill MJ, Justice A, D'Arminio Monforte A, Lampe F, Miró JM, Staszewski S, Sterne JA. Does Short-term Virologic Failure Translate to Clinical Events in ARV-naïve Patients Initiating ART in Clinical Practice? *AIDS* 2008; 22(18):2481-92.
257. Murphy R, Costagliola D. Increased Cardiovascular Risk in HIV Infection: drugs, virus and immunity. *AIDS* 2008; 22(13):1625-1627.
258. Piketty C, Selinger-Leneman H, Grabar S, Duvivier C, Bonmarchand M, Abramowitz L, Costagliola D, Mary-Krause M, FHDH-ANRS CO 4. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. *AIDS* 2008; 22(10):1203-1211.
259. Sagot-Lerolle N, Lamine A, Chaix ML, Boufassa F, Aboulker JP, Costagliola D, Goujard C, Paller C, Delfraissy JF, Lambotte O; ANRS EP39 study. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. *AIDS*. 2008; 22(10):1125-9.
260. Selinger-Leneman H, Matheron S, Mahamat A, Moreau J, Costagliola D, Abgrall S, for the Clinical Epidemiology Group of the French Hospital Database on HIV (ANRS CO4). Dual nucleoside reverse transcriptase inhibitor therapy in the combination antiretroviral therapy era and predictors of discontinuation or switch to combination antiretroviral therapy. *J Acquir Immune Defic Syndr* 2008; 47(2):206-211.
261. Slama L, Lanoy E, Valantin MA, Bastard JP, Chermak A, Boutekadjirt A, William-Faltaos D, Billaud E, Molina JM, Capeau J, Costagliola D, Rozenbaum W. Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). *Antiviral therapy* 2008; 13(1): 67-76.
262. Spano JP, Costagliola D, Katlama C, Mounier N, Oksenhendler E, Khayat D. AIDS-related malignancies: state of the art and therapeutic challenges. *J Clin Oncol* 2008; 26(9): 4834–4842.
263. Valantin MA, E. Lanoy E, M. Bentata M, Kalmykova O, Boutekadjirt A, Allavena C, Rozenbaum W, Peytavin G, Amellal B, Calvez V, Costagliola D, Katlama C and the NONUKE ANRS 108 study team. Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96 week randomized ANRS 108 NONUKE trial. *HIV Med* 2008; 9(8): 625-635.
264. Vogt A, Mahé B, Costagliola D, Bonduelle O, Hadam S, Schaefer G, Schaefer H, Katlama C, Sterry W, Autran B, Blume-Peytavi U, Combadiere B. Transcutaneous anti-influenza vaccination promotes both CD4 and CD8 T cell immune responses in humans. *J Immunol* 2008;180(3):1482-1489.

2009

265. Ayouba A, Lien TT, Nouhin J, Vergne L, Aghokeng AF, Ngo-Giang-Huong N, Diop N, Kane CT, Valéa D, Rouet F, Joulia-Ekaza D, Toni TD, Nerrienet E, Ngole EM, Delaporte E, Costagliola D, Peeters M, Chaix ML. Low Prevalence of HIV-1 drug resistance mutations in untreated, recently infected patients, from Burkina Faso, Côte d'Ivoire, Senegal, Thailand and Vietnam: The ANRS 12134 study. *AIDS Res Hum Retroviruses* 2009; 25: 1193-1196.
266. Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro Murillo AM, Mocroft A, Bonnet F, Clifford G, Touloumi G, Miro JM, Chene G, Lundgren J, Egger M. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy: European multi-cohort study. *AIDS* 2009; 23(15):2029-2037.
267. Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro Murillo AM, Mocroft A, Bonnet F, Clifford G, Karafoulidou A, Miro JM, Chene G, Lundgren J, Egger M. Incidence and risk factors of HIV-related non-Hodgkin lymphoma in the era of combination antiretroviral therapy: European multi-cohort study *Antivir Ther*. 2009; 14(8): 1065-74.
268. Bonnet F, Burty C, Lewden C, Costagliola D, May T, Bouteloup V, Rosenthal E, Jouglu E, Cacoub P, Salmon D, Chene G, Morlat P. Changes in cancer mortality among HIV-infected patients: The Mortalité 2005 survey. *Clin Infect Dis* 2009; 48(5): 633-639.
269. Chaix ML, Descamps D, Wirden M, Bocket L, Delaugerre C, Tamalet C, Schneider V, Izopet J, Masquelier B, Rouzioux C, Meyer L, Costagliola D; ANRS AC11 Resistance Group; Cohort PRIMO ANRS CO 6; FHDH ANRS CO4 Study Groups. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. *AIDS* 2009; 23(6): 717-24.
270. Debre P, Costagliola D, Legrand R, Vieillard V. Towards a vaccine for HIV infection: Role of the gp41 envelope protein. *Bull Acad Natl Med* 2009; 193 (1): 127-136.
271. Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, Katlama C, Costagliola D, and the ANRS 121 Hippocampe study group. Greater decrease in bone mineral density with PI regimens compared to NNRTI regimens in HIV-1 infected naive patients. *AIDS* 2009; 23(7): 817-824.
272. Fontas E, Kousignian I, Pradier C, Duvivier C, Poizot-Martin I, Durier C, Jarrousse B, Weiss L, Levy Y, Costagliola D, on behalf of the FHDH ANRS CO4 and ANRS CO14. Interleukine 2 therapy does not increase the risk of Hodgkin's or non-Hodgkin's lymphoma in HIV-infected patients; results from FHDH ANRS CO4. *J Acquir Immune Defic Syndr* 2009; 50(2): 206-214.

273. Grabar S, Selinger-Leneman H, Abgrall S, Pialoux G, Weiss L, Costagliola D. Prevalence and comparative characteristics of long-term non-progressors and HIV controller patients in the French Hospital Database on HIV. *AIDS* 2009 ; 23(9):1163–1169.
274. Guiguet M, Boué F, Cadranet J, Lang JM, Rosenthal E, Costagliola D, on behalf of the Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. *Lancet Oncology* 2009; 10: 1152-1159.
275. Guiguet M, Kendjo E, Carcelain G, Abgrall S, Mary-Krause M, Tattevin P, Yazdanpanah Y, Costagliola D, Duval X, on behalf of the FHDH-ANRS CO4 Epidemiology Group. CD4 cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naïve patients with CD4 cell counts above 200/mm³. *Antivir Ther* 2009, 14(3): 451-457.
276. Hernan MA, McAdams M, McGrath N, Lanoy E, Costagliola D. Observation plans in longitudinal studies with time-varying treatments. *Stat Methods Med Res.* 2009; 18(1): 27–52.
277. Lanoy E, Lewden C, Lièvre L, Tattevin P, Boileau J, Aouba A, Chêne G, Costagliola D, ANRS CO4 FHDH and Groupe d'Etude Mortalité 2000. How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French Hospital Database on HIV, Mortalité 2000 Survey and death certificates. *HIV Med* 2009 ; 10(4): 236-245.
278. Lanoy E, May M, Mocroft A, Phillips A, Justice A, Chêne G, Furrer H, Sterling T, D'Arminio Monforte A, Force L, Gill J, Harris R, Hogg RS, Rockstroh J, Saag M, Staszewski S, de Wolf F, Sterne JAC, Costagliola D. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. *AIDS* 2009; 23(16):2199-2208.
279. Lièvre M, Costagliola D, Evans S, Fourrier A, Imbs JL, Levy-Bruhl D, Merle L, Micallef J, Oger E. Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood. *Neurology.* 2009; 73(17):1426-1427.
280. Marin B, Thiébaud R, Bucher HC, Rondeau V, Costagliola D, Dorrucchi M, Hamouda O, Prins M, Walker AS, Porter K, Sabin C, Chêne G on behalf of the CASCADE Collaboration. Non-AIDS defining deaths and immunodeficiency in the era of combination antiretroviral therapy. CASCADE, 1996-2006. *AIDS* 2009; 23(13):1743-1753.
281. Martinez V, Diemert MC, Braibant M, Potard V, Charuel JL, Barin F, Costagliola D, Caumes E, Clauvel JP, Autran B, Musset L and the ALT ANRS CO 15 study group. Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV-DNA and immune activation. *Clin Infect Dis.* 2009; 48(1): 123-32.
282. Moore DM, Harris R, Lima V, Hogg B, May M, Yip B, Justice A, Mocroft A, Reiss P, Lampe F, Chêne G, Costagliola D, Elzi L, Mugavero MJ, D'Arminio Monforte A, Sabin C, Podzamczek D, Fätkenheuer G, Staszewski S, Gill J, Sterne JAC and the Antiretroviral Therapy Cohort Collaboration (ART-CC). Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. *J Acquir Immune Defic Syndr* 2009; 52(3):357-363.
283. Mouala C, Guiguet M, Houzé S, Damond F, Pialoux G, Viget N, Costagliola D, Le Bras J, Matheron S, on behalf of the FHDH-ANRS CO4 Clinical Epidemiology Group. Impact of HIV infection on severity of imported malaria is restricted to patients with CD4 cell counts <350/mm³. *AIDS* 2009; 23(15): 1997-2004.
284. Mounier N, Katlama C, Costagliola D, Chichmanian RM, Spano JP. Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice. *Crit Rev Oncol Hematol.* 2009; 72(1):10-20.
285. Murphy RL, Autran B, Katlama C, Brucker G, Debre P, Calvez V, Clotet B, Clumeck N, Costagliola D, Deeks SG, Dorrell L, Gatell J, Haase A, Klein M, Lazzarin A, McMichael AJ, Papagno L, Schacker TW, Wain-Hobson S, Walker BD, Youle M. A step ahead on the HIV collaboratory. *Science* 2009; 324(5932): 1264-1265.
286. Paraskevis D, Pybus O, Magiorkinis G, Hatzakis A, Wensing AM, van de Vijver DA, Albert J, Angarano G, Asjo B, Balotta C, Boeri E, Camacho R, Chaix ML, Coughlan S, Costagliola D, De Luca A, de Mendoza C, Derdelinckx I, Grossman Z, Hamouda O, Hoepelman IM, Horban A, Korn K, Kuecherer C, Leitner T, Loveday C, Macrae E, Maljkovic I, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Perrin L, Puchhammer-Stockl E, Ruiz L, Salminen M, Schmit JC, Schuurman R, Soriano V, Stanczak J, Stanojevic M, Struck D, Van Laethem K, Violin M, Yerly S, Zazzi M, Boucher CA, Vandamme AM. Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. *Retrovirology*, 6:49 (20 May 2009).
287. Potard V, Weiss L, Lamontagne F, Rouveix E, Beck-Wirth G, Drogoul-Vey MP, Faouzi Souala M, Costagliola D and the French hospital database on HIV, ANRS CO4: Trends in post-infection CD4 cell counts and Plasma HIV-1 RNA levels in HIV-1-infected patients in France between 1997 and 2005. *J Acquir Immune Defic Syndr* 2009; 52(3):422-426.

288. Rosenthal E, Salmon-Céron D, Lewden C, Bouteloup V, Pialoux G, Bonnet F, Karmochkine M, May T, François M, Burty C, Jougla E, Costagliola D, Morlat P, Chêne G, Cacoub P and the MORTAVIC/MORTALITE 2005 Study Group. Liver-related deaths in human immunodeficiency virus-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2005 Study in collaboration with the Mortalité 2005 survey, ANRS EN 19). *HIV Med* 2009; 10(5):282-289.
289. Salmon-Ceron D, Rosenthal E, Lewden C, Bouteloup V, May T, Burty C, Bonnet F, Costagliola D, Jougla E, Semaille C, Morlat P, Cacoub P, Chêne G, the ANRS EN19 Mortalité Study Group and Mortavic. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: the French national Mortalité 2005 study. *J Hepatol* 2009; 50(4): 736-745.
290. Soulié C, Assoumou L, Ghosn J, Duvivier C, Peytavin G, Ait-Arkoub Z, Molina JM, Costagliola D, Katlama C, Calvez V, Marcelin AG. Nucleoside reverse transcriptase inhibitor-sparing regimen (nucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial. *AIDS*. 2009; 23(12):1605-1608.
291. Sterne JAC, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, Jönsson Funk M, Geskus R, Gill J, Dabis F, Miró JM, Justice A, Ledergerber B, Fätkenheuer G, Hogg R, D'Arminio Monforte A, Saag M, Smith C, Staszewski S, Egger M, Cole SR (When to start consortium). Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. *Lancet* 2009; 373(9672): 1352-1363.
292. Zwahlen M, Harris R, May M, Hogg R, Costagliola D, de Wolf F, Gill J, Fätkenheuer G, Lewden C, Saag M, Staszewski S, d'Arminio Monforte A, Casabona J, Lampe F, Justice A, von Wyl V, Egger M. Mortality of HIV-infected patients starting potent antiretroviral therapy: Comparison with general population in eight countries. *Int J Epidemiol* 2009; 38(6):1624-1633.

2010

293. Abgrall S, Del Giudice P, Melica G, Costagliola D, on behalf of FHDH-ANRS CO4. HIV-associated tuberculosis and immigration in a high-income country: incidence trends and risk factors in recent years. *AIDS* 2010; 24(5):763-771.
294. Aslangul E, Assoumou L, Bittar R, Valantin MA, Kalmykova O, Peytavin G, Fiévet MH, Boccara F, Bonnefont-Rousselot D, Melchior JC, Giral P, Costagliola D. Rosuvastatin versus pravastatin in dyslipidemic HIV1-infected patients receiving protease inhibitors; the ANRS 126 randomized trial. *AIDS* 2010; 24: 77-83.
295. Assoumou L, Cozzi-Lepri A, Brun-Vézinet F, DeGruttola V, Kuritzkes D, Phillips A, Zolopa A, Miller V, Flandre P, Costagliola D on behalf of the Standardization and Clinical Relevance of HIV Drug Resistance Testing Project from the Forum for Collaborative HIV Research. Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets. *AIDS* 2010; 24(3): 365-371.
296. Assoumou L, Houssaïni A, Costagliola D, Flandre P; on behalf of the Standardization and Clinical Relevance of HIV Drug Resistance Testing Project from the Forum for Collaborative HIV Research. Relative contributions of baseline patient characteristics and the choice of statistical methods to the variability of genotypic resistance scores: the example of didanosine. *J Antimicrob Chemother* 2010; 65(4): 752-760.
297. Cain LE, Robins JM, Lanoy E, Logan R, Costagliola D, Hernán MA. When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data. *Int J Biostat* 2010; 6(2): 18.
298. Colin X, Lafuma A, Costagliola D, Lang JM, Guillon P. The Cost of Managing HIV Infection in Highly Treatment-Experienced, HIV-Infected Adults in France. *Pharmacoeconomics*. 2010 Dec 23;28(S1):59-68.
299. Colin X, Lafuma A, Costagliola D, Smets E, Mauskopf J, Guillon P. Modelling the Budget Impact of Darunavir in the Treatment of Highly Treatment-Experienced, HIV-Infected Adults in France. *Pharmacoeconomics*. 2010 Dec 23;28(S1):183-197.
300. Combadière B, Vogt A, Mahé B, Costagliola D, Hadam S, Bonduelle O, Sterry W, Staszewski S, Schaefer H, van der Werf S, Katlama C, Autran B, Blume-Peytavi U. Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial. *PLoS One* 2010 May 26;5(5): e10818.
301. Costagliola D, Lang S, Mary-Krause M, Boccara F. Abacavir and Cardiovascular Risk: Reviewing the Evidence. *Curr HIV/AIDS Rep* 2010; 7(3): 127-33.
302. Descamps D, Chaix ML, Montes B, Pakianather S, Charpentier C, Storto A, Barin F, Dos Santos G, Krivine A, Delaugerre C, Izopet Jmarcelin AG, Maillard A, Morand-Joubert L, Pallier C, Plantier JC, Tamalet C, Cottalorda J, Desbois D, Calvez V, Brun-Vézinet F, Masquelier B, Costagliola D. Increasing prevalence of transmitted drug resistance mutations and non-B subtypes circulation in antiretroviral naïve chronically HIV-infected patients from 2001 to 2006/2007 in France. *J Antimicrob Chemother* 2010; 65(12): 2620-2627.

303. Fontas E, Kousignian I, Pradier C, Poizot-Martin I, Durier C, Weiss L, Levy Y, Costagliola D, on behalf of FHDH ANRS CO4 and ANRS CO14. IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy. Results from the ANRS CO4 cohort. *J Antimicrob Chemoth* 2010; 65(10): 2215-23.
304. Gill J, May M, Lewden C, Saag M, Mugavero M, Reiss P, Ledergerber B, Mocroft A, Harris R, Fux CA, Justice A, Costagliola D, Casabona J, Hogg RS, Khaykin P, Lampe F, Vehreschild J, Sterne JAC. Causes of death in HIV-1 infected patients treated with antiretroviral therapy 1996-2006: collaborative analysis of 13 HIV cohort studies. *Clin Infect Dis* 2010; 50(10): 1387–1396.
305. Guihot A, Tubiana R, Breton G, Marcelin AG, Samri A, Assoumou L, Goncalves E, Bricaire F, Costagliola D, Calvez V, Rouzioux C, Autran B, Katlama C, Carcelain G; ALT-ANRS CO-15 study group; DECAMUNE study group. Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy. *AIDS* 2010; 24(4):614-617.
306. Hessamfar-Bonarek M, Morlat P, Salmon D, Cacoub P, May T, Bonnet F, Rosenthal E, Costagliola D, Lewden C, Chêne G and the Mortalité 2000 & 2005 study groups. Causes of death in HIV-infected women: persistent role of AIDS. The “Mortalité 2000 & 2005” Surveys (ANRS EN19). *Int J epidemiol* 2010; 39(1): 135-146.
307. Kousignian I, Launay O, Mayaud C, Rabaud C, Costagliola D, Abgrall S; on behalf of the FHDH-ANRS CO4. Does enfuvirtide increase the risk of bacterial pneumonia in patients receiving combination antiretroviral therapy? *J Antimicrob Chemoth* 2010; 65(1):138-144.
308. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, Boccara F, Bingham A, Costagliola D for the Clinical Epidemiology Group of the French Hospital Database on HIV. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. *AIDS* 2010; 24(8): 1228-1230.
309. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, Boccara F, Costagliola D for the Clinical Epidemiology Group of the French Hospital Database on HIV. Impact of individual antiretroviral drugs on the risk of myocardial infarction in HIV-infected patients: a case-control study nested within the FHDH ANRS Cohort CO4. *Arch Intern Med* 2010; 170(14): 1228-1238.
310. Lanoy E, Costagliola D, Engels EA. Skin cancers associated with HIV infection and solid organ transplant among elderly adults. *Int J Cancer*. 2010, 126(7): 1724-1731.
311. Lodi S, Guiguet M, Costagliola D, Fisher M, De Luca A, Porter K and the CASCADE collaboration. Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. *JNCI* 2010; 102 :784-792.
312. Lodwick L, Costagliola D, Reiss P, Carlo Torti C, Teira R, Dorrucchi M, Ledergerber B, Mocroft A, Podzamczar D, Cozzi-Lepri A, Obel N, Masquelier B, Staszewski S, García F, De Wit S, Castagna A, Antinori A, Judd A, Ghosn J, Touloumi G, Mussini C, Duval X, Ramos J, Meyer L, Warszawski J, Thorne C, Masip J, Perez-Hoyos S, Tookey P, Pillay D, van Sighem A, Lo Caputo S, Günthard H, Paredes R, De Luca A, Paraskevis D, Fabre-Colin C, Kjaer J, Chene G, Lundgren J, Phillips A. Triple class virologic failure in HIV-infected patients on antiretroviral therapy for up to 10 years. *Arch Intern Med* 2010; 170(5):410-419.
313. Maïga AI, Descamps D, Morand-Joubert L, Malet I, Derache A, Cisse M, Koita V, Akonde A, Diarra B, Wiriden M, Tounkara A, Verlinden Y, Katlama C, Costagliola D, Masquelier B, Calvez V, Marcelin AG. Resistance Associated Mutations to Etravirine (TMC-125) in Antiretroviral Naive Patients infected with non-B HIV-1 subtypes. *Antimicrob Agents Chemother* 2010; 54(2) :728-733.
314. Phillips A, Costagliola D, Sabin C, Sterne J. Early initiation of treatment for HIV infection. *Lancet* 2010; 375(9715): 639.
315. Piketty C, Weiss L, Assoumou L, Burgard M, Mélard A, Ragnaud JM, Bentata M, Girard PM, Rouzioux C, Costagliola D and the ANRS 116 SALTO study group. A High HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir. *J Med Virol* 2010; 82(11):1819-1828.
316. Potard V, Chassany O, Lavignon M, Costagliola D, Spire B. Better health related quality of life after switching from a virologically effective regimen to a regimen containing efavirenz or nevirapine. *AIDS Care* 2010; 22 :54-61.
317. Raboud JM, Diong C, Carr A, Grinspoon S, Mulligan K, Sutinen J, Rozenbaum W, Rodrigo B, Cavalcanti RB, Wand H, Costagliola D, Walmsley S for the Glitazone and Lipoatrophy Meta-Analysis Working Group. A Meta-Analysis of Six Placebo-Controlled Trials of Thiazolidinedione Therapy for HIV Lipoatrophy. *HIV Clinical Trials* 2010; 11(1): 39-50.
318. Ray M, Logan R, Sterne JAC, Hernández-Díaz S, Robins JM, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D, Lanoy E, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Justice A, Goulet J, Lodi S, Phillips A, Seng R, Meyer L, Pérez-Hoyos S, García de Olalla P, Hernán MA. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. *AIDS* 2010; 24: 123–137.

319. Silvain J, Beygui F, Ankri A, Bellemain-Appaix A, Pena A, Barthelemy O, Cayla G, Gallois V, Galier S, Costagliola D, Collet JP, Montalescot G. Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test. *J Am Coll Cardiol*. 2010; 55(7):617-625.
320. Valantin MA, Bittar R, de Truchis P, Bollens D, Slama L, Giral P, Bonnefont-Rousselot, D, Petour P, Aubron-Olivier C, Costagliola D, Katlama C. Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients. *J Antimicrob Chemoth* 2010; 65(3): 556-561.
321. Weiss L, Piketty C, Assoumou L, Didier C, Caccavelli L, Donkova-Petrini V, Levy Y, Girard PM, Burgard M, Viard JP, Rouzioux C, Costagliola D and The ANRS 116 SALTO study group. Relationship between regulatory T cells and immune activation in human immunodeficiency virus-infected patients interrupting antiretroviral therapy. *Plos One* 2010; 5(7): e11659.
322. Xie J, Lu W, Samri A, Costagliola D, Schnuriger A, da Silva BC, Blanc C, Larsen M, Theodorou I, Rouzioux C, Autran B; and the ALT-ANRS-CO15 study group. Distinct differentiation profiles of HIV-Gag and Nef-specific central memory CD8+ T cells associated with HLA-B57/5801 and virus control. *AIDS* 2010; 24(15): 2323-2329.
323. Yazdanpanah Y, Sloan C.E, Charlois-Ou C, Le Vu S, Semaille C, Costagliola D, Pillonel J, Poullié AI, Scemama O, Deuffic-Burban S, Losina E, Walensky RP, Freedberg KA, Paltiel AD. Routine HIV screening in France: Clinical impact and cost-effectiveness. *PLoS One* 2010; 5(10): e13132.

2011

324. Antinori A, Coenen T, Costagliola D, Dedes N, Ellefson M, Gatell J, Girardi E, Johnson M, Kirk O, Lundgren J, Mocroft A, D'arminio Monforte A, Phillips A, Raben D, Rockstroh J, Sonneborg A, De Wolf F. Late presentation of HIV infection : a consensus definition. *HIV Med* 2011; 12(1): 61-64.
325. Appay V, Fastenackels S, Katlama C, Ait-Mohand H, Schneider L, Guihot A, Keller M, Grubeck-Loebenstein B, Simon A, Lambotte O, Hunt PW, Deeks SG, Costagliola D, Autran B, Sauce D. Old age and anti-CMV immunity are associated with altered T cell reconstitution in HIV-1 infected patients. *AIDS* 2011 ; 25(15) : 1813-22.
326. Aslangul E, Fellahi S, Assoumou L, Bastard JP, Capeau J, Costagliola D. High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors. *AIDS* 2011; 25(8): 1128-31.
327. Boccara F, Mary-Krause M, Teiger E, Lang S, Lim P, Wahbi K, Beygui F, Milleron P, Steg PG, Funck-Brentano C, Slama M, Girard PM, Costagliola D, Cohen A, on behalf the PACS-investigators. Acute coronary syndrome in HIV-infected patients: characteristics and 1-year prognosis. *Eur Heart J* 2011; 25(1): 115-118.
328. Bommenel T, Launay O, Meynard JL, Gilquin J, Katlama C, Lascaux AS, Mahamat A, Martinez V, Pradier C, Rouveix E, Simon A, Costagliola D, Abgrall S on behalf of FHDH-ANRS CO4. Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a 3-drug regimen containing either efavirenz, nevirapine or abacavir. *J Antimicrob Chemoth* 2011; 66(8):1869-1877.
329. Boué F, Reynes J, Rouzioux C, Emilie D, Souala F, Tubiana R, Goujards C, Lancar, R, Costagliola D. Alpha interferon administration during structured Interruptions of combination Antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial. *AIDS* 2011; 25(1): 115-118.
330. Brieger D, Collet JP, Silvain J, Landivier A, Barthélémy O, Beygui F, Bellemain-Appaix A, Mercadier A, Choussat R, Vignolles N, Costagliola D, Montalescot G. Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention. *Catheter Cardiovasc Interv* 2011; 77(2): 182-90.
331. Cain LE, Logan R, Robins JM, Sterne JAC, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernán MA. When to initiate combined antiretroviral therapy to reduce rates of mortality and AIDS in HIV-infected individuals in developed countries. *Ann Intern Med* 2011; 154(8):509-515.
332. Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), Castro H, Judd A, Gibb DM, Butler K, Lodwick RK, van Sighem A, Ramos JT, Warszawski J, Thorne C, Noguera-Julian A, Obel N, Costagliola D, Tookey PA, Colin C, Kjaer J, Grarup J, Chene G, Phillips A. Risk of triple-class virological failure in children with HIV: a retrospective cohort study. *Lancet* 2011; 377(9777): 1580-7.
333. García F, Climent N, Assoumou L, Gil C, González N, Alcamí J, León A, Romeu J, Dalmau J, Martínez-Picado J, Lifson J, Autran B, Costagliola D, Clotet B, Gatell J.M, Plana M, Gallart T for DCV2/MANON07-ORVACS study group. A Therapeutic Dendritic Cell-based Vaccine for HIV-1 Infection. *J Infect Dis* 2011; 203(4): 473-478.

334. Gasnault J*, Costagliola D*, Hendel-Chavez H, Dulioust A, Pakianather S, Mazet AA, de Goer de Herve MG, Lancar R, Lascaux AS, Porte L, Delfraissy JF, Taoufik Y for the ANRS 125 Trial Team. Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early five-drug combination antiretroviral therapy. *Plos one* 2011; 6(6): e20967.

*co-primary authors

335. Lanoy E, Guiguet M, Bentata M, Rouveix E, Dhiver C, Poizot-Martin I, Costagliola D, Gasnault J, on behalf the FHDH-ANRS CO4. Survival after neuroAIDS: association with antiretroviral CNS Penetration-Effectiveness score. *Neurology* 2011; 76: 644-651.
336. Lanoy E, Rosenberg PS, Fily F, Lascaux AS, Martinez V, Partisani M, Poizot-Martin I, Rouveix E, Engels EA, Costagliola D, Goedert J. HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. *Blood* 2011; 118(1):44-49.
337. Lanoy E, Spano JP, Bonnet F, Guiguet M, Boué F, Cadranel J, Carcelain G, Couderc LJ, Frange P, Girard PM, Oksenhendler E, Poizot-Martin I, Semaille C, Agut A, Katlama C, Costagliola D and the ONCOVIH study group. The spectrum of malignancies in HIV-infected patients in 2006 in France: The ONCOVIH study. *Int J cancer* 2011; 129(2): 467-475.
338. Lodwick R, Alioum A, Archibald C, Birrell P, Commenges D, Costagliola D, De Angelis D, Donoghoe M, Garnett G, Ghys P, Law M, Lundgren J, Ndawinz J, Presanis A, Rhodes P, Sabin C, Salminen M, Sommen C, Stanecki K, Stover J, Supervie V, Sweeting M, van de Laar M, van Sighem A, Wand H, Wilson D, Yan P, Phillips A, Working Group on Estimation of HIV Prevalence in Europe. HIV in hiding: Methods and data requirements for the estimation of the number of people living with undiagnosed HIV. *AIDS* 2011; 25(8): 1017-23.
339. Ndawinz JDA, Costagliola D, Supervie V. New method for estimating HIV incidence and time from infection to diagnosis using HIV surveillance data: results for France. *AIDS* 2011; 25(15): 1905-13.
340. Papagno L, Alter G, Assoumou L, Murphy RL, Garcia F, Clotet B, Larsen M, Braibant M, Marcelin A-G, Costagliola D, Altfeld M, Katlama C, Autran B and the ORVACS Study Group. Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. *AIDS* 2011; 25(1): 27-36.
341. Sauce D, Larsen M, Fastenackels S, Pauchard M, Ait-Mohand H, Schneider L, Guihot A, Boufassa F, Zaunders J, Iguertsira M, Bailey M, Gorochov G, Duviolier C, Carcelain G, Kelleher AD, Simon A, Meyer L, Costagliola D, Deeks S, Lambotte O, Autran B, Hunt P, Katlama C, Appay V. HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. *Blood* 2011; 117(19): 5142-51.

2012

342. Barthélémy O, Silvain J, Brieger D, Mercadier A, Lancar R, Bellemain-Appaix A, Beygui F, Collet JP, Costagliola D, Montalescot G. Bleeding Complications in primary percutaneous coronary intervention of ST elevation myocardial Infarction in a radial center. *Catheter Cardiovasc Interv* 2012; 79(1): 104-12.
343. Bittar R, Giral P, Aslangul E, Assoumou L, Valantin MA, Kalmykova O, Federspiel MC, Cherfils C, Costagliola D, Bonnefont-Rousselot D and the ANRS 126 study group. Effects of rosuvastatin versus pravastatin on LDL diameter in HIV-1-infected patients receiving ritonavir-boosted PI. *AIDS* 2012; 26(14): 1801-1805.
344. Bittar R, Giral P, Aslangul E, Assoumou L, Valantin M, Kalmykova O, Fesel-Fouquier V, Costagliola D, Bonnefont-Rousselot D and the ANRS 126 study group. Determinants of low-density-lipoprotein particle diameter during antiretroviral therapy including protease inhibitors in HIV-1-infected patients. *Antiviral therapy* 2012; 17(5): 855-860.
345. Cain LE, Phillips A, Lodi S, Sabin C, Bansi L, Justice A, Tate J, Logan R, Robins JM, Sterne JAC, van Sighem A, de Wolf F, Bucher HC, Elzi L, Touloumi G, Vourli G, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Abgrall S, Costagliola D, Hernán MA and the HIV-CAUSAL Collaboration. The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. *AIDS* 2012; 26(13): 1691-1705.
346. Casalino E, Bernot B, Bouchaud O, Alloui C, Choquet C, Bouvet E, Damond F, Firmin S, Delobelle A, Ename-Nkoumazok B, Der Sahakian G, Viard JP, Zak Dit Zbar O, Aslangul E, Krivine A, Zundel J, Ghosn J, Nordmann P, Claessens YE, Tahi T, Riou B, Gautheret-Dejean A, Katlama C, Hausfater P, Brun-Vézinet F, Costagliola D. Twelve months of routine HIV screening in 6 emergency departments in the Paris area: Results from the ANRS URDEP study. *Plos One* 2012; 7(10): e46437.
347. Costagliola D. Impact des nouveaux antirétroviraux chez les patients infectés par le VIH en échec virologique. *Med Sci* 2012;28(8-9):706-707.

348. Costagliola D, Lodwick R, Ledergerber B, Torti C, van Sighem A, Podzamczar D, Mocroft A, Dorrucchi M, Masquelier B, de Luca A, Jansen K, De Wit S, Obel N, Fätkenheuer G, Touloumi G, Mussini C, Castagna A, Stephan C, García F, Zangerle R, Duval X, Perez-Hoyos S, Meyer L, Ghosn J, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Phillips A. Trends over calendar time in virological and clinical outcomes in individuals with HIV-1 infection and virologic failure of drugs from three antiretroviral drug classes: a cohort study. *Lancet Infect Dis* 2012; 12(2): 119 - 127.
349. del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Perez-Hoyos S, Jarrin I, Phillips A, Lodi S, van Sighem A, de Wolf F, Sabin C, Bansi L, Justice A, Goulet J, Miro JM, Ferrer E, Meyer L, Seng R, Touloumi G, Gargalianos P, Costagliola D, Abgrall S, Hernan MA and the HIV-CAUSAL Collaboration. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. *Clin Infect Dis* 2012; 54(9): 1364-137.
350. Goehrs JM, Borel T, Costagliola D et les participants à la table ronde N° 6 de Giens XXVII. La mise en place des cohortes en France : pourquoi, pour qui, comment et avec quels moyens ? *Thérapie* 2012; 67(4):375-80.
351. Guergnon J, Dalmasso C, Broet P, Meyer L, Westrop SJ, Imami N, Vicenzi E, Morsica G, Tinelli M, Zanone Poma B, Goujard C, Potard V, Gotch FM, Casoli C, Cossarizza A, Macciardi F, Debré P, Delfraissy JF, Galli M, Autran B, Costagliola D, Poli G, Theodorou I, Riva A, GISHEAL Consortium. Single-nucleotide polymorphism-defined class I and class III major histocompatibility complex genetic subregions contribute to natural long-term nonprogression in HIV infection. *J Infect Dis* 2012; 205(5): 718-724.
352. Guiguet M, Ghosn J, Duvivier C, Meynard JL, Gras G, Partisani ML, Teicher E, Mahamat A, Rodenbourg F, Launay O, Costagliola D, on behalf of the FHDH-ANRS CO4. Boosted protease inhibitor monotherapy as a maintenance strategy: an observational study in the FHDH-ANRS CO4 cohort. *AIDS* 2012; 26(18):2345–2350.
353. Harari A, Rozot V, Cavassini M, Bellutti Enders F, Vigano S, Tapia G, Castro E, Burnet S, Lange J, Moog C, Garin D, Costagliola D, Autran B, Pantaleo G, Bart P. Immunization with NYVAC Vaccine Induces Potent Polyfunctional HIV-Specific T-Cell Responses in Chronically HIV-1-Infected Patients Successfully Treated with ART. *Eur J Immunol* 2012; 42(11): 3038-48.
354. Jarzebowski W, Caumes E, Dupin N, Farhi D, Lascaux AS, Piketty C, de Truchis P, Bouldouyre MA, Derradji O, Pacanowski J, Costagliola D, Grabar S for the FHDH (ANRS CO4) study team. Effect of early syphilis infection on plasma viral load and CD4 cell count in human immunodeficiency virus-infected men: Results from the FHDH-ANRS CO4 cohort. *Arch Intern Med* 2012; 172(16): 1237-1243.
355. Lambert-Niclot S, Masquelier B, Cohen Codar I, Soulie C, Delaugerre C, Morand-Joubert L, Charpentier C, Ferre V, Plantier JC, Montes B, Carret S, Perrot V, Peytavin G, Costagliola D, Calvez V, Marcelin AG; on behalf of the EOLE Study Group. Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice. *J Antimicrob Chemother* 2012; 67(10): 2487-2493.
356. Lang S, Mary-Krause M, Simon A, Partisani M, Gilquin J, Cotte L, Boccarda F, Costagliola D, for the French Hospital Database on HIV-ANRS CO4. HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals. *Clin Infect Dis* 2012; 55(4): 600–7.
357. Mary-Krause M, Viard JP, Ename-Mkoumazok B, Bentata M, Valantin MA, Missy P, Darasteanu I, Roux C, Kolta S, Costagliola D, Rozenberg S. Prevalence of low bone mineral density in HIV-1 infected men and women, and a proposal for screening strategy. *J Clin Dens* 2012; 15(4): 422-33.
358. May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, Thiébaud R, Gill MJ, Kirk O, van Sighem A, Saag MS, Navarro G, Sobrino-Vegas P, Lampe F, Ingle S, Guest JL, Crane HM, D'Arminio Monforte A, Vehreschild JJ, Sterne JA. Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. *Int J Epidemiol* 2012; 41(6): 1807-20.
359. Meyssonier V, Guihot A, Chevet K, Veziris N, Assoumou L, Bourgarit A, Costagliola D, Caumes E, Carcelain G. Performance of Quantiferon for the diagnosis TB. *Med Mal Infect.* 2012; 42(12):579-84.
360. Nakagawa F, Lodwick R, Costagliola D, van Sighem A, Torti C, Podzamczar D, Mocroft A, Ledergerber B, Dorrucchi M, Cozzi-Lepri A, Jansen K, Masquelier B, García F, De Wit S, Stephan C, Niels Obel N, Fätkenheuer G, Castagna A, Sambatakou H, Mussini C, Ghosn J, Zangerle R, Duval X, Meyer L, Perez-Hoyos S, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Phillips A. Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug experienced people with HIV in Europe. *J Acquir Immune Defic Syndr* 2012; 59(3): 294-299.
361. Piketty C, Selinger-Leneman H, Bouvier AM, Belot A, Mary-Krause M, Duvivier C, Bonmarchand M, Abramowitz L, Costagliola D, Grabar S. The incidence of HIV-related anal cancer remains elevated despite long-term cART: Results from the French Hospital Database on HIV (FHDH-ANRS CO4 cohort). *J Clin Oncol* 2012; 30(35): 4360-66.

362. Rozenberg S, Lanoy E, Bentata M, Viard JP, Valantin MA, Missy P, Darasteanu I, Roux C, Kolta S, Costagliola D and the ANRS 120 Fosivir study group. Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120). *AIDS Res Hum Retroviruses* 2012; 28(9): 772-780.
363. Sala C, Durand B, Costagliola D, Ducrot C, Calavas D. Is The Age-Period-Cohort Model Well Suited to an Epidemic Context? The Case of the French BSE Epidemic. *Stat Commun Infect Dis* 2012; 4(1).
364. Spano JP, Lanoy E, Mounier N, Katlama C, Costagliola D, Heard I. Breast cancer among HIV infected individuals from the ONCOVIH study in France: Therapeutic implications regarding potential drug-drug interactions. *Eur J Cancer* 2012; 48(18):3335-41.
365. Supervie V, Costagliola D. Undiagnosed HIV prevalence in France: no evidence against universal HIV screening. *AIDS* 2012; 26(8): 2419.
366. Triant VA, Josephson F, Rochester CG, Althoff KN, Marcus K, Munk R, Cooper C, D'Agostino RB, Costagliola D, Sabin CA, Williams PL, Hughes S, Post WS, Chandra-Strobos N, Guaraldi G, Young SS, Obenchain R, Bedimo R, Miller V, Strobos J. Adverse Outcome Analyses of Observational Data: Assessing Cardiovascular Risk in HIV Disease. *Clin Infect Dis* 2012; 54(3): 408-13.

2013

367. Abgrall S, Ingle SM, May MT, Cornish R, Costagliola D, Mercie P, Cavassini M, Reekie J, Samji H, Gill MJ, Crane HM, Tate J, Sterling TR, Antinori A, Reiss P, Saag MS, Mugavero MJ, Phillips A, Manzardo C, Wasmuth JC, Stephan C, Guest JL, Sirvent JLG, Sterne JAC; Antiretroviral Cohort Collaboration. Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009. *AIDS* 2013; 27(5): 803-813.
368. Antoni G, Guernon J, Meaudre C, Samri A, Boufassa F, Goujard C, Lambotte O, Autran B, Rouzioux C, Costagliola D, Meyer L, Theodorou I. MHC-driven HIV-1 control on the long run is not systematically determined at early times post HIV-1 infection. *AIDS* 2013; 27:1707-1716.
369. Assoumou L, Descamps D, Yerly S, Dos Santos G, Marcelin AG, Delaugerre C, Morand-Joubert L, Ruffault A, Izopet J, Plantier JC, Pakianather S, Montes B, Chaix ML, Wirden M, Costagliola D, Masquelier B; on behalf the ANRS AC11 Resistance Group. Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study. *J Antimicrob Chemother* 2013; 68(6):1400-5.
370. Assoumou L, Katlama C, Viard V, Bentata M, Simon A, Roux C, Kolta S, Costagliola D, Rozenberg S and the ANRS Osteovir study group. Changes in bone mineral density over a two-year period in HIV-1-infected men under cART with osteopenia. *AIDS* 2013; 27(15): 2425-30.
371. Boccara F, Lang S, Meuleman C, Ederhy S, Mary-Krause M, Costagliola D, Capeau J, Cohen A. HIV and Coronary Heart Disease: Time for a Better Understanding. *J Am Coll Cardiol* 2013; 61(5): 511-23.
372. Costagliola D. Risk of cancers in HIV infection. *Enferm Infecc Microbiol Clin* 2013; 31(5):275-6.
373. Costagliola D, Hernán MA. β -Blocker use for patients with or at risk for coronary artery disease. *JAMA*. 2013; 309(5): 439.
374. Descamps D, Assoumou L, Chaix ML, Chaillon A, Pakianather S, de Rougemont A, Storto A, Dos Santos G, Krivine A, Delaugerre C, Montes B, Izopet J, Charpentier C, Wirden M, Maillard A, Morand-Joubert L, Pallier C, Plantier JC, Guinard J, Tamalet C, Cottalorda J, Marcelin AG, Desbois D, Henquell C, Calvez V, Brun-Vézinet F, Masquelier B, Costagliola D on behalf the ANRS AC-11 Resistance Group. National Sentinel Surveillance of Transmitted Drug Resistance in Antiretroviral-Naive Chronically HIV-Infected Patients in France Over a Decade: 2001-2011. *J Antimicrob Chemother* 2013; 68(11):2626-31.
375. Hleyhel M, Belot A, Bouvier AM, Tattevin P, Pacanowski J, Genet P, De Castro N, Dupont C, Lavolé A, Pradier C, Salmon D, Simon A, Martinez V, Costagliola D, Grabar S; on behalf of the FHDH-ANRS CO4 cohort. Risk of AIDS-defining cancers among HIV1-infected patients in France between 1992 and 2009: Results from the FHDH-ANRS CO4 cohort. *Clin Infect Dis* 2013; 57(11):1638-47.
376. Lacombe JM, Boue F, Grabar S, Viget N, Gazonnes S, Lascaux-Cametz AS, Pacanowski J, Partisani M, Launay O, Matheron S, Rosenthal E, Rouveix E, Tattevin P, de Truchis P, Costagliola D, Goedert JJ. Risk of Kaposi sarcoma during the first months on combination antiretroviral therapy. *AIDS* 2013; 27(4): 635-643.
377. Ledergerber B, Costagliola D, Lodwick R, Torti C, van Sighem A, Podzamczar D, Mocroft A, Dorrucchi M, Masquelier B, Günthard HF, de Luca A, Jansen K, De Wit S, Obel N, Fätkenheuer G, Chrysos G, Mussini C, Castagna A, Stephan C, García F, Zangerle R, Duval X, Perez-Hoyos S, Meyer L, Ghosn J, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Phillips A. Predictors of CD4 cell counts of HIV-1 - infected persons after virologic failure to all three original antiretroviral drug classes. *J Infect Dis* 2013; 207(5): 759-67.

378. Mocroft A, Lundgren JD, Sabin ML, d'Arminio Monforte A, Brockmeyer N, Casabona J, Castagna A, Costagliola D, Dabis F, De Wit S, Fätkenheuer G, Furrer H, Johnson AM, Lazanas MK, Catherine C, Moreno S, Obel N, Post FA, Reekie J, Reiss P, Sabin C, Skaletz-Rorowski A, Suarez-Lozano I, Torti C, Warszawski J, Zangerle R, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Kirk O for the Late Presenters Working Group on behalf of the Collaboration of Observational HIV Epidemiological Research Europe study (COHERE) in EuroCoord. Risk factors and outcomes for late presentation for HIV-positive persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). *Plos Med* 2013; 10(9):e1001510.
379. Montlahuc C, Guiguet M, Abgrall S, Daneluzzi V, de Salvador F, Launay O, Martinez V, Partisani M, Pradier C, Rouveix E, Valin N, Grabar S, Costagliola D on behalf of the FHDH ANRS CO4 cohort. Impact of late presentation on the risk of death among HIV-infected people in France (2003-2009). *J Acquir Immune Defic Syndr* 2013; 64(2):197-203.
380. Ndawinz J, Chaix B, Koulla-Shiro S, Delaporte E, Okouda B, Abanda A, Tchomthe S, Mboui E, Costagliola D, Supervie V. Factors Associated With Late Antiretroviral Therapy Initiation in Cameroon: a Representative Multilevel Analysis. *J Antimicrob Chemoth* 2013; 68(6):1388-99.
381. Piketty C, Cochand-Priollet B, Lanoy E, Si-Mohamed A, Trabelsi S, Tubiana R, Girard PM, Weiss L, Costagliola D, and the Valparaiso Study Group. Lack of regression of anal squamous intraepithelial lesions despite immune restoration under cART. *AIDS* 2013; 27(3): 401-406.
382. Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, Potard V, Versmisse P, Melard A, Prazuck T, Descours B, Guernon J, Viard JP, Boufassa F, Lambotte O, Goujard C, Meyer L, Costagliola D, Venet A, Pancino G, Autran B, Rouzioux C for the ANRS VISCONTI Study Group. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy. ANRS VISCONTI study. *Plos Path* 2013; 9(3):e1003211.
383. Terrier B, Costagliola D, Prevot S, Chavez H, Missy P, Rince P, Costello R, Escaut L, Gabarre J, Joly B, Letranchant L, Le Guill S, Morineau-Le Houssine P, Simon A, Canioni D, Hermine O, Cacoub P, Taoufik Y, Raphael M, Besson C. Characteristics of B-cell Lymphomas in HIV-HCV coinfecting patients during the combined antiretroviral therapy era. An ANRS CO16 LYMPHOVIR cohort study. *J Acquir Immune Defic Syndr* 2013; 63(2):249-253.

2014

384. Avila D, Althoff KN, Muglin C, Wools-Kaloustian K, Koller M, Dabis F, Nash D, Gsponer T, Sungkanuparph S, McGowan C, May M, Cooper D, Chimbetete C, Wolff M, Collier A, McManus H, Davies MA, Costagliola D, Crabtree-Ramirez B, Chaiwarith R, Cescon A, Cornell M, Diero L, Phanuphak P, Sawadogo A, Ehmer J, Eholie SP, Li PCK, Fox MP, Gandhi NR, González E, Lee CKC, Hoffmann CJ, Kambugum A, Keiser O, Ditangco R, Prozesky H, Lampe F, Kumarasamy N, Kitahata M, Lugina E, Lyamuya R, Vonthanak S, Fink V, d'Arminio-Monforte A, P Luz PM, Chen YMA, Minga A, Casabona J, Mwangi A, Choi JY, Newell ML, Bukusi EA, Ngonyani K, Merati TP, Otieno J, Bosco MB, Phiri S, Ng OT, Anastos K, Rockstroh J, Santos I, Oka S, Somi G, Stephan C, Teira R, Wabwire D, Wandeler G, Boule A, Reiss P, Wood R, Chi BH, Williams C, Sterne JA, Egger M. Immunodeficiency at the start of combination antiretroviral therapy in low-, middle- and high-income countries. *J Acquir Immune Defic Syndr* 2014; 65(1):e8-e16.
385. Boufassa F, Le Chenadec J, Meyer L, Costagliola D, Hunt PW, Florencia Pereyra F, Deeks S, Pancino G, Taulera O, Lichterfeld M, Delobel P, Saez-Cirion A, Lambotte L for the ANRS CO18 HIV Controllers Cohort, the Cascade Collaboration in EuroCoord, the SCOPE Cohort and the International HIV Controllers Study. Blunted response to combination antiretroviral therapy in HIV elite controllers: An international HIV controller collaboration. *Plos One* 2014; 9(1): e85516.
386. Boule A, Schomaker M, May MT, Hogg RS, Shepherd BE, Monge S, Keiser O, Lampe FC, Giddy J, Ndirangu J, Garone D, Fox M, Ingle SM, Reiss P, Dabis F, Costagliola D, Castagna A, Ehren K, Campbell C, Gill MJ, Saag M, Justice AC, Guest J, Crane HM, Egger M, Sterne JAC. Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe, or North America: a collaborative analysis of prospective studies. *Plos Med* 2014; 11(9): e1001718.
387. Caniglia EC, Cain LE, Justice A, Tate J, Logan R, Sabin C, Winston A, van Sighem A, Miro JM, Podzamczar D, Olson A, Arribas JR, Moreno S, Meyer L, del Romero J, Dabis F, Bucher HC, Wandeler G, Vourli G, Skoutelis A, Lanoy E, Gasnault J, Costagliola D, Hernán M. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurological conditions. *Neurology* 2014; 83(2):134-41.
388. Costagliola D. Demographics of HIV and aging. *Curr Opin HIV AIDS* 2014; 9(4):294-301.
389. Denis B, Guiguet M, de Castro N, Mechaï F, Revest M, Mahamat A, Melica Gregoire G, Lortholary O, Costagliola D. Critical importance of long-term adherence to care in HIV infected patients in the cART era: new insights from *Pneumocystis jirovecii* pneumonia cases over 2004-2011 in the FHDH-ANRS CO4 cohort. *Plos One* 2014; 9(4):e94183.

390. Fabre-Mersseman V, Tubiana R, Papagno L, Bayard C, Briceno O, Fastenackels S, Dudoit Y, Rostane H, Salmon D, Costagliola D, Caby F, Sauce D, Viard JP, Appay V. Vitamin D supplementation is associated with reduced immune activation levels in HIV-1-infected patients on suppressive antiretroviral therapy. *AIDS* 2014; 28(18):2677-82.
391. Ghosn J, Leruez-Ville M, Blanche J, Delobelle A, Beaudoux C, Mascard L, Lecuyer H, Canestri A, Landman R, Zucman D, Ponscarne D, Rami A, Viard JP, Spire B, Rouzioux C, Costagliola D, Suzan-Monti M. HIV-1 DNA levels in peripheral blood mononuclear cells and cannabis use are associated with intermittent HIV shedding in semen of men who have sex with men on successful antiretroviral regimens. *Clin Infect Dis* 2014; 58(12): 1763-70.
392. Godin O, Etain B, Henry C, Bougerol T, Courtet P, Mayliss L, Passerieux C, Azorin JM, Kahn JP, Gard S, Costagliola D, Leboyer M; for the FondaMental Advanced Centers of Expertise in Bipolar Disorders (FACE-BD) Collaborators. Metabolic syndrome in a French cohort of patients with bipolar disorder: results from the FACE-BD cohort. *J Clin Psychiatry* 2014;75(10):1078-1085.
393. Hattab S, Guihot A, Guiguet M, Fourati S, Carcelain G, Caby F, Marcelin AG, Autran B, Costagliola D, Katlama C Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study. *BMC Infect Dis* 2014; 14(1): 122.
394. Hleyhel M, Bouvier AM, Belot A, Tattevin P, Pacanowski J, Genet P, de Castro N, Berger JL, Dupont C, Lavole A, Pradier C, Salmon D, Simon A, Martinez V, Spano JP, Costagliola D, Grabar S. Risk of non AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from the FHDH-ANRS CO4 cohort. *AIDS* 2014, 28(14):2109-18.
395. Katlama C, Assoumou L, Valantin MA, Soulié C, Duvivier C, Chablais L, Kolta S, Pialoux G, Mercié P, Simon A, Costagliola D, Peytavin G, Marcelin AG and the ANRS 157 study group. Maraviroc plus raltegravir failed to maintain virologic suppression in HIV-infected patients with lipohypertrophy: Results from the ROCnRAL ANRS 157 study. *J Antimicrob Chemoth* 2014; 69(6):1648-52.
396. Lang S, Mary-Krause M, Partisani M, Gilquin J, Simon A, Cotte L, Boccard F, Costagliola D, for the French Hospital Database on HIV-ANRS CO4. Is impaired kidney function an independent predictor of the risk of myocardial infarction in HIV-infected individuals? *AIDS* 2014; 28(13):1987-89.
397. Lodi S, del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Olson A, van Sighem A, Reiss P, Sabin C, Jose S, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Vourli G, Antoniadou A, Dabis F, Vandenhede M, Costagliola D, Abgrall S, Hernán MA, the HIV-CAUSAL Collaboration. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries. *AIDS*. 2014; 28(16): 2461-73.
398. Mary-Krause M, Grabar S, Lièvre L, Abgrall S, Billaud E, Boué F, Boyer L, Cabié A, Cotte L, De Truchis P, Duval X, Duvivier C, Enel P, Gasnault J, Gaud C, Gilquin J, Guiguet M, Katlama C, Khuong MA, Lacombe JM, Lang S, Lascaux AS, Launay O, Mahamat A, Matheron S, Meynard JL, Pavie J, Pilorgé F, Piroth L, Poizot-Martin I, Potard V, Pradier C, Reynes J, Rouveix E, Selinger-Leneman H, Simon A, Tattevin P, Tissot-Dupont H, Viard JP, Viget N, Costagliola D. Cohort profile: French Hospital Database on HIV (FHDH-ANRS CO4). *Int J Epidemiol* 2014; 43(5):1425-36.
399. May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, D'Arminio Monforte A, Casabona J, Hogg RS, Mocroft A, Lampe F, Dabis F, Fätkenheuer G, Sterling TR, del Amo J, Gill JM, Crane HM, Saag MS, Guest J, Brodt HR, Sterne JA. Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). *Int J Epidemiol* 2014; 43(3):691-702.
400. Morlat P, Roussillon C, Henard S, Salmon D, Bonnet F, Cacoub P, Georget A, Aouba A, Rosenthal E, May T, Chauveau M, Diallo B, Costagliola D, Chêne G; for the ANRS EN20 Mortalité 2010 Study Group. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. *AIDS* 2014; 28(8):1181-91.
401. Nakagawa F, Lodwick R, Smith C, Costagliola D, van Sighem A, Ledergerber B, d'Arminio Monforte A, Dorrucchi M, Torti C, Suarez-Lozano I, Obel N, Brockmeyer N, Thiebaut R, Lundgren J, Castagna A, Belén Alejos B, De Wit S, Zangerle R, Pantazis N, Ehren K, Casabona J, Grarup J, Chêne G, Phillips A. Factors associated with short-term changes in HIV viral load and CD4 cell count in antiretroviral-naïve individuals. *AIDS* 2014; 28(9):1351-6.
402. Pantazis N, Porter K, Costagliola D, De Luca A, Ghosn J, Guiguet M, Johnson A, Kelleher AD, Morrison C, Thiebaut R, Wittkop L, Touloumi G on behalf of CASCADE Collaboration in EuroCoord. Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort study. *Lancet HIV* 2014; 1(3): e119 - e126.
403. Potard V, Rey D, Poizot-Martin I, Mokhtari S, Pradier C, Rozenbaum W, Brun-Vezinet F, Costagliola D on behalf of FHDH ANRS CO4. Lopinavir/r no longer recommended as first line regimen: a comparative effectiveness analysis. *J Int AIDS Soc* 2014; 17(1): 19070.

404. Seang S, Fourati S, Keita Y, Blanc C, Tubiana R, Schneider L, Valantin MA, Caby F, Calin R, Lambert-Niclot S, Marcelin AG, Calvez V, Costagliola D, Katlama C. Rapid plasma viral suppression in naive HIV-infected patients with high CD4 cells and low viraemia initiating a dual nucleoside reverse transcriptase inhibitor strategy: a proof-of-concept study. *J Antimicrob Chemother* 2014; 69(12):3356-9.
405. Supervie V, Ndawinz JDA, Lodi S, Costagliola D. The undiagnosed HIV epidemic in France and its implications for HIV screening strategies. *AIDS* 2014; 28 (12): 1797-1804.
406. Supervie V, Viard JP, Costagliola D, Breban R. Heterosexual Risk of HIV Transmission Per Sexual Act Under Combined Anti-Retroviral Therapy: Systematic Review and Bayesian Modeling. *Clin Infect Dis*. 2014; 59 (1): 115-122.
407. Terrier B, Costagliola D, Besson C. Characteristics of B-cell lymphomas in HIV/ HCV-coinfected patients. *J Acquir Immune Defic Syndr* 2014; 67(2): e86-7.
408. Weiss L, Chevalier MF, Assoumou L, Didier C, Girard PM, Piketty C, Costagliola D, Rouzioux C; the ANRS 116 SALTO Study Group. T-cell activation positively correlates with cell-associated HIV-DNA level in viremic patients with primary or chronic HIV-1 infection. *AIDS* 2014; 28(11):1683-1687.

2015

409. Abgrall S, Rachas A, Tourret J, Isnard-Bagnis C, Billaud E, Tattevin P, Costagliola D, Guiguet M, Durieux P, on behalf of FHDH-ANRS CO4. A multifaceted intervention designed to improve medical management of moderate to advanced chronic kidney disease in HIV-infected patients: a cluster randomised trial. *Clin Infect Dis* 2015; 61(3):375-84.
410. Achenbach CJ, Assoumou L, Deeks SG, Wilkin TJ, Berzins B, Casazza JP, Lambert-Niclot S, Koup RA, Costagliola D, Calvez V, Katlama C, Autran B, Murphy RL for the EraMune 02 study team. Effect of therapeutic intensification followed by HIV DNA prime and rAd 5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial. *Lancet HIV* 2015; 2(3): e82–e91.
411. Assoumou L, Weiss L, Piketty C, Burgard M, Melard A, Girard PM, Rouzioux C, Costagliola D, and the ANRS 116 SALTO study group. A low HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a higher probability of maintaining viral control. *AIDS* 2015; 29(15): 2003-2007.
412. Besson C, Lancar R, Prevot S, Brice P, Meyohas MC, Marchou B, Gabarre J, Bonnet F, Goujard C, Lambotte O, Boué F, Mounier N, Partisani M, Raffi F, Costello R, Hendel-Chavez H, Algarte-Genin M, Trabelsi S, Marchand L, Raphael M, Taoufik Y, Costagliola D. High risk features contrast with favorable outcomes in HIV-associated Hodgkin lymphoma in the modern cART era, ANRS CO16 LYMPHOVIR cohort. *Clin Infect Dis* 2015; 61(9):1469-75.
413. Cacoub P, Dabis F, Costagliola D, Almeida K, Lert F, Piroth L, Semaille C. Burden of HIV and hepatitis C co-infection: the changing epidemiology of hepatitis C in HIV-infected patients in France. *Liver Int* 2015; 35(1): 65-70.
414. Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JAC, van Sighem A, Reiss P, Bucher HC, Fehr J, Touloumi G, Pappas V, Esteve A, Casabona J, Monge S, Moreno S, R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende M, Abgrall S, Costagliola D, Hernán MA. Boosted lopinavir versus boosted atazanavir-containing regimens and immunologic, virologic and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries. *Clin Infect Dis* 2015; 60(8):1262-8.
415. Campillo-Gimenez L, Assoumou L, Valantin MA, Pajanirassa P, Villemonteix J, Soulié C, Marcelin AG, Costagliola D, Capeau J, Autran B, Katlama C, Guihot A; the ROCnRAL ANRS 157 Study Group. Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremia. *AIDS* 2015; 29(7): 853-6.
416. Delaugerre C*, Ghosn J*, Lacombe JM, Pialoux G, Cuzin L, Launay O, Menard A, De Truchis P, Costagliola D for the FHDH –ANRS CO4. Significant reduction in HIV virologic failure during a 15-year period in a setting with free healthcare access. *Clin Infect Dis* 2015; 60 (3): 463-472.

*co-primary authors

417. Denis B, Guiguet M, de Castro N, Mechaï F, Revest M, Melica G, Costagliola D, Lortholary O on behalf of FHDH ANRS-CO4. Relevance of EORTC criteria for the diagnosis of invasive aspergillosis (IA) in HIV-infected patients, and survival trends over a 20-year period in France. *Clin Infect Dis* 2015; 61(8): 1273-1280.
418. Gill J, Costagliola D. Myocardial Infarction in HIV infected persons: Time to focus on the silent elephant in the room? *Clin Infect Dis* 2015; 60(9):1424-5.
419. Grabar S, Tattevin P, Selinger-Leneman H, de La Blanchardiere A, de Truchis P, Rabaud C, Rey D, Daneluzzi V, Ferret S, Lascaux AS, Hanslik T, Costagliola D, Launay O. Incidence of Herpes Zoster in HIV-Infected Adults in the Combined Antiretroviral Treatment (cART) Era: Results from the FHDH-ANRS CO4 Cohort. *Clin Infect Dis* 2015; 60(8):1269-77.

420. Hattab S, Guiguet M, Carcelain G, Fourati S, Guihot A, Autran B, Caby F, Marcelin AG, [Costagliola D](#), Katlama C. Soluble biomarkers of immune activation and inflammation in HIV infection: impact of two years of effective first-line cART. *HIV Med* 2015; 16(9): 553-62.
421. Heard I, Etienney I, Potard V, Poizot-Martin I, Moore C, Lesage AC, Ressiot E, Crenn-Hebert C, Fléjou JF, Cubie H, [Costagliola D](#), Darragh TM; for the ANRS-C017 VIHGY Study Group. High prevalence of Anal Human Papillomavirus-associated cancer precursors in a contemporary cohort of asymptomatic HIV-infected women. *Clin Infect Dis*. 2015; 60(10):1559-68.
422. Heard I, Potard V, Bergeron C, Cartier I, [Costagliola D](#). Interobserver variability of cervical cytology in HIV-infected women. *Cytopathology* 2015; 26(6):362-7.
423. Helleberg M, May MT, Ingle SM, Dabis F, Reiss P, Fätkenheuer G, [Costagliola D](#), d'Arminio A, Cavassini M, Smith C, Justice AC, Gill MJ, Sterne JAC, Obel N. Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America: ART-CC. *AIDS* 2015; 29(2):221-9.
424. Hleyhel M, Belot A, Bouvier AM, Tattevin P, Pacanowski J, Genet P, De Castro N, Berger JL, Dupont C, Lavole A, Pradier C, Salmon D, Simon A, Martinez V, Spano JP, [Costagliola D](#), Grabar S on behalf of FHDH-ANRS CO4. Trends in survival after cancer diagnosis among HIV-Infected individuals between 1992 and 2009. Results from the FHDH-ANRS CO4 Cohort. *Int J Cancer* 2015; 137(10), 2443–2453.
425. Jarrin I, Pantazis N, Dalmau J, Phillips AN, Olson A, Mussini C, Boufassa B, [Costagliola D](#), Porter K, Blanco J, Del Amo J, Martinez-Picado J, for CASCADE Collaboration in EuroCoord. Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved? *AIDS* 2015; 29(17):2323-2333.
426. Katlama C, [Costagliola D](#), Autran B. Tackling latency as a barrier to an HIV cure: what next? *Lancet HIV*. 2015; 2(12): e504-e505.
427. Kesteman T, Lapostolle A, [Costagliola D](#), Massari V, Chauvin P. Impact of migration origin on individual protection strategies against sexual transmission of HIV in Paris metropolitan area, SIRS cohort study, France. *BMC Public Health* 2015;15:807.
428. Lang S, [Costagliola D](#). Is statin preventing cancer in HIV-1 infected individuals? An inappropriate methodology is a more likely explanation. *AIDS* 2015; 29(7): 857.
429. Lang S, Lacombe JM, Mary-Krause M, Partisani M, Bidegain F, Cotte L, Aslangul A, Cheret A, Boccara F, Meynard JL, Pradier C, Roger PM, Tattevin P, [Costagliola D](#), Molina JM, on behalf of the French Hospital Database on HIV. Is impact of statin therapy on all-cause mortality different in HIV-infected individuals compared to general population? Results from the FHDH-ANRS CO4 cohort. *Plos One* 2015; 10(7):e0133358.
430. Lodi S, Phillips A, Logan R, Olson A, [Costagliola D](#), Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrin I, Jose S, Sabin C, Miguel A Hernán MA, HIV-CAUSAL Collaboration. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. *Lancet HIV* 2015; 2(8):e335-343.
431. Massari V, Lapostolle A, Gruposso MC, Dray-Spira R, [Costagliola D](#), Chauvin P. Which adults in the Paris metropolitan area have never been tested for HIV? A 2010 multilevel, cross-sectional, population-based study. *BMC Infect Dis* 2015; 15:278.
432. Mocroft A, Lundgren J, Antinori A, d'Arminio Monforte A, Brännström J, Bonnet F, Brockmeyer N, Casabona J, Castagna A, [Costagliola D](#), De Wit S, Fätkenheuer G, Furrer H, Jadand C, Johnson A, Lazanas M, Leport C, Moreno S, Mussini C, Obel N, Post F, Reiss P, Sabin C, Skaletz-Rorowski A, Suarez-Loano I, Torti C, Warszawski J, Wittkop L, Zangerle R, Chene G, Raben D, Kirk O. Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. *Eurosurveillance* 2015; 20(47).
433. de Monteynard LA, Dray-Spira R, De Truchis P, Grabar S, Launay O, Meynard JL, Khuong-Josses MA, Gilquin J, Rey D, Simon A, Pavie J, Mahamat A, Matheron S, [Costagliola D](#), Abgrall S, on behalf of the French Hospital Database on HIV. Later cART initiation in migrant men from sub-Saharan Africa without advanced HIV disease in France. *Plos One* 2015; 10(3):e0118492.
434. Ndawinz JDA, Anglaret X, Delaporte E, Koulla-Shiro S, Gabillard D, Minga A, [Costagliola D](#), Supervie V. Time from HIV seroconversion to antiretroviral treatment and time lost in starting antiretroviral treatment: New epidemiological indicators for estimating the gap between WHO recommendations and current reality. *Bull World Health Organ* 2015; 93(8):521-528.
435. Potard V, Reynes J, Ferry T, Aubin C, Finkielsztejn L, Yazdanpanah Y, [Costagliola D](#) on behalf of FHDH ANRS CO4. Durability and effectiveness of maraviroc-containing regimens in HIV-1-infected individuals with virological failure in routine clinical practice. *Plos One* 2015; 10(12):e0144746.
436. Pourcher G, [Costagliola D](#), Martinez V. Obesity in HIV-infected patients in France: Prevalence and surgical treatment options. *J Visc Surg* 2015; 152(1):33-7.

437. Rosenthal E, Roussillon C, Salmon-Céron D, Georget A, Hénard S, Huleux T, Gueit I, Mortier E, Costagliola D, Morlat P, Chêne G, Cacoub P; the Mortalité 2010 and GERMIVIC study groups. Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: the Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) EN 20 Mortalité 2010 survey. *HIV Med* 2015; 16(4):230-239.
438. Soulié C, Assoumou L, Darty M, Rodriguez C, Donati F, Sayon S, Peytavin G, Valantin MA, Caby F, Schneider L, Canestri A, Costagliola D, Katlama C, Calvez V, Marcelin AG; ROCnRAL ANRS-157 Study Group. Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial). *J Antimicrob Chemother* 2015; 70(12):3339-44.
439. Supervie V, Archibald CP, Costagliola D, Delpech V, Hall HI, Lot F, van Sighem A, Wilson DP. GBD 2013 and HIV incidence in high income countries. *Lancet* 2015; 385(9974): 1177.
440. Supervie V, Viard JP, Costagliola D, Breban R. Risk of HIV transmission under combined anti-retroviral therapy: toward risk zero? *J Acquir Immune Defic Syndr* 2015; 68(3):e41-e42.
441. Vandenhende MA, Roussillon C, Henard S, Morlat P, Georget A, May T, Rosenthal E, Salmon D, Cacoub P, Costagliola D, Chene G, Bonnet F for the ANRS EN20 Mortalité 2010 study group. Cancer-related causes of death among HIV-infected patients in France in 2010: evolution since 2000. *Plos One* 2015; 10(6):e0129550.

2016

442. Borges ÁH, Lundh A, Tendal B, Bartlett JA, Clumeck N, Costagliola D, Daar ES, Echeverría P, Gisslén M, Huedo-Medina TB, Hughes MD, Huppler Hullsiek K, Khabo P, Komati S, Kumar P, Lockman S, MacArthur RD, Maggiolo F¹⁷, Matteelli A, Miro JM, Oka S, Petoumenos K, Puls RL, Riddler SA, Sax PE, Sierra-Madero J, Torti C, Lundgren JD. Non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based regimens for initial treatment of HIV infection: a systematic review and meta-analysis of randomised trials. *Clin Infect Dis* 2016;63(2):268-80.
443. Caby F, Guihot A, Lambert-Niclot S, Guiguet M, Boutolleau D, Agher R, Valantin MA, Tubiana R, Calvez V, Marcelin AG, Carcelain G, Autran B, Costagliola D, Katlama C. Determinants of a low CD4/CD8 ratio in HIV-1-infected individuals despite long-term viral suppression. *Clin Infect Dis* 2016; 62(10):1297-303.
444. Cain LE, Caniglia EC, Phillips A, Olson A, Muga R, Pérez-Hoyos S, Abgrall S, Costagliola D, Rubio R, Jarrín I, Bucher H, Fehr J, van Sighem A, Reiss P, Dabis F, Vandenhende MA, Logan R, Robins J, Sterne JAC, Justice A, Tate J, Touloumi G, Pappas V, Esteve A, Casabona J, Seng R, Meyer L, Jose S, Sabin C, Hernán MA. Efavirenz vs. boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-positive individuals. *Medicine* 2016; 95(41):e5133.
445. Cain LE, Saag MS, Petersen M, May MT, Ingle SM, Logan R, Robins JM, Abgrall S, Shepherd BE, Deeks SG, Gill JM, Touloumi G, Vourli G, Dabis F, Vandenhende MA, Reiss P, van Sighem A, Samji H, Hogg RS, Rybniker J, Sabin CA, Jose S, del Amo J, Moreno S, Rodriguez B, Cozzi-Lepri A, Boswell SL, Stephan C, Perez-Hoyos S, Jarrin I, Guest JL, D'ArminioMonforte A, Antinori A, Moore R, Campbell CNJ, Casabona J, Meyer L, Seng S, Phillips AN, Bucher HC, Egger M, Mugavero MJ, Haubrich R, Geng EH, Olson A, Eron JJ, Napravnik S, Kitahata MM, Van Rompaey SE, Teira R, Justice AC, Tate JP, Costagliola D, Sterne JAC, Hernan MA on behalf of the Antiretroviral Therapy Cohort Collaboration, the Centers for AIDS Research Network of Integrated Clinical Systems, and the HIV-CAUSAL Collaboration. Using observational data to emulate a randomized trial of dynamic treatment switching strategies: an application to antiretroviral therapy. *Int J epidemiol* 2016; 45(6): 2038-2049.
446. Calin R, Hamimi C*, Lambert-Niclot S*, Carcelain G, Bellet J, Assoumou L, Tubiana R, Calvez V, Dudoit Y, Costagliola D*, Autran B*, Katlama C and the ULTRASTOP Study Group. Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir: results from the ULTRASTOP study. *AIDS* 2016; 30(5):761-769.
447. The HIV-CAUSAL Collaboration and the Center for AIDS Research Network of Integrated Clinical Systems. Caniglia EC, Sabin C, Robins JM, Logan R, Cain LE, Abgrall S, Mugavero MJ, Hernández-Díaz S, Meyer L, Seng R, Drozd DR, Seage III GR, Bonnet F, Dabis F, Moore RR, Reiss P, van Sighem A, Mathews WC, del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Olson A, Justice A, Tate J, Bucher HC, Egger M, Touloumi G, Sterne JA, Costagliola D, Saag M, Hernán MA. When to monitor CD4 cell count and HIV RNA to reduce mortality and AIDS-defining illness in virologically suppressed HIV-positive persons on antiretroviral therapy in high-income countries: a prospective observational study. *J Acquir Immune Defic Syndr* 2016; 72(2):214-221.
448. Costagliola D, May M. Survival in individuals living with HIV. *Curr Opin HIV AIDS* 2016; 11(5): 451-454.
449. Gantner P, Assoumou L, Leruez-Ville M, David L, Suzan-Monti M, Costagliola D, Rouzioux C, Ghosn J. HIV-1 RNA in seminal plasma correlates with detection of HIV-1 DNA in semen cells but not with CMV shedding among men who have sex with men on successful antiretroviral regimens. *J Antimicrob Chemother* 2016; 71(11):3202-3205.

450. Guihot A, Dentone C, Assoumou L, Parizot C, Calin R, Seang S, Soulié C, Marcelin AG, Calvez V, Autran B, Katlama C, Costagliola D, Carcelain G. Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia. *AIDS* 2016; 30(2):327-30.
451. Heard I, Poizot-Martin I, Potard V, Etienney I, Crenn-Hebert C, Moore C, Touraine P, Cubie H*, Costagliola D*, for the ANRS-C017 VIHGY Study Group. Prevalence of and risk factors for Anal Oncogenic human papillomavirus infection among HIV-Infected Women in France in the cART era. *J Infect Dis* 2016; 213:1455-61.
452. Katlama C, Lambert-Niclot S, Assoumou L, Papagno L, Lecardonnel F, Zoorob R, Tambussi G, Clotet B, Youle M, Achenbach CJ, Murphy RL, Calvez V, Costagliola D, Autran B; EraMune-01 study team. Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial. *AIDS* 2016; 30(2):221-30.
453. Lazarus JV, Safreed-Harmon K, Barton SE, Costagliola D, Dedes N, del Amo Valero J, Gattell JM, Batista-Leite R, Mendão L, Porter K, Vella S, Rockstroh JK. Beyond viral suppression of HIV – the new quality of life frontier. *BMC Med* 2016; 14(1):94.
454. Leblanc J, Rousseau A, Hejblum G, Durand-Zaleski I, De Truchis P, Lert F, Costagliola D, Simon T, Cremieux AC. The impact of nurse-driven targeted HIV screening in 8 emergency departments: study protocol for the dici-vih cluster-randomized two-period crossover trial. *BMC Infect Dis* 2016; 16(1): 51.
455. de Monteynard LA, Matheron S, Gilquin J, Pavie J, de Truchis P, Grabar S, Launay O, Meynard JL, Khuong-Josses MA, Rey D, Simon A, Mahamat A, Dray-Spira R, Costagliola D, Abgrall S. Influence of geographic origin, sex and HIV transmission group on the outcome of first line combined antiretroviral therapy (cART) in France. *AIDS* 2016; 30(14): 2235-2246.
456. Okulicz JF, Boufassa F, Costagliola D, Ganesan A, Lambotte O. Cancers In Elite Controllers: Appropriate Follow-up is Essential. *AIDS* 2016; 30(11):1852-5.
457. Pantazis N, Touloumi G, Meyer L, Olson A, Costagliola D, Kelleher T, Lutsar I, Chaix ML, Fisher M, Moreno S, Porter K on behalf of CASCADE Collaboration in EuroCoord. The impact of short-course cART in primary HIV infection on viral suppression and immunologic response in later treatment. *AIDS* 2016; 30(6): 879-88.
458. Potard V, Simon A, Lacombe JM, Parienti JJ, Costagliola D on behalf of FHDH ANRS CO4. Switching to raltegravir from a virologically effective boosted protease inhibitor regimen: a comparative effectiveness analysis from the French Hospital Database on HIV (FHDH-ANRS CO4). *Clin Infect Dis* 2016; 63(9):1254-1261.
459. Slama L, Landman R, Assoumou L, Benalycherif A, Samri A, Joly V, Pialoux G, Valin N, Cabié A, Duvivier C, Lambert-Niclot S, Marcelin AG, Peytavin G, Costagliola D, Girard PM on behalf of the IMEA 040 DATA study group. Efficacy and safety of once-daily Ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analog backbone in HIV-1-infected cART-naïve patients with severe immunosuppression: a 48-Week, non-comparative, randomized, multicenter trial (IMEA 040, DATA Trial). *J Antimicrob Chemother* 2016; 71(8): 2252-2261.
460. Spano JP, Poizot-Martin I, Costagliola D, Boué F, Rosmorduc O, Lavolé A, Choquet S, Heudel PE, Leblond V, Gabarre J, Valantin MA, Solas C, Guihot A, Carcelain G, Autran B, Katlama C, Quéro L. Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working Group. *Ann Oncol.* 2016; 27(3):397-408.
461. Supervie V, Costagliola D. Time for a revolution in tracking the HIV epidemics. *Lancet HIV* 2016, 3(8):e337-8.
462. Supervie V, Marty L, Lacombe JM, Dray-Spira R, Costagliola D and the FHDH-ANRS CO4 study group. Looking beyond the cascade of HIV care to end the AIDS epidemic: estimation of the time interval from HIV infection to viral suppression. *J Acquir Immune Defic Syndr* 2016; 73(3): 348-355.
463. Weiss L, Chevalier MF*, Assoumou L*, Paul JL, Alhenc-Gelas M, Didier C, Taïbi S, Manea M, Campa P, Girard PM, Costagliola D and the IMEA 043-CESAR trial working group. Rosuvastatin is effective to decrease CD8 T-cell activation only in HIV-infected patients with high residual T-cell activation under antiretroviral therapy. *J Acquir Immune Defic Syndr* 2016; 71(4):390-8.

2017

464. Besson C, Lancar R, Prevot S, Algarte-Genin M, Delobel P, Bonnet F, Meyohas Mc, Partisani M, Oberic L, Gabarre J, Goujard C, Boue F, Coppo P, Costello R, Hendel-Chavez H, Mekkerri N, Dos Santos G, Recher C, Delarue R, Casasnovas Ro, Taoufik Y, Mounier N, Costagliola D. HIV-associated diffuse large B-cell lymphoma in the modern cART era; results from the ANRS CO16 LYMPHOVIR cohort. *AIDS* 2017; 31(18):2493-2501.
465. Bittar R, Aslangul E, Giral P, ^[SEP] Assoumou L, Valantin MA, Kalmykova O, Federspiel MC, Cherfils C, Costagliola D, Bonnefont-Rousselot D, the ANRS 126 study group . Lack of effects of statins on high-density lipoprotein subfractions in HIV-1-infected patients receiving protease inhibitors C. R. *Biologies* 2017; 340(2):109-113.

466. Boccara F, Miantezila Basilua J, Mary-Krause M, Lang S, Teiger E, Steg PG, Funck-Brentano C, Girard PM, Costagliola D, Cohen A, Guiguet M; on behalf the PACS-HIV investigators (Prognosis of Acute Coronary Syndrome in HIV-infected patients). Statin therapy and low-density lipoprotein cholesterol reduction in HIV-infected individuals after acute coronary syndrome: Results from the PACS-HIV lipids substudy. *Am Heart J* 2017; 183: 91-101.
467. Caby F, Mary-Krause M, Duval X, Guiguet M, Boue F, Gallien S, Genet P, Gras G, Odile Launay O, Le Loup G, Lelievre JD, Moreau J, Tattevin P, Teicher E, Zucman D, Weiss L, Grabar S, Costagliola D, on behalf of FHDH-ANRS CO4. CD4/CD8 ratio restoration in long-term treated HIV-1-infected individuals: Incidence and determinants. *AIDS* 2017; 31(12):1685–1695.
468. Caniglia EC, Cain LE, Sabin C, Robins JM, Logan R, Abgrall S, Mugavero MJ, Hernández-Díaz S, Meyer L, Seng R, Drozd DR, Seage III GR, Bonnet F, Dabis F, Moore RD, Reiss P, van Sighem A, Mathews WC, del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Justice A, Tate J, Gill J, Pacheco A, Bucher HC, Egger M, Furrer H, Porter K, Touloumi G, Crane H, Sterne JA, Costagliola D, Saag M, Hernán MA. Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed HIV-positive individuals on combination antiretroviral therapy in high income countries: a prospective, observational study. *Lancet HIV* 2017 ; 4(6):e251-e259.
469. Chêne G, Phillips A, Costagliola D, Sterne J, Furrer H, del Amo J, Mocroft A, d'Arminio Monforte A, Dabis F, Miro JM, Barger D, Termote M, Schwimmer C, Salbøl Brandt R, Friis-Moller N, Raben D, Haerry D, Egger M, Weller I, De Wit S for Cohere in EuroCoord. Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. *Int J Epidemiol* 2017; 46(3): 797-797n.
470. Godin O, Henry C, Leboyer M, Azorin JM, Aubin V, Bellivier F, Polosan M, Courtet P, Gard S, Kahn JP, Loftus J, Passerieux C, Costagliola D, Etain B. Sleep quality, chronotype and metabolic syndrome components in bipolar disorders during the remission period: Results from the FACE-BD cohort. *Chronobiol Int* 2017; 34(8):1114-1124.
471. Godin O, Leboyer M, Schürhoff F, Boyer L, Andrianarisoa M, Brunel L, Bulzacka E, Aouizerate B, Berna F, Capdevielle D, D'Amato T, Denizot H, Dubertret C, Dubreucq J, Faget C, Gabayet F, Llorca PM, Mallet J, Misdrahi D, Passerieux C, Rey R, Richieri R, Schandrin A, Urbach M, Vidailhet P, Costagliola D, Fond G, FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group. Predictors of rapid high weight gain in schizophrenia: Longitudinal analysis of the French FACE-SZ cohort. *J Psychiatr Res.* 2017; 94:62-69.
472. Gourlay A, Noori T, Pharris A, Axelsson M, Costagliola D, Cowan S, Croxford S, d'Arminio Monforte A, del Amo J, Delpuch V, Díaz A, Girardi E, Gunsenheimer-Bartmeyer B, Hernando V, Jose S, Leierer G, Nikolopoulos G, Obel N, Op de Coul E, Paraskeva D, Reiss P, Sabin C, Sasse A, Schmid D, Sonnerborg A, Spina A, Suligoi B, Supervie V, Touloumi T, Van Beckhoven D, van Sighem A, Vourli G, Zangerle R, Porter K and the European HIV continuum of care working group. The HIV continuum of care in European Union countries in 2013: data and challenges. *Clin Infect Dis* 2017; 64(12):1644-1656.
473. Grabar S, Selinger-Leneman H, Abgrall S, Pialoux G, Weiss L, Costagliola D. Loss of long-term non-progressor and HIV controller status over time in the French Hospital Database on HIV - ANRS CO4. *Plos One* 2017; 12(10):e0184441.
474. Henry C*, Godin O*, Courtet P, Azorin JM, Gard S, Bellivier F, Polosan M, Kahn JP, Roux P, Aubin V, the FACE-BD collaborators, Costagliola D, Leboyer M, Etain B. Outcomes of bipolar patients assessed in the French Expert Center network: a 2 year-follow-up observational study (FACE-BD) *Bipolar Dis* 2017; 19(8):651-660.
475. Judd A, Lodwick R, Noguera-Julian A, Gibb D, Butler K, Costagliola D, Sabin C, van Sighem A, Ledergerber B, Torti C, Mocroft A, Podzamczar D, Dorrucchi M, De Wit S, Obel N, Dabis F, Cozzi-Lepri A, García F, Brockmeyer N, Warszawski J, Gonzalez Tome M, Mussini C, Touloumi G, Zangerle R, Ghosn J, Castagna A, Fätkenheuer G, Stephan C, Meyer L, Campbell MA, Chene G, Phillips A, the Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Higher rates of triple class virologic failure in perinatally HIV-infected teenagers compared to heterosexually infected young adults in Europe. *HIV Med* 2017; 18(3): 171-180.
476. Lodi S, Costagliola D, Sabin C, del Amo J, Logan R, Abgrall S, Reiss P, van Sighem A, Jose S, Blanco R, Hernando V, Bucher HC, Kovari H, Ferran Segura KH, Ambrosioni J, Gogos CA, Pantazis N, Sterne J, Dabis F, Vandenhende MA, Meyer L, Seng R, Gill J, Krentz H, Phillips A, Porter K, Grinsztejn B, Pacheco AG, Muga R, Tate J, Justice A, Hernán MA. Effect of immediate initiation of antiretroviral treatment in HIV-positive individuals aged 50 years or older. *J Acquir Immune Defic Syndr* 2017; 76(3):311-318.
477. Lusivika-Nzinga C, Selinger-Leneman H, Grabar S, Costagliola D, Carrat F. Performance of the marginal structural cox model for estimating individual and joined effects of treatments given in combination. *BMC Med Res Methodol* 2017;17(1):160.

478. Writing Group on HIV Epidemiologic Estimates in Countries With Migrant Populations From High Prevalence Areas: Nakagawa F, Delpech V, Ahmadou A, Albert J, Bezemer D, Cortina-Borja M, Brown A, Cambiano V, Costagliola D, De Luca A, Kouyos R, Lodwick R, Lundgren J, Pantazis N, Smith C, Supervie V, Tookey P, Touloumi G, Yin Z, Van Sighem A, Phillips AN on behalf of the SSOPHIE project working group in EuroCoord. An epidemiological modelling study to estimate the composition of HIV-positive populations including migrants from endemic settings: an application in the UK. *AIDS* 2017; 31(3):417-425.
479. Pourcher V, Desnoyer A*, Assoumou L*, Lebbé C, Curjol A, Marcelin AG, Cardon F, Gibowski S, Salmon D, Chennebault JM, Poizot-Martin I, Peytavin G, Boué F*, Costagliola D*. Phase II trial of lenalidomide in HIV-infected patients with previously treated Kaposi's sarcoma: Results of the ANRS 154 Lenakap Trial. *AIDS Res Hum Retroviruses* 2017; 33(1):1-10.
480. Supervie V, Assoumou L, Breban R, Lert F, Costagliola D, Pialoux G, Landman R, Girard PM, Slama L. Risk of HIV transmission during combined ART initiation for HIV-infected persons with severe immunosuppression. *J Antimicrob Chemother* 2017; 72(11): 3172-3176.
481. Trickey A, May MT, Schommers P, Tate J, Ingle S, Guest J, Gill J, Zangerle R, Saag M, Reiss P, d'Arminio Monforte A, Johnson M, Lima V, Sterling T, Cavassini M, Wittkop L, Costagliola D, Sterne JAC. CD4:CD8 ratio and CD8 count as prognostic markers for mortality in HIV-positive patients on ART. *Clin Infect Dis* 2017; 65(6) :959-966.
482. Wittkop L, Arsandaux J, Treviño A, Schim van der Loeff M, Anderson J, van Sighem A, Böni J, Brun-Vézinet F, Soriano V, Boufassa F, Brockmeyer N, Calmy A, Dabis F, Jarrín I, Dorrucchi M, Duque V, Fätkenheuer G, Zangerle R, Ferrer E, Porter K, Judd A, Sipsas N, Lambotte O, Shepherd L, Lepout C, Morrison C, Mussini C, Obel N, Ruelle J, Schwarze-Zander C, Sonnerborg A, Teira R, Torti C, Valadas E, Colin C, Friis-Moeller N, Costagliola D, Thiébaud R, Chene G, Matheron S. CD4 cell count response to first-line combination antiretroviral treatment in HIV-2 compared to HIV-1 positive patients - A Multinational Multicohort European Study. *J Antimicrob Chemother* 2017; 72 (10):2869-2878.

2018

483. The leDEA and COHERE Cohort Collaborations, Anderegg N, Panayidou K, Abo Y, Alejos B, Althoff KN, Anastos K, Antinori A, Balestre E, Becquet R, Castagna A, Castelnovo B, Chêne G, Coelho L, Collins IJ, Costagliola D, Crabtree-Ramírez B, Dabis F, d'Arminio Monforte A, Davies MA, De Wit S, Delpech V, De La Mata NL, Duda S, Freeman A, Gange SJ, Grabmeier-Pfistershammer K, Günsenheimer-Bartmeyer B, Jiamsakul A, Kitahata MM, Law M, Manzardo C, McGowan C, Meyer L, Moore R, Mussini C, Nakigozi C, Nash D, Tek Ng O, Obel N, Pantazis N, Poda A, Raben D, Reiss P, Rigger L, Sabin C, Sinayobye J, Sonnerborg A, Stoeckle M, Thorne C, Torti C, Twizere C, Wasmuth JC, Wittkop L, Wools-Kaloustian K, Yotebieng M, Kirk O, Egger M. Global trends in CD4 cell count at start of antiretroviral therapy: collaborative study of treatment programs. *Clin Infect Dis* 2018;66(6):893-903.
484. Caniglia EC, Phillips A, Porter K, Sabin CA, Winston A, Logan R, Gill J, Vandenhende MA, Barger D, Lodi S, Moreno S, Arribas JR, Pacheco A, Cardoso SW, Chryso G, Gogos C, Abgrall S, Costagliola D, Meyer L, Seng R, van Sighem A, Reiss P, Muga R, Hoyos SP, Braun D, Hauser C, Barrufet P, Leyes M, Tate J, Justice A, Hernán MA. Commonly prescribed antiretroviral therapy regimens and incidence of AIDS-defining neurological conditions. *J Acquir Immune Defic Syndr* 2018; 77(1):102-109.
485. Gobert A, Veyri M, Poizot-Martin I, Lavolé A, Solas C, Paliche R, Katlama C, Costagliola D, Spano JP. Cancer et VIH : Quoi de nouveau en 2017 ? *Bull cancer* 2018, 105(3):256-62.
486. Godin O, Leboyer M, Schürhoff F, Llorca PM, Boyer L, Andre M, Andrianarisoa M, Aouizerate B, Berna F, Capdevielle D, Chereau I, Dorey JM, Dubertret C, Dubreucq J, Faget C, Lancon C, Leignier S, Mallet J, Misdrahi D, Passerieux C, Rey R, Roux P, Vidailhet P, Costagliola D, Fond G; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group. Metabolic Syndrome and Illness Severity Predict Relapse at 1-Year Follow-Up in Schizophrenia: The FACE-SZ Cohort. *J Clin Psychiatry* 2018;79(6).
487. Hughes RA, May MT, Tilling K, Taylor N, Wittkop L, Reiss P, Gill J, Schommers P, Costagliola D, Guest JL, Lima VD, Monforte AD, Smith C, Cavassini M, Saag M, Sterling TR, Sterne JAC. Long-term trends in CD4 cell counts, CD8 cell counts, and the CD4: CD8 ratio. *AIDS* 2018; 32(10):1361-1367.
488. Leblanc J, Hejblum G, Costagliola D, Durand-Zaleski I, Lert F, de Truchis P, Rousseau A, Semaille C, Simon F, Pateron D, Simon T, Crémieux AC. Targeted HIV screening in eight emergency departments: the DICI-VIH cluster-randomized two-period crossover trial. *Ann Emerg Med* 2018;72(1):41-53.e9.
489. Marty L, Cazein F, Panjo H, Pillonel J, Costagliola D, Supervie V. Revealing geographical and population heterogeneity in HIV incidence, undiagnosed HIV prevalence and time to diagnosis to improve prevention and care: Estimates for France. *J Int AIDS Soc* 2018; 21(3):e25100.

490. Melliez H, Mary-Krause M, Bocket L, Guiguet M, Abgrall S, de Truchis P, Katlama C, Martin-Blondel G, Aurelia Henn A, Matthieu Revest M, Robineau O, Khuong-Josses M-A, Canestri A, De Castro N, Joly V, Mokhtari S, Risso K, Gasnault J*, Costagliola D*. Risk of Progressive multifocal leukoencephalopathy in the combined antiretroviral therapy era in the French hospital database on HIV (ANRS-C04). *Clin Infect Dis* 2018; 67(2):275-282.
491. de Monteynard LA, Matheron S, Grabar S, de Truchis P, Gilquin J, Pavie J, Launay O, Meynard JL, Khuong-Josses MA, Rey D, Aba Mahamat A, Dray-Spira R, Simon A, Costagliola D, Abgrall S. Influence of geographic origin on AIDS and serious non-AIDS morbidity/mortality during cART among heterosexual HIV-infected men and women in France. *Plos One* 2018; 13(10):e0205385.
492. Moulignier A, Savatovsky J, Assoumou L *, Lescure FX*, Lamirel C, Godin O, Valin N, Tubiana R, Canestri A, Roux P, Sadik JC, Salomon L, Abrivard M, Katlama C, Yazdanpanah Y, Pialoux G, Girard PM, Costagliola D, on behalf of the MicroBREAK study group. Silent cerebral small-vessel disease twice as prevalent in middle-aged well-controlled c-ART-treated HIV-infected individuals than in the HIV-uninfected individuals. *Clin Infect Dis* 2018; 66(11):1762-69.
493. Peckeu L, Brandel JP, Welaratne A, Costagliola D*, Haik S*. Susceptibility to Creutzfeldt-Jakob disease after human growth hormone treatment in France. *Neurology* 2018; 91:e724-e731
494. Potard V, Goujard C, Valantin MA, Lacombe JM, Lahoulou R, Chéret A, Girard PM, Costagliola D on behalf of the French Hospital Database on HIV (FHDH-ANRS CO4). Impact of etravirine on hospitalization rate between 2005 and 2011 among heavily treated HIV-1-infected individuals on failing regimens. *BMC Infect Dis* 2018;18:326.
495. Roul H, Mary-krause M, Ghosn J, Delaugerre C, Pialoux G, Cuzin L, Launay O, Lacombe JM, Menard A, De Truchis P, Delfraissy JF, Weiss L, Costagliola D. CD4 cell count recovery after combined antiretroviral therapy in the modern cART era. *AIDS* 2018; 32(17):2605-2614.
496. de Truchis P, Assoumou L, Landman R, Mathez D, Le Dû D, Bellet J, Amat K, Katlama C, Gras G, Bouchaud O, Duracinsky M, Abe E, Alvarez JC, Izopet J, Saillard J, Melchior JC, Leibowitch J, Costagliola D*, Girard PM*, Perronne C; ANRS 162-4D Study Group. Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial. *J Antimicrob Chemother* 2018; 73(3):738-47.

2019

497. Assoumou L, Thormann F, Soulié C, Caby F, Dudoit Y, Marcelin AG, Goudot P, Blanc C, Coriat P, Katlama C, Costagliola D, Pourcher V. Routine screening for HIV, hepatitis B virus and hepatitis C virus in individuals undergoing oral and maxillofacial surgery. *HIV Med*. 2019, 20(5):353-358.
498. Baldé A, Lang S, Wagner A, Ferrieres J, Montaye M, Tattevin P, Cotte L, Aslangul E, Bidegain F, Cheret A, Mary-Krause M, Meynard JL, Partisani M, Roger PM, Boccara F, Costagliola D. Trends in the risk of myocardial infarction among HIV-1-infected individuals relative to the general population in France: Impact of gender and immune status. *Plos One* 2019; 14(1): e0210253.
499. Baldé A, Lièvre L, Maiga AI, Diallo F, Maiga IA, Costagliola D, Abgrall S. Risk factors for loss to follow-up, transfer or death among people living with HIV on first ART regimen in Mali. *HIV Med* 2019; 20(1): 47-53.
500. Caniglia EC, Robins JM, Cain LE, Sabin C, Logan R, Abgrall S, Mugavero MJ, Hernández-Díaz S, Meyer L, Seng R, Drozd DR, Seage III GR, Bonnet F, Le Marec F, Moore RD, Reiss P, van Sighem A, Mathews WC, Jarrín I, Alejos B, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Gill J, Pacheco A, Grinsztejn B, Napravnik S, Jose S, Phillips A, Justice A, Tate J, Bucher HC, Egger M, Furrer H, Miro J, Casabona J, Porter K, Touloumi G, Crane H, Costagliola D, Saag M, Hernán MA. Emulating a trial of joint dynamic strategies: an application to monitoring and treatment of HIV-positive individuals. *Stat Med* 2019; 38(13):2428-2446.
501. Costagliola D, Potard V, Lang S, Abgrall S, Duviervier C, Fischer H, Joly V, Lacombe JM, Valantin MA, Mary-Krause M, Rozenberg S on behalf of FHDH ANRS CO4. Impact of antiretroviral drugs on fracture risk in HIV-infected individuals: A case-control study nested within the French Hospital Database on HIV (FHDH-ANRS CO4). *J Acquir Immune Defic Syndr* 2019; 80:214–223.
502. Godin O, Fond G, Bulzacka E, Schürhoff F, Boyer L, Myrtille A, Andrianarisoa M, Aouizerate B, Berna F, Capdevielle D, Chereau I, Dorey JM, Dubertret C, Dubreucq J, Faget C, Lancon C, Leignier S, Mallet J, Misdrahi D, Passerieux C, Rey R, Roux P, Vidailhet P, Costagliola D, FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group, Leboyer M, Llorca PM. Validation and refinement of the clinical staging model in a French cohort of outpatient with schizophrenia (FACE-SZ). *Prog Neuropsychopharmacol Biol Psychiatry* 2019; 92:226-234.
503. Grabar S, Hleyhel M, Belot A, Bouvier Am, Tattevin P, Pacanowski J, Genet P, Pradier C, Salmon D, Simon A, Pourcher V, Spano JP, Poizot-Martin I, Costagliola D. Invasive cervical cancer in HIV-infected women: risk and survival relative to that of the general population in France. *HIV Med* 2019; 20(3):222-229.

504. Gras L, May M, Ryder LP, Trickey A, Helleberg M, Obel N, Thiebaut R, Guest J, Gill J, Crane H, Lima VD, d'Arminio Monforte A, Sterling TR, Miro J, Moreno S, Stephan C, Smith C, Tate J, Shepherd L, Saag M, Rieger A, Gillor D, Cavassini M, Montero M, Ingle SM, Reiss P, Costagliola D, Wit FWNM, Sterne J, de Wolf F, Gekus R, for the Antiretroviral Therapy Cohort Collaboration (ART-CC). Determinants of restoration of CD4 and CD8 Cell Counts and their ratio in HIV-1 positive individuals with sustained virological suppression on antiretroviral therapy. *J Acquir Immune Defic Syndr* 2019; 80(3):292-300.
505. Januel E, Godin O, Moulignier A, Lescure FX, Savatovsky J, Lamirel C, Valin N, Tubiana R, Canestri A, Roux P, Sadik JC, Salomon L, Katlama C, Yazdanpanah Y, Pialoux G, Girard PM, Costagliola D, Assoumou L for the microvascular brain retina and kidney (microbreak) study group. Impact of ART classes on the increasing risk of cerebral small-vessel disease in middle-aged, well-controlled, cART-treated, HIV-infected individuals. *J Acquir Immune Defic Syndr* 2019, 81(5):547-551.
506. Katlama C, Assoumou L, Valantin MA, Soulie C, Martinez E, Beniguel L, Bouchaud O, Raffi F, Molina JM, Fellahi S, Peytavin G, Marcelin AG, Kolta S, Capeau J, Gibowski S, Cardon F, Reynes J, Costagliola D. Dual Therapy combining raltegravir plus etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a protease inhibitor based regimen: Results from the phase II ANRS 163 ETRAL study. *J Antimicrob Chemother* 2019; 74(9):2742-2751.
507. Lê MP, Valantin MA, Assoumou L, Soulie C, Le Mestre S, Weiss L, Yazdanpanah Y, Molina JM, Bouchaud O, Raffi F, Reynes J, Calvez V, Marcelin AG, Costagliola D, Katlama C, Peytavin G; ANRS-163 ETRAL study group. Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study. *Pharmacotherapy* 2019; 39(4):514-520.
508. Lemoine M, Assoumou L, De Wit S, Girard PM, Valantin MA, Katlama C, Necsoi C, Campa P, Huefner AD, Schulze zur Wiesch J, Rougier H, Bastard JP, Stocker H, Mauss S, Serfaty L, Ratzu V, Menu Y, Schlue J, Behrens G, Bedossa P, Capeau J, Ingiliz P*, Costagliola D* on behalf of the ANRS-ECHAM group. Diagnostic accuracy of noninvasive markers of steatosis, NASH and liver fibrosis in HIV-monoinfected individuals at-risk of non-alcoholic fatty liver disease (NAFLD): results from the ECHAM study. *J Acquir Immune Defic Syndr* 2019; 80(4):e86-e94.
509. Lodi S, Phillips A, Lundgren J, Logan R, Sharma S, Cole SR, Babiker A, Law M, Chu H, Byrne D, Horban A, Sterne JAC, Porter K, Sabin C, Costagliola D, Abgrall S, Gill J, Touloumi G, Pacheco AG, van Sighem A, Reiss P, Bucher HC, Montoliu Giménez A, Jarrin I, Wittkop L, Meyer L, Perez-Hoyos S, Justice A, Neaton JD, Hernán MA; INSIGHT START Study Group and the HIV-CAUSAL Collaboration Effect estimates in randomized trials and observational studies: comparing apples with apples. *Am J Epidemiol* 2019; 188(8):1569-1577.
510. Lupo J, Germi R, Costagliola D, Morand P, Besson C. Utility of Epstein-Barr Virus biomarkers in HIV-related lymphomas in the modern combined antiretroviral therapy era. *Clin Infect Dis*. 2019; 68(5):891-892.
511. Lupo J, Germi R, Lancar R, Algarte-Genin M, Hendel-Chavez H, Taoufik Y, Mounier N, Partisani M, Bonnet F, Meyohas MC, Marchou B, Semanova T, Prevot S, Costagliola D, Morand P, Besson C. Epstein-Barr virus biomarkers have no prognostic value in HIV-related Hodgkin lymphoma in the modern cART era. *AIDS* 2019; 33(6):993-1000.
512. Marty L, Van Beckhoven D, Ost C, Deblonde J, Costagliola D, Sasse A, Supervie V. Estimates of the HIV undiagnosed population in Belgium reveals higher prevalence for MSM with foreign nationality and for geographic areas hosting big cities. *J Int AIDS Soc* 2019; 22(8):e25371.
513. Matignon M, Lelièvre JD, Lahiani A, Abbassi K, Desvaux D, Diallo A, Peraldi MN, Taburet AM, Saillard J, Delaugerre C, Costagliola D, Assoumou L, Grimbert P, ANRS 153 TREVE study group. Low incidence of acute rejection within six months of kidney transplantation in HIV-infected recipients treated with raltegravir: the ANRS 153 Treve trial. *HIV Med* 2019; 20(3):202-213.
514. Olearo F, Nguyen H, Bonnet F, Yerly S, Wandeler G, Stoeckle M, Cavassini M, Scherrer A, Costagliola D, Schmid P, Günthard HF, Bernasconi E, Boeni J, D'Arminio Monforte A, Zazzi M, Rossetti B, Neau D, Bellecave P, Rijnders B, Reiss P, Wit F, Kouyos R, Calmy A. Impact of the M184V/I mutation on the efficacy of abacavir/lamivudine/dolutegravir therapy in human immunodeficiency virus treatment-experienced patients. *Open Forum Infect Dis* 2019; 6(10):ofz330.
515. Potard V, Gallien S, Canestri A, Costagliola D. Use of darunavir in HIV-1 infected individuals in routine clinical practice from 2012 to 2016 in France. *J Antimicrob Chemother* 2019; 74(11):3305-3314.
516. Tourret J, Guiguet M, Lassalle M, Grabar S, Lièvre L, Isnard-Bagnis C, Barrou B, Costagliola D, Couchoud C, Abgrall S, Tézenas Du Montcel S. Access to the waiting list and to kidney transplantation for people living with HIV: a national registry study. *Am J Transplant*. 2019; 19(12):3345-55.
517. Vourli G, Pharris A, Cazein F, Costagliola D, Dabis F, Del Amo J, Delpech V, Díaz A, Girardi E, Gourlay A, Gunsenheimer-Bartmeyer B, Hernando V, Nikolopoulos G, Porter K, Rosińska M, Sabin C, Suligoi B, Supervie V, Wit F, Touloumi G. Are European HIV cohort data within EuroCoord representative of the diagnosed HIV population? *AIDS* 2019; 33(1):133-143.

2020

518. Adenot I, Camus D, Epis de Fleurian AA, Tassy D, Bourguignon S, Chabin N, Chambrin PY, [Costagliola D](#), Huot L, Joly AS, Le Lous G, Martelli N, Orlikowski D, Petit V, Puc C, Roussel C, Wilquin-Bequet F. Accès précoce des patients aux technologies de santé : faut-il innover en vue d'une prise en charge précoce ? *Therapie*. 2020; 75(1):57-69.
519. Assoumou L, Racine C, Fellahi S, Lamaziere A, Farabos D, Beniguel L, Bastard JP, Feve B, Gibowski S, Katlama C, [Costagliola D](#), Capeau J. Fat gain differs by sex and hormonal status in persons living with suppressed HIV switched to raltegravir/etravirine. *AIDS* 2020; 34(12):1859-1862.
520. Baldé A, Lièvre L, Maiga AI, Diallo F, Maiga IA, [Costagliola D](#), Abgrall S. Re-engagement in care of people living with HIV lost to follow-up after initiation of antiretroviral therapy in Mali: Who returns to care? *PLoS One* 2020;15(9):e0238687.
521. Besson C, Noe N, Lancar R, Prevot S, Algarte-Genin M, Rosenthal E, Bonnet F, Meyohas MC, Partisani M, Oberic L, Gabarre J, Goujard C, Cheret A, Arvieux C, Katlama C, Salmon D, Boué F, Costello R, Hendel-Chavez H, Taoufik Y, Fontaine H, Coppo P, Mounier N, Delobel P, [Costagliola D](#) on behalf of the Lymphovir and FHDH Study Groups. HCV or HBV coinfection and lymphoma risk in people living with HIV. *AIDS* 2020; 34 (4), 599-608.
522. Boccara F, Mary-Krause M, Potard V, Teiger E, Lang S, Hammoudi N, Chauvet M, Ederhy S, Dufour-Soulat L, Ancedy Y, Nhan P, Adavane S, Steg PG, Funck-Brentano C, [Costagliola D](#), Cohen A, on behalf the PACS-HIV (Prognosis of Acute Coronary Syndrome in HIV-infected patients) Investigators. Human Immunodeficiency Viral Infection and Long-Term Residual Cardiovascular Risk After Acute Coronary Syndrome. *J Am Heart Assoc* 2020; 9(17):e017578.
523. [Costagliola D](#), Potard V, Lang S, de Castro N, Cotte L, Duval X, Duvivier C, Grabar S, Mary-Krause M, Partisani M, Ronot-Bregigeon S, Simon A, Tattevin P, Weiss L, Zucman D, Katlama C, Raffi F, Boccara F on behalf of ANRS CO4 FHDH. Is the risk of myocardial infarction in PLHIV associated with atazanavir or darunavir? A nested case-control study within the French Hospital Database on HIV. *J Infect Dis* 2020; 221(4): 516-522.
524. El Ket N, Kendjo E, Thellier M, Assoumou L, Potard V, Taieb A, Tantaoui I, Caumes E, Piarroux R, Roussel C, Buffet P, [Costagliola D](#), Jauréguiberry S. Propensity score analysis of artesunate versus quinine for severe imported *Plasmodium falciparum* malaria in France. *Clin Infect Dis* 2020; 70(2):280-287.
525. Godin O, Leboyer M, Mazroui Y, Aouizerate B, Azorin JM, Raoul B, Bellivier F, Polosan M, Courtet P, Dubertret C, Henry C, Kahn JP, Loftus J, Olié E, Passerieux C, [Costagliola D](#), Etain B; FondaMental Advanced Centers of Expertise in Bipolar Disorders (FACE-BD) Collaborators. Trajectories of functioning in bipolar disorders: A longitudinal study in the FondaMental Advanced Centers of Expertise in Bipolar Disorders cohort. *Aust N Z J Psychiatry* 2020 ; 54(10): 985-996.
526. Katlama C, Assoumou L, Valantin MA, Soulié C, Martinez E, Béniguel L, Bouchaud O, Raffi F, Molina JM, Fellahi S, Peytavin G, Marcelin AG, Kolta S, Capeau J, Gibowski S, Cardon F, Reynes J, [Costagliola D](#). Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study-authors' response. *J Antimicrob Chemother* 2020; 75(12):3699-3700.
527. Lancar R, Missy P, Dupuy A, Beaulieu Ph, Fardet L, [Costagliola D](#)*, Chosidow O*. Risk factors for seborrheic dermatitis flares-up: A case-control and a case-crossover study. *Acta Derm Venereol* 2020; 100(17): adv00292.
528. Laut K, Antinori A, Bartmeyer B, Beniowski M, Bonnet F, Brännström J, Casabona J, Castagna C, Chene G, [Costagliola D](#), d'Arminio Monforte A, del Amo J, De Wit S, Faetkenheuer G, Furrer H, Gasiorowski J, Jadand C, Kirk O, Lazanas MK, Suarez-Lozano I, Lundgren J, Mikhalik J, Mocroft A, Moreno S, Mussini C, Obel N, Paduta D, Raben D, Reiss P, Riordan A, Sabin CA, Smidt J, Torti C, Trofimova T, Vassilenko A, Vasylyev M, Warszawski J, Wittkop L, Yakovlev A, Zangerle R. Estimating the burden of HIV late presentation and its attributable morbidity and mortality across Europe 2010-2016. *BMC Infect Dis* 2020; 20:728.
529. Lescure FX, Fellahi S, Pialoux G, Bastard JP, Eme AL, Esteve E, Lebrette MG, Guiard-Schmid JB, Capeau J, Ronco P, [Costagliola D](#), Plaisier E. Prevalence of tubulopathy and association with renal function loss in HIV-infected patients. *Nephrol Dial Transplant* 2020; 35(4):607-615.
530. Levy Y*, Lelièvre JD*, Assoumou L, Aznar E, Pulido F, Tambussi G, Crespo M, Meybeck A, Molina JM, Delaugerre C, Izopet J, Peytavin G, Cardon F, Diallo A, Lancar R, Béniguel L, [Costagliola D](#). Addition of maraviroc versus placebo to standard antiretroviral therapy for initial treatment of advanced HIV-infection: a randomized trial. *Ann Intern Med* 2020; 172(5):297-305.
531. Makinson A, Dubois J, Eymard-Duvernay S, Leclercq P, Poizot-Martin I, Bernard L, Vassallo M, Barbuat C, Gény C, Thouvenot E, [Costagliola D](#), Zins M, Simony M, Reynes J, Berr C and the ANRS EP58 HAND 55-70 Study Group. Increased Prevalence of Neurocognitive impairment in Aging People Living with HIV, the ANRS EP58 HAND 55-70 Study. *Clin Infect Dis* 2020; 70(12):2641-2648.

532. Makinson A, Tron L, Grabar S, Milleron B, Reynes J, Le Moing V, Morquin D, Lert F, Costagliola D, Guiguet M. Potential lung cancer screening outcomes using different age and smoking thresholds in the ANRS-CO4 French Hospital Database on HIV cohort. *HIV Medicine* 2020; 21 (3), 180-188.
533. Melliez H, Mary-Krause M, Guiguet M, Carrieri P, Abgrall S, Enel P, Gallien S, Duval X, Duvivier C, Pavie J, Siguier M, Freire-Maresca A, Tattevin P, Costagliola D. Risk of severe bacterial infection in people living with HIV infection in the cART era. *J Infect Dis* 2020; 222(5):765-776.
534. Palich R, Veyri M, Valantin MA, Marcelin AG, Guihot A, Pourcher V, Jary A, Solas C, Makinson A, Poizot-Martin I, Costagliola D, Spano JP, Katlama C, for the Cancervih Study Group Recurrence and occurrence of Kaposi's sarcoma in HIV-infected patients on antiretroviral therapy despite suppressed HIV viremia. *Clin Infect Dis* 2020; 70(11):2435-2438.
535. Peckeu L, Brandel JP, Welaratne A, Amar E, Costagliola D*, Haïk S*. Factors influencing the incubation of an infectious form of Creutzfeldt-Jakob disease. *Clin Infect Dis* 2020; 70(7):1487-1490.
536. Peiffer-Smadja N, Costagliola D. Re: Early Outpatient treatment of symptomatic, high-risk Covid-19 patients that should be ramped-up immediately as key to the pandemic crisis. *Am J Epidemiol* 2020; 189(11):1443-1444.
537. Philippe L, Lancar R, Laurent C, Algarte-Genin M, Chassagne-Clément C, Fabiani B, Chenard MP, Lazure T, Parrens M, Charlotte F, Delattre C, Gibault L, Capron F, Goubin-Versini I, Petitjean B, Boué F, Mounier N, Costello R, Costagliola D, Prevot S*, Besson C*, ANRS-CO16 LYMPHOVIR cohort. In situ BCL-2 expression is an independent prognostic factor in HIV-associated DLBCL, a LYMPHOVIR cohort study. *Br J Haematol* 2020; 188(3):413-423.
538. Puppo C, Spire B, Morel S, Génin M, Béniguel L, Costagliola D, Ghosn J, Mabire X, Molina JM, Rojas Castro D, Préau M. How PrEP users constitute a community in the MSM population through their specific experience and management of stigmatization. The example of the French ANRS-PREVENIR study. *AIDS Care* 2020; 32(sup2):32-39.
539. Soulie C, Assoumou L, Abdi B, Sayon S, Nguyen T, Valantin MA, Beniguel L, Ferre V, Alloui C, Montes B, Avettand-Fenoel V, Delaugerre C, Descamps D, Martinez E, Reynes J, Peytavin G, Costagliola D, Katlama C, Calvez V, Marcelin A on behalf of the Etral ANRS 163 study group. Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL Trial). *J Antimicrob Chemother* 2020; 75(7):1943-1949.
540. Trickey A, May MT, Gill MJ, Grabar S, Vehreschild J, Wit FWNM, Bonnet F, Cavassini M, Abgrall S, Berenguer J, Wyen C, Reiss P, Grabmeier-Pfistershammer K; Guest J, Shepherd L, Teira Ramon, d'Arminio Monforte A, del Amo J, Justice A, Costagliola D, Sterne J. Cause-specific mortality after diagnosis of cancer among HIV-positive patients: a collaborative analysis of cohort studies. *Int J cancer* 2020; 146(11):3134-3146.
541. Vasseur L, Prévot S, Mounier N, Costagliola D, Besson C. Favorable outcome of HIV-associated Burkitt lymphoma in the modern combined antiretroviral therapy era. *Eur J Cancer* 2020; 138:189-192.
542. Vourli G, Noori T, Pharris A, Porter K, Axelsson M, Begovac J, Cazein F, Costagliola D, Cowan S, Croxford S, d'Arminio Monforte A, Delpech V, Díaz A, Girardi E, Gunsenheimer-Bartmeyer B, Hernando V, Leierer G, Lot F, Nunez O, Obel N, Op de Coul E, Paraskeva D, Patrinos S, Reiss P, Schmid D, Sonnerborg A, Suligoi B, Supervie V, van Sighem A, Zangerle R, Touloumi G, and the European HIV continuum of care working group. HIV Continuum of Care in 11 EU countries at the end of 2016 overall and by key population: have we made progress? *Clin Infect Dis* 2020; 71(11):2905-2916.

2021

543. Abe E, Assoumou L, de Truchis P, Amat K, Gibowski S, Gras G, Bellet J, Saillard J, Katlama C, Costagliola D, Girard PM, Landman R, Alvarez JC. Pharmacological data of a successful 4-days-a-week regimen in HIV antiretroviral therapy (ANRS 162-4D trial). *Br J Clin Pharmacol* 2021; 87(4):1930-1939.
544. Ader F, Peiffer-Smadja N, Poissy J, Bouscambert-Duchamp M, Belhadi D, Diallo A, Delmas C, Saillard J, Dechanet A, Mercier N, Dupont A, Alfaiate T, Lescure Fx, Raffi F, Goehringer F, Kimmoun A, Jaureguiberry S, Reignier J, Nseir S, Danion F, Clere-Jehl R, Bouillier K, Navellou Jc, Tolsma V, Cabie A, Dubost C, Courjon J, Leroy S, Mootien J, Gaci R, Mourvillier B, Faure E, Pourcher V, Gallien S, Launay O, Lacombe K, Lanoix Jp, Makinson A, Martin-Blondel G, Bouadma L, Botelho-Nevers E, Gagneux-Brunon A, Epaulard O, Piroth L, Wallet F, Richard Jc, Reuter J, Staub T, Lina B, Noret M, Andrejak C, Lê Mp, Peytavin G, Hites M, Costagliola D*, Yazdanpanah Y*, Burdet C**, Mentre F**, on behalf of the DisCoVeRy study group. An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN- β -1a and hydroxychloroquine in hospitalized patients with COVID-19. *Clin Microbiol Infect* 2021; 27(12):1826-1837.
545. Bach JF, Berche P, Chatenoud L, Costagliola D, Valleron AJ. COVID-19: individual and herd immunity. *Comptes Rendus Biologies* 2021; 344(1):7-18

546. Caby F, Guiguet M, Weiss L, Winston A, Miro JM, Konopnicki D, Le Moing V, Bonnet F, Reiss P, Mussini C, Poizot-Martin I, Taylor N, Skoutelis A, Meyer L, Goujard C, Bartmeyer B, Boesecke C, Antinori A, Quiros-Roldan E, Wittkop L, Frederiksen C, Thurnheer MC, Svedhem V, Jose S, [Costagliola D](#), Mary-Krause M, Grabar S. CD4/CD8 ratio and the risk of Kaposi sarcoma or non-Hodgkin lymphoma in the context of efficiently treated HIV infection: a collaborative analysis of 20 European cohort studies. *Clin Infect Dis* 2021; 73(1): 50-59.
547. Castry M, Cousien A, Bellet J, Champenois K, Pialoux G, Yazdanpanah Y, [Costagliola D](#), Grabar S, Deuffic-Burban S; for the French Hospital Database on HIV (ANRS CO4-FHDH Cohort). Hepatitis C virus incidence among men who have sex with men living with HIV in France: results from the French Hospital Database on HIV (ANRS CO4-FHDH) cohort study, 2014-2017. *Eurosurveillance* 2021; 26(38).
548. Gault N, Esposito-Farese M, Revest M, Inamo J, Jocelyn; Cabié A, André; Polard E, Hulot JS, Ghosn J, Chirouze C, Deconinck L, Diehl JL, Poissy J, Epaulard O, Lefevre B, Piroth L, De Montmollin E, Oziol E, Etienne M, Laouenan C, Rossignol P, [Costagliola D](#), Vidal-Petiot E and the French-Covid cohort investigators and study group. Chronic use of Renin-Angiotensin-Aldosterone-System blockers and mortality in COVID-19: a multicenter prospective cohort and literature review. *Fundamental & Clinical Pharmacology* 2021; 35:1141–1158.
549. Grabar S, [Costagliola D](#). Epidemiology of Kaposi's Sarcoma. *Cancers* 2021; 13, 5692.
550. Jijon S, Molina JM, [Costagliola D](#), Supervie V, Breban R. Can HIV epidemics among men who have sex with men be eliminated through participation in PrEP rollouts? *AIDS* 2021; 35(14):2347-2354.
551. Lievin R, Hendel-Chavez H, Baldé A, Lancar R, Algarte-Génin M, Krzysiek R, [Costagliola D](#), Assoumou L, Taoufik Y Besson C. Increased production of B cell effector cytokines and perturbed peripheral B cell compartment in HIV-related classical Hodgkin Lymphoma. *Cancers* 2021, 14(1), 128.
552. Lupo J, Germe R, Lancar R, Algarte-Genin M, Hendel-Chavez H, Taoufik Y, Mounier N, Partisani M, Bonnet F, Meyohas MC, Marchou B, Filippova A, Prevot S, [Costagliola D](#), Morand P, Besson C. Prospective evaluation of blood Epstein Barr virus DNA load and antibody profile in HIV-related non-Hodgkin lymphomas. *AIDS* 2021; 35(6):861-868.
553. Marty L, Lemsalu L, Kivite-Urtane A, [Costagliola D](#), Kaupe R, Linina I, Upmace I, Rützel K, Supervie S and the Hermetic study group. Revealing HIV epidemic dynamics and contrasting responses in two WHO Eastern European countries: Insights from modeling and data triangulation. *AIDS* 2021; 35(4):675-680.
554. Moulignier A, [Costagliola D](#). Metabolic Syndrome and Cardiovascular Disease Impacts on the Pathophysiology and Phenotype of HIV-Associated Neurocognitive Disorders. *Curr Top Behav Neurosci*. 2021; 50:367-399.
555. Potard V, Gallien S, Canestri A, [Costagliola D](#). Use of rilpivirine in HIV-1 infected individuals in routine clinical practice from 2012 to 2017 in France. *J Antimicrob Chemother* 2021; 19;76(2):467-476.
556. Thorball CW, Oudot-Mellakh T, Ehsan N, Hammer C, Santoni FA, Niay J, [Costagliola D](#), Goujard C, Meyer L, Wang SS, Hussain SK, Theodorou I, Cavassini M, Rauch H, Battegay M, Hoffmann M, Schmid P, Bernasconi E, Günthard HF, Mohammadi P, McLaren PJ, Rabkin CS, Besson C*, Fellay J*. Genetic variation near *CXCL12* is associated with susceptibility to HIV-related non-Hodgkin lymphoma. *Haematologica* 2021; 106(8):2233-2241.
557. Veyri M, Lavolé A, choquet S, [Costagliola D](#), Solas C, Katlama C, Poizot-Martin I, Spano JP. Do people living with HIV face more secondary cancers than general population: From the French CANCERVIH network. *Bull Cancer* 2021; 108(10):908-914

2022

558. Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D, Diallo A, Lê MP, Peytavin G, Staub T, Greil R, Guedj J, Paiva JA, [Costagliola D*](#), Yazdanpanah Y*, Burdet C**, Mentré F**; DisCoVeRy Study Group. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. *Lancet Infect Dis* 2022;22(2):209-221.
559. Baron M, Soulié C, Lavolé A, Assoumou L, Abbar B, Fouquet B, Rousseau A, Veyri M, Samri A, Makinson A, Choquet S, Mazières J, Brosseau S, Autran B, [Costagliola D](#), Katlama C, Cadranel J, Marcelin AG, Lambotte O, Spano JP, Guihot A, The French Cooperative Thoracic Intergroup Ifct Chiva-Investigators, The Anrs Co OncoVIHAC Study Group. Impact of Anti PD-1 Immunotherapy on HIV Reservoir and Anti-Viral Immune Responses in People Living with HIV and Cancer. *Cells*. 2022 Mar 17;11(6):1015.
560. Delaugerre C, Assoumou L, Maylin S, Minier M, Gabassi A, Genin M, Beniguel L, Ghosn J, de Lamballerie X, El Mouhebb M, [Costagliola D](#), Carrat F, Molina JM and Prevenir and SAPRIS-Sero study groups. SARS CoV-2 seroprevalence among HIV-negative participants using tenofovir/emtricitabine based PrEP in 2020 – a Sub-study of ANRS PREVENIR and INSERM SAPRIS-Sero cohorts. *Open Forum Infect Dis* 2022; 9(7), ofac188.

561. Diallo A, Trøseid M, Simensen VC, Boston A, Demotes J, Olsen IC, Chung F, Paiva JA, Hites M, Ader F, Arribas Lopez JR, Barratt-Due A, Melien Ø, Tacconelli E, Staub T, Greil R, Tsiodras S, Briel M, Esperou H, Mentre F, Eustace J, Saillard J, Delmas C, Le Mestre S, Dumousseaux M, Costagliola D, Røttingen JA, Yazdanpanah Y. Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group. *Clin Microbiol Infect* 2022; 28(1):1-5.
562. Fillatre P, Dufour MJ, Behillil S, Vatan R, Reusse P, Gabellec A, Velmans N, Montagne C, Geffroy Du Coudret S, Droumaguet E, Merour V, Enouf V, Buzele R, Valence M, Guillotel E, Gagniere B, Baidaliuk A, Zhukova A, Tourdjman M, Thibault V, Grohier C, Pronier C, Lescure FX, Simon-Loriere E, Costagliola D, Van Der Werf S, Tattevin P, Massart N. A new SARS-CoV-2 variant poorly detected by RT-PCR on nasopharyngeal samples, with high lethality: an observational study. *Clin Microbiol Infect* 2022; 28(2): 298.e9-298.e15.
563. Katlama C, Dudoit Y, Huyard J, Blanc C, Soulié C, Schneider L, Faycal A, Lenclume L, Hamani N, Qatib N, Tubiana R, Seang S, Sellem B, Costagliola D, Palich R, Valantin MA, Assoumou L Household transmission of SARS-CoV-2 infection in the Paris/Ile-de-France area. *Eur J Clin Microbiol Infect Dis* 2022; 41(3):445-454.
564. Landman R, de Truchis P, Assoumou L, Lambert S, Bellet J, Amat K, Lefebvre B, Allavena C, Katlama C, Yazdanpanah Y, Molina JM, Petrov-Sanchez V, Gibowski S, Alvarez JC, Leibowitch J, Capeau J, Fellahi S, Duracinsky M, Morand-Joubert L, Costagliola D, Girard PM and ANRS 170 QUATUOR study group. A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial. *Lancet HIV* 2022 9(2):e79-e90.
565. Leboyer M, Godin O, Llorca PM, Aubin V, Bellivier F, Belzeaux R, Courtet P, Costagliola D, Dubertret C, M'Bailara K, Haffen E, Henry C, Laouamri H, Passerieux C, Pelletier A, Polosan M, Roux P, Schwan R, Samalin L; FondaMental Advanced Center of Expertise for Bipolar Disorders (FACE-BD) collaborators, Olié E, Etain B. Key findings on bipolar disorders from the longitudinal FondaMental Advanced Center of Expertise-Bipolar Disorder (FACE-BD) cohort. *J Affect Disord.* 2022; 307: 149-156.
566. Liegeon G, Assoumou L, Ghosn J, El Mouhebb M, Palich R, Palacios C, Slama L, Surgers L, Genin M, Beniguel L, Goldwirt L, Duvivier C, Rojas Castro D, Costagliola D, Molina JM, on behalf of the ANRS-PREVENIR Study Group. Impact on Renal Function of Daily and On-demand HIV Pre-Exposure Prophylaxis in the ANRS-PREVENIR Study. *J Antimicrob Chemother* 2022; 77(12):3427-3435.
567. Lingas G, Néant N, Gaymard A, Belhadi D, Peytavin G, Hites M, Staub T, Greil R, Paiva JA, Poissy J, Peiffer-Smadja N, Costagliola D, Yazdanpanah Y, Wallet F, Gagneux-Brunon A, Mentré F, Ader F, Burdet C, Guedj J, Bouscambert-Duchamps M. Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modeling analysis of the randomized, controlled, open-label DisCoVeRy trial. *J Antimicrob Chemother* 2022; 77(5):1404-1412.
568. Martin-Blondel G, Lescure FX, Assoumou L, Charpentier C, Chaplain JM, Perpoint T, Grouteau G, Cordel H, Pialoux G, Pacanowski J, Thy, Bauvois A, Laureillard D, Hamrouni F, Algarte-Genin M, Poissy J, Descamps D, Costagliola D, for the CoCliCo study group. Increased risk of severe COVID-19 in hospitalized patients with SARS-CoV-2 Alpha variant infection: a multicentre matched cohort study. *BMC Infect Dis* 2022; 22(1):540.
569. Marty L, Diawara Y, Rachas A, Grabar S, Costagliola D, Supervie V. Projection of age of individuals living with HIV and time since ART initiation in 2030: estimates for France *J Int AIDS Soc* 2022, 25(S4): e25986.
570. Molina JM, Ghosn J, Assoumou L, Delaugerre C, Algarte-Genin M, Pialoux G, Katlama C, Slama L, Liegeon G, Beniguel L, Ohayon M, Mouhim H, Goldwirt L, Spire B, Loze B, Surgers L, Pavie J, Lourenco J, Ben-Mechlia M, Le Mestre S, Rojas-Castro D, Costagliola D, for the ANRS PREVENIR Study Group. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil: Results from the ANRS Prevenir cohort study. *Lancet HIV* 2022; 9(8): e554-e562.
571. Pourcher V, Capeau J, Dudoit Y, Boccarda F, Soulié C, Ndoadoumgue AL, Charlotte F, Béréziat V, AG Marcelin AG, Peytavin G, Boutron-Ruault MC, Tubax C, D'Avout A, Valantin MA, Schneider L, Costagliola D, Katlama C, Assoumou L, Pourcher G. Comparison of HIV-infected and non-infected patients undergoing bariatric surgery: the ObeVIH study. *J Acquir Immune Defic Syndr* 2022; 90(2):240-248.
572. Robert R, Cottin Y, Potard V, Mary-Krause M, Lang S, Teiger E, Collet JP, Chauvet-Droit M, Ederhy S, Soulat-Dufour L, Ancedy Y, Adavane-Scheuble S, Nhan P, Steg PG, Funck-Brentano C, Costagliola D, Cohen A, Boccarda F; on behalf the PACS-HIV Investigators. Coronary angiographic features and major adverse cardiac or cerebrovascular events in people living with human immunodeficiency virus presenting with acute coronary syndrome. *Circ Cardiovasc Interv* 2022; 15(6): e011945.
573. Trøseid M, Hentzien M, Ader F, Wagner Cardoso SW, Arribas JR, Molina JM, Mueller N, Hites M, Bonnet F, Manuel O, Costagliola D, Grinsztejn B, Olsen IC, Yazdapanah Y, Calmy A. Immunocompromized patients have been neglected in Covid-19 trials: A call for action. *Clin Microbiol Infect* 2022; 28(9):1182-1183.

2023

574. Amstutz A, Speich B, Mentré F, Rueegg CS, Belhadi D, Assoumou L, Burdet C, Murthy S, Dodd LE, Wang Y, Tikkinen KAO, Ader F, Hites M, Bouscambert M, Trabaud MA, Fralick M, Lee TC, Pinto R, Barratt-Due A, Lund-Johansen F, Müller F, Nevalainen OPO, Cao B, Bonnett T, Griessbach A, Taji Heravi A, Schönenberger C, Janiaud P, Werlen L, Aghlmandi S, Schandelmaier S, Yazdanpanah Y, Costagliola D, Olsen IC, Briel M. Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. *Lancet Respir Med*. 2023; 1(5):453-464.
575. Choufany M, Weiss L, Makinson A, Roul H, Livrozet JM, Pourcher V, Melica G, Rioux C, Viard JP, Marshall E, Grabar S, Costagliola D. Decrease in CD4 T-cell count and risk of severe morbid conditions in people with human immunodeficiency virus infection with controlled viral load after initiating combined antiretroviral therapy between 2006 and 2018. *Clin Infect Dis* 2023; 76(8):1364-1371.
576. Costagliola D. Cardiovascular diseases and exposure to integrase inhibitors: causal interpretation of treatment effect in observational studies. *Clin Infect Dis* 2023; 77(5):738-739.
577. Flahault A, Calmy A, Costagliola D, Drapkina O, Drosten C, Eckerle I, Larson HJ, Legido-Quigley H, Noakes C, Kazatchkine M, Kluge H. No Time for Complacency on COVID-19 in Europe. *Lancet* 2023; 401(10392):1909-1912.
578. Gault N, Bachelet D, Laouénan C, Borie R, Cracowski C, Poissy J, Faure K, Lainé F, Lefèvre B, Isnard M, Patrier J, Launay O, Costagliola D, Ghosn J*, Bouadma L*, on behalf of the French COVID cohort study group and the French COVID investigators study group. Impact of corticosteroids use on mid-term sequelae in survivors of COVID-19 admitted to hospital: a prospective cohort study. *J Med Virol*. 2023; 95(6):e28819.
579. Grabar S, Potard V, L Piroth L, Abgrall S, Bernard L, Allavena C, Caby F, De Truchis P, Duvivier C, Enel P, Katlama C, Khuong MA, Launay O, Matheron S, Melica G, Melliez H, Meynard JL, Pavie J, Slama L, Bregigeon S, Tattevin P, Capeau J, Costagliola D. Striking differences in weight gain after cART initiation depending on early or advanced presentation: Results from the ANRS CO4 FHDH cohort. *J Antimicrob Chemother* 2023; 78(3):757-768.
580. Lambert-Niclot S, Abdi B, Bellet J, Fofana D, de Truchis P, Amat K, Alvarez JC, Surgers L, Allavena C, Zaegel-Faucher O, Morlat P, Palich R, Gibowski S, Costagliola D, Girard PM, Landman R, Assoumou L, Morand-Joubert L, ANRS 170 QUATUOR study group. Four-days/week antiretroviral maintenance strategy (ANRS 170 quatuor): substudies of reservoirs and ultrasensitive drug resistance. *J Antimicrob Chemother* 2023; 78(6):1510-1521.
581. Lemoine M, Assoumou L, Girard PM, Valantin MA, Katlama C, De Wit S, Campa P, Rougier H, Meynard JL, Necsoi C, Huefner AD, Van Luzen J, Schulze Zur Wiesch J, Bastard JP, Fellahi S, Mauss S, Stankov MV, Baumgarten A, Post G, Serfaty L, Ratzu V, Menu Y, Schlue J, Bedossa P, Capeau J, Costagliola D, Behrens G, Ingiliz P; ANRS-ECHAM group. Screening HIV patients at risk for NAFLD using MRI-PDFF and transient elastography: a European multicenter prospective study. *Clin Gastroenterol Hepatol* 2023; 21(3):713-722.
582. Matulyte E, Davidaviciene E, Kancauskiene Z, Diktanas S, Kausas A, Velyvyte D, Urboniene J, Lipnickiene V, Laurencikaite M, Danila E, Costagliola D, Matulionyte R; WEEPI collaboration group. The socio-demographic, clinical characteristics and outcomes of tuberculosis among HIV infected adults in Lithuania: a thirteen-year analysis. *PLoS One* 2023; 23;18(3): e0282046.
583. Matulyte E, Kancauskiene Z, Kausas A, Urboniene J, Lipnickiene V, Kopeykiniene J, Gudaitis T, Raudonis S, Danila E, Costagliola D, Matulionyte R. Latent Tuberculosis Infection and Associated Risk Factors among People Living with HIV and HIV-Uninfected Individuals in Lithuania. *Pathogens* 2023; 12(8):990.
584. Mercier N, Belhadi D, DeChanet A, Delmas C, Saillard J, Dumousseaux M, Le Mestre S, Fougerou-Leurent C, Ferrane A, Burdet C, Espérou H, Ader F, Hites M, Peiffer-Smadja N, Poissy J, Andrejak C, Artur Paiva J, Tacconelli E, Staub T, Greil R, Costagliola D, Mentré F, Yazdanpanah Y, Diallo A on behalf of the DisCoVeRy Safety Working group. Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial. *Pharmacol Res Perspect* 2023; 11:e01072.
585. Néant N, Lingas G, Gaymard A, Belhadi D, Hites M, Staub T, Greil R, Paiva JA, Poissy J, Peiffer-Smadja N, Costagliola D, Yazdanpanah Y, Bouscambert-Duchamp M, Gagneux-Brunon A, Ader F, Mentré F, Wallet F, Burdet C, Guedj J; DisCoVeRy study group. Association between SARS-CoV-2 viral kinetics and clinical score evolution in hospitalized patients. *CPT Pharmacometrics Syst Pharmacol* 2023; 12(12):2027-2037.
586. Protiere C, Sagaon-Teyssier L, Donadille C, Sow A, Gaubert G, Girard G, Mora M, L. Assoumou L, Beniguel L, Michels D, Ghosn J, Costagliola D, Rojas Castro D, Molina JM, Spire B, ANRS PREVENIR Study-Group. Perception of PrEP-related stigma in PrEP users: results from the ANRS-PREVENIR cohort. *HIV medicine* 2023; 24(8):938-945.
587. Requena MB, Grabar S, Lanoy E, Pialoux G, Billaud E, Duvivier C, Merle P, Piroth L, Tattevin P, Salmon D, Weiss L, Costagliola D, Lacombe K. Mortality in HCV-cured versus HCV-uninfected people with HIV: a matched analysis in the ANRS CO4 FHDH cohort. *AIDS* 2023; 37:1297-1306.

588. Rubinstein P, Moore PC, Bimali M, Rudek MA, Chadburn A, Ratner L, Henry D, Cesarman E, DeMarco CE, [Costagliola D](#), Taoufik Y, Ramos JC, Sharon E, Reid EG, Ambinder R, Mounier N, Besson C, Noy A, for the AIDS Malignancy Consortium and the Lymphoma Study Association. Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC085), phase 2 results from an open-label, single arm, multicenter Phase 1/2 trial. *Lancet Haematology* 2023; 10(8): e624-e632.
589. Terzić V, Levoyer L, Figarella M, Bigagli E, Mercier N, de Gastines L, Gibowski S, Trøseid M, Demotes J, Olsen IC, Hites M, Ader F, Arribas Lopez JR, Mentré F, Espérou H, [Costagliola D](#), Røttingen JA, Poissy J, Rozé JC, Warris A, O'Leary J, Fernandes RM, Assoumou L, Hankard R, Turner MA, Yazdanpanah Y, Diallo A; EU-Response safety group; c4c safety group. Implementation of a centralised pharmacovigilance system in academic pan-European clinical trials: Points to consider for academic sponsors and lessons learnt from EU-Response and Connect4Children consortia. *British Journal of Clinical Pharmacology* 2023; 89(4): 1318-28.
590. Trøseid M*, Arribas JR*, Assoumou L, Holten AR, Poissy J, Terzić V, Mazzaferri F, Baño JR, Eustace J, Hites M, Joannidis M, Paiva JA, Reuter J, Püntmann I, Patrick-Brown TDJH, Westerheim E, Nezvalova-Henriksen K, Beniguel L, Dahl TB, Bouscambert M, Halanova M, Péterfi Z, Tsiodras S, Rezek M, Briel M, Ünal S, Schlegel M, Ader F, Lacombe K, Amdal CD, Rodrigues S, Tonby K, Gaudet A, Heggelund L, Mootien J, Johannessen A, Møller JH, Pollan BD, Tveita AA, Kildal AB, Richard JC, Dalgard O, Simensen VC, Baldé A, de Gastines L, Del Álamo M, Aydin B, Lund-Johansen F, Trabaud MA, Diallo A, Halvorsen B, Røttingen JA, Tacconelli E**, Yazdanpanah Y**, Olsen IC*, [Costagliola D*](#); EU SolidAct study group. Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial. *Critical care* 2023; 7(1):9.

2024

591. Assoumou L, Baldé A, Katlama C, Abbar B, Delobel P, Allegre T, Lavole A, Makinson A, Zaegel-Faucher O, Greillier L, Soulie C, Veyri M, Bertheau M, Algarte Genin M, Gibowski S, Marcelin AG, Bihan K, Baron M, [Costagliola D](#), Lambotte O*, Spano JP*, on behalf of the ANRS CO24 ONCOVIHAC Study Group. Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: Insights from the National Prospective Real-World ONCOVIHAC ANRS CO24 cohort study. *J Immunother Cancer* 2024; 12(8):e009728.
592. Chawki S, Goldwirt L, Mouhebb ME, Gabassi A, Taouk M, Bichard I, Loze B, Amara A, Brand R, Siegel A, McGowan I, [Costagliola D](#), Assoumou L, Molina JM, Delaugerre C; ANRS PREVENIR Study group. Ex vivo rectal tissue infection with HIV-1 to assess time to protection following oral PrEP with TDF/FTC (a sub-study of the ANRS PREVENIR study). *AIDS* 2024; 38(4): 455–464.
593. Ghosn J, Assoumou L, Ouattara M, Rubenstein E, Pialoux G, Katlama C, Surgers L, Duvivier C, Pavie J, Viard JP, Algarte-Genin M, Gibowski S, Ollivier M, [Costagliola D*](#), Molina JM*. Impact of vaccination with third generation modified vaccinia Ankara and sexual behaviour on mpox incidence in men who have sex with men: analysis among participants of the ANRS-174 DOXYVAC trial. *Lancet Reg Health Eur.* 2024; 45:101020.
594. Hites M, Massonnaud CR, Jamard S, Goehringer F, Danion F, Reignier J, de Castro N, Garot D, Lapique EL, Lacombe K, Tolsma V, Faure E, Malvy D, Staub T, Courjon J, Cazenave-Roblot F, Riise AMD, Leturmier P, Martin-Blondel G, Roger C, Akinosoglou K, Moing VL, Piroth L, Sellier P, Lescure X, Trøseid M, Clevenbergh P, Dalgard O, Gallien S, Gousseff M, Loubet P, Vardon-Bounes F, Visée C, Belkhir L, Botelho-Nevers É, Cabié A, Kotanidou A, Lanternier F, Rouveix-Nordon E, Silva S, Thiery G, Poignard P, Carcelain G, Diallo A, Mercier N, Terzic V, Bouscambert-Duchamp M, Gaymard A, Trabaud MA, Destras G, Josset L, Belhadi D, Billard N, Guedj J, Han TH, Couffin-Cadiergues S, Dechanet A, Delmas C, Espérou H, Fougere-Leurent C, Mestre SL, Métois A, Noret M, Bally I, Dergan-Dylon S, Tubiana S, Kalif O, Bergaud N, Leveau B, Eustace J, Greil R, Hajdu E, Halanova M, Paiva JA, Piekarska A, Baño JR, Tonby K, Trojánek M, Tsiodras S, Unal S, Burdet C, [Costagliola D](#), Yazdanpanah Y, Peiffer-Smadja N, Mentré F, Ader F; DisCoVeRy study group. Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): a phase 3, randomized, double-blind, placebo-controlled trial. *J Infect.* 2024; 88(3): 106120.
595. Liévin R, Maillard A, Hendel-Chavez H, Krzysiek R, Lancar R, Algarte-Genin M, [Costagliola D](#), Assoumou L, Taoufik Y, Besson C. Immune reconstitution and evolution of B cell stimulating cytokines after R-CHOP therapy for HIV-associated DLBC. *Blood Adv* 2024;8(23):6017-6027.
596. Molina JM, Bercot B, Assoumou L, Rubenstein E, Algarte-Genin M, Pialoux G, Katlama C, Surgers L, Bébéar C, Dupin N, Ouattara M, Slama L, Pavie J, Duvivier C, Loze B, Goldwirt L, Gibowski S, Ollivier M, Ghosn J, [Costagliola D](#); ANRS 174 DOXYVAC Study Group. Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial design. *Lancet Infect Dis.* 2024 May 23:S1473-3099(24)00236-6.
597. Pantazis N, Sabin CA, Grabar S, Van der Valk m, Jarrin I, van Sighem A, Meyer L, Carlander C, Gill J, Volny-Anne A, Spire B; Tariq S, Burns F, [Costagliola D](#), Ruiz-Burga E, Touloumi G, Porter K, Cascade Collaboration. Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration. *Lancet HIV* 2024; 11(10):e660-e669.

598. Terzic V, Basilua JM, Billard N, de Gastines L, Belhadi D, Fougerou-Leurent C, Peiffer-Smadja N, Mercier N, Delmas C, Ferrane A, Dechanet A, Poissy J, Espérou H, Ader F, Hites M, Andrejak C, Greil R, Paiva JA, Staub T, Tacconelli E, Burdet C, Costagliola D, Mentré F, Yazdanpanah Y, Diallo A, and the DisCoVeRy study group. Cardiac adverse events and remdesivir in hospitalized patients with coronavirus disease 2019 (COVID-19): A post hoc safety analysis of the randomized DisCoVeRy trial. *Clin Infect Dis* 2024; 79(2):382-391.
599. Vanier A, Fernandez J, Kelley S, Alter L, Semenzato P, Alberti C, Chevret S, Costagliola D, Cucherat M, Falissard B, Gueyffier F, Lambert J, Lengliné E, Locher C, Naudet F, Porcher R, Thiébaud R, Vray M, Zohar S, Cochat P, Le Guludec D. Rapid access to innovative medicinal products while ensuring relevant health technology assessment. Position of the French National Authority for Health. *BMJ Evid Based Med* 2024; 19;29(1):1-5.

2025

600. Viermyr HK, Tonby K, Ponzi E, Trouillet-Assant S, Poissy J, Arribas JR, Dyon-Tafani V, Bouscambert-Duchamp M, Assoumou L, Halvorsen B, Basdag Tekin N, Diallo A, De Castines L, Munthe LA, Murphy SL, Ueland T, Michelsen AE, Lund-Johansen F, Aukrust P, Mootien J, Dervieux B, Zerbib Y, Richard JC, Prével R, Malvy D, Timsit JF, Peiffer-Smadja N, Roux D, Piroth L, Ait-Oufella H, Vieira C, Dalgard O, Heggelund L, Müller KE, Horjen Møller J, Kildal AB, Skogen V, Aballi S, Sjøberg Øgaard JD, Dyrhol-Riise AM, Tveita A, Alirezaylavasani A, Costagliola D, Yazdanpanah Y, Christoffer Olsen I, Børresdatter Dahl T, Kared H, Rygh Holten A, Trøseid M. Safety of baricitinib in vaccinated patients with severe and critical COVID-19: Sub study of the randomised Bari-SolidAct trial. *eBioMedicine* 2025; 111:105511.

Acceptés

601. Liegeon G, Assoumou L, Béniguel L, Palich R, Pialoux G, Slama L, Surgers L, Duvivier C, Ohayon M, Mouhim H, Pavie J, Hoan Vu D, Michels D, Ben Mechlia M, Spire B, Ghosn J, Molina JM*, Costagliola D. Engagement in PrEP care at one year among men who have sex with men enrolled in the French ANRS PREVENIR cohort study. *Open Forum Infect Dis* 2025.
602. Ingle SM, Trickey A, Lankina A, McGinnis KA, Justice A, Cavassini M, d' Arminio Monforte A, van Sighem A, Gill MJ, Crane HM, Obel N, Jarrin I, Wallner E, Guest J, Silverberg MJ, Vourli G, Wittkop L, Sterling TR, Satre DD, Burkholder GA, Costagliola D, Sterne JAC. Harmonization of alcohol use data and mortality across a multi-national HIV cohort collaboration. *Alcohol Clin Exp Res* 2025.

*contributed equally to the work, **contributed equally to the work